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INTRODUCTION AND RATIONALE  
Hypertension is a frequently encountered complication of pregnancy and has a 
number of possible etiologies.  Its onset may predate a pregnancy or develop during the 
antenatal, intrapartum or post-partum course. In a minority of cases it is associated with 
proteinuria, and this usually indicates a multi-system disease, also known as pre-
eclampsia. This condition remains a leading cause of maternal and perinatal mortality, 
and is responsible worldwide for over 200,000 maternal deaths each year. However, 
hypertension alone may be the first signs of pre-eclampsia and therefore cannot be 
presumed innocent. In addition it is increasingly recognized that chronic hypertension has 
associated perinatal problems (Shennan, 2007). 
Pre-eclampsia is a major cause of maternal and fetal mortality and morbidity. The 
incidence of pre-eclampsia is 2-10%, depending on the population studied and definitions 
of pre-eclampsia (Confidential Enquiries into Maternal Deaths, 2001; Confidential 
Enquiry into Stillbirths and Deaths in Infancy, 2001; American College of Obstetricians and 
Gynecologists [ACOG], 2002). 
Pre-eclampsia  is classically defined as hypertension of at least 140/90 mmHg 
measured on 2 separate occasions at least 4 h apart and arising de novo in previously 
normotensive women after the twentieth week of gestation, accompanied by significant 
proteinuria, all of which are resolved by 6 weeks post-partum. Such a definition, whilst 
appropriate in the research setting, excludes the presence of symptoms, therefore many 
clinicians employ a diagnosis that relies upon 2 or more, of the following symptoms 
being present; hypertension of at least 140/90 mmHg on 2 separate occasions at least 4 h 
apart, significant proteinuria 0.3 g/l of protein per 24 h [0.5 g/24 h], and symptoms 
including headache, photophobia, visual disturbance, epigastric pain, alteration in the 
conscious state (Magee et al., 2008).
 
Also, many clinicians consider that rises in the diastolic blood pressure of 15 
mmHg and the systolic blood pressure of greater than 30 mmHg above booking values 
should be regarded as significant if other features of pre-eclampsia syndrome are present 
(Hayman, 2004). The National Institute for Clinical Excellence (NICE) guidelines on 
antenatal care have reduced the number of antenatal visits recommended for healthy 
woman at low risk (NICE, 2003). As the randomized controlled trials on which this 
recommendation was based were never powered to identify important outcomes such as 
mortality, and as the failure to identify and act on known risk factors at booking 
contributes to deaths from pre-eclampsia, it is important to define risk at the beginning of 
pregnancy (Confidential Enquiries into Maternal Deaths, 2001). 
We may therefore have underestimated the importance of antenatal care booking 
of risk factors for early onset pre-eclampsia, a type with considerable maternal and 
perinatal morbidity and mortality. Many risk factors that can be assessed at antenatal care 
booking including history (age, parity, previous pre-eclampsia, family history of pre-
eclampsia, multiple pregnancy, time between pregnancies, and pre-existing medical 
conditions as; insulin dependent diabetes (IDDM), chronic hypertension, renal disease, 
autoimmune disease and antiphospholipid syndrome) and physical examination (body 
mass index (BMI), blood pressure, and proteinuria) (Mattar and Sibai, 2000; Roberts 
and Catov, 2008). 
In one systematic review of controlled studies, it was found that antiphospholipid 
antibodies, a history of pre-eclampsia, pre-existing diabetes, multiple pregnancy, family 
history, nulliparity, a raised BMI before pregnancy or at booking, maternal age > 40, 
renal disease, hypertension, ≥ 10 years since the last pregnancy, and raised blood pressure 
at antenatal care booking all increased the risk of a woman developing pre-eclampsia 
(Duckitt and Harrington, 2005).
 
This prospective study was carried out to reach an overall estimate for the 
importance of antenatal care booking of the risk of pre-eclampsia. This provides an 
evidence base from which healthcare professionals can assess each pregnant woman's 
risk of pre-eclampsia at her booking visit and tailor her antenatal care according to need. 
 
 
AIM OF THE WORK 
The aim of this work is to evaluate the antenatal care booking during pregnancy 
and its effects on maternal and fetal outcomes. 
STUDY OBJECTIVES 
 To evaluate the adequacy of antenatal care booking visits during pregnancy. 
 To evaluate the effects of antenatal care booking on maternal and fetal outcomes. 
STUDY QUESTIONS 
 Are the antenatal care booking visits during pregnancy of the studied patients adequate or 
not? 
 What are the effects of antenatal care booking on maternal and fetal outcomes? 
STUDY HYPOTHESES 
 The antenatal care booking visits during pregnancy of the studied patients are inadequate. 












HYPERTENSIVE DISORDERS DURING PREGNANCY  
How pregnancy incites or aggravates hypertension remains unsolved despite 
decades of intensive research. Indeed, hypertensive disorders remain among the most 
significant and intriguing unsolved problems in obstetrics. Hypertensive disorders 
complicate 5 to 10 percent of all pregnancies, and together they are one member of the 
deadly triad—along with hemorrhage and infection—that contributes greatly to maternal 
morbidity and mortality. Of these disorders, the preeclampsia syndrome, either alone or 
superimposed on chronic hypertension, is the most dangerous. New-onset hypertension 
during pregnancy—termed gestational hypertension—is followed by signs and symptoms 
of preeclampsia almost half the time, and preeclampsia is identified in 3.9 percent of all 
pregnancies (Martin et al., 2012). 
The World Health Organization (WHO) systematically reviews maternal mortality 
worldwide, and in developed countries, 16 percent of maternal deaths were reported to be 
due to hypertensive disorders (Khan et al., 2006). This proportion is greater than three 
other leading causes that include hemorrhage—13 percent, abortion—8 percent, and 
sepsis—2 percent. In the United States from 1998 to 2005, Berg and colleagues (2010) 
reported that 12.3 percent of 4693 pregnancy-related maternal deaths were caused by 
preeclampsia or eclampsia. The rate was similar to that of 10 percent for maternal deaths 
in France from 2003 through 2007 (Saucedo et al., 2013). Importantly, more than half of 
these hypertension-related deaths were preventable (Berg et al., 2005). 
TERMINOLOGY AND DIAGNOSIS 
In this country for the past two decades, pregnancy hypertension was considered 
using the terminology and classification promulgated by the Working Group of the 
National High Blood Pressure Education Program—NHBPEP (2000).  
To update these, a Task Force was appointed by President James Martin for the 
American College of Obstetricians and Gynecologists (2013b) to provide evidence-
based recommendations for clinical practice.  
The basic classification was retained, as it describes four types of hypertensive disease: 
1. Gestational hypertension—evidence for the preeclampsia syndrome does not 
develop and hypertension resolves by 12 weeks postpartum 
2. Preeclampsia and eclampsia syndrome 
3. Chronic hypertension of any etiology 
4. Preeclampsia superimposed on chronic hypertension. 
Importantly, this classification differentiates the preeclampsia syndrome from other 
hypertensive disorders because it is potentially more ominous. This concept aids 
interpretation of studies that address the etiology, pathogenesis, and clinical management 
of pregnancy-related hypertensive disorders. 
Diagnosis of Hypertensive Disorders 
Hypertension is diagnosed empirically when appropriately taken blood pressure 
exceeds 140 mm Hg systolic or 90 mm Hg diastolic. Korotkoff phase V is used to define 
diastolic pressure. Previously, incremental increases of 30 mm Hg systolic or 15 mm Hg 
diastolic from mid-pregnancy blood pressure values had also been used as diagnostic 
criteria, even when absolute values were < 140/90 mm Hg. These incremental changes 
are no longer recommended criteria because evidence shows that such women are not 
likely to experience increased adverse pregnancy outcomes (Levine et al., 2000; North 
et al., 1999). That said, women who have a rise in pressure of 30 mm Hg systolic or 15 
mm Hg diastolic should be observed more closely because eclamptic seizures develop in 
some of these women whose blood pressures have stayed < 140/90 mm Hg (Alexander 
et al., 2006).  
A sudden rise in mean arterial pressure later in pregnancy—also known as “delta 
hypertension”—may also signify preeclampsia even if blood pressure is < 140/90 mm Hg 
(Macdonald-Wallis et al., 2012; Vollaard et al., 2007). 
Concept of “Delta Hypertension” 
The systolic and diastolic blood pressure levels of 140/90 mm Hg have been 
arbitrarily used since the 1950s to define “hypertension” in non-pregnant individuals. 
These levels were selected by insurance companies for a group of middle-aged men. It 
seems more realistic to define normal-range blood pressures that fall between an upper 
and lower limit for blood pressure measurements for a particular population—such as 
young, healthy, pregnant women. A schematic example is shown in Figure 1 using 
arbitrary blood pressure readings. Data curves for both women show blood pressure 
measurements near the 25th percentile until 32 weeks. These begin to rise in patient B, 
who by term has substantively increased blood pressures. However, her pressures are still 
< 140/90 mm Hg, and thus she is considered to be “normotensive.” This rather acute 
increase in blood pressure is termed as “delta hypertension.” Some of these women will 
develop eclamptic seizures or HELLP (hemolysis, elevated liver enzyme levels, low 
platelet count) syndrome while still normotensive. 
GESTATIONAL HYPERTENSION 
This diagnosis is made in women whose blood pressures reach 140/90 mm Hg or 
greater for the first time after midpregnancy, but in whom proteinuria is not identified 
(Table I). Almost half of these women subsequently develop preeclampsia syndrome, 
which includes findings such as headaches or epigastric pain, proteinuria, and 
thrombocytopenia. Even so, when blood pressure increases appreciably, it is dangerous to 
both mother and fetus to ignore this rise only because proteinuria has not yet developed.  
 
 
FIGURE 1. Schematic shows normal reference ranges for blood pressure changes 
across pregnancy. Patient A (blue) has blood pressures near the 20th percentile 
throughout pregnancy. Patient B (red) has a similar pattern with pressures at about the 
25th percentile until about 36 weeks when blood pressure begins to increase. By term, it 
is substantively higher and in the 75th percentile, but she is still considered 
“normotensive.” 






As Chesley (1985) emphasized, 10 percent of eclamptic seizures develop before 
overt proteinuria can be detected. Finally, gestational hypertension is reclassified by some 
as transient hypertension if evidence for preeclampsia does not develop and the blood 
pressure returns to normal by 12 weeks postpartum. 
PREECLAMPSIA SYNDROME 
Preeclampsia is best described as a pregnancy-specific syndrome that can affect 
virtually every organ system. And, although preeclampsia is much more than simply 
gestational hypertension with proteinuria, appearance of proteinuria remains an important 
diagnostic criterion. Thus, proteinuria is an objective marker and reflects the system-wide 
endothelial leak, which characterizes the preeclampsia syndrome (Lindheimer et al., 
2008a). 
Abnormal protein excretion is arbitrarily defined by 24-hour urinary excretion 
exceeding 300 mg; a urine protein: creatinine ratio ≥ 0.3; or persistent 30 mg/dL (1+ 
dipstick) protein in random urine samples (Lindheimer et al., 2008a). None of these 
values is sacrosanct, and urine concentrations vary widely during the day, as do dipstick 
readings. Thus, assessment may show a dipstick value of 1+ to 2+ from concentrated 
urine specimens from women who excrete < 300 mg/day. It is likely that determination of 
spot urine: creatinine ratio is a suitable replacement for a 24-hour urine measurement. It 
is now appreciated that overt proteinuria may not be a feature in some women with the 
preeclampsia syndrome (Sibai et al., 2009).  
Because of this, the Task Force (2013) suggested other diagnostic criteria, which 
are shown in Table I. Evidence of multiorgan involvement may include 
thrombocytopenia, renal dysfunction, hepatocellular necrosis (“liver dysfunction”), 
central nervous system perturbations, or pulmonary edema. 
 
Indicators of Preeclampsia Severity 
The markers listed in Table I are also used to classify preeclampsia syndrome 
severity. Although many use a dichotomous “mild” and “severe” classification, the Task 
Force (2013) discourages the use of “mild preeclampsia.” It is problematic that there are 
criteria for the diagnosis of “severe” preeclampsia, but the default classification is either 
implied or specifically termed as “mild,” “less severe,” or “non-severe”. There are no 
generally agreed-on criteria for “moderate” preeclampsia—an elusive third category. The 
criteria listed in Table II, which are categorized as “severe” versus “non-severe.” 
Importantly, while it is pragmatic that non-severe classifications include “moderate” and 
“mild,” these have not been specifically defined (Alexander et al., 2003; Lindheimer et 
al., 2008b). 
Some symptoms are considered to be ominous. Headaches or visual disturbances 
such as scotomata can be premonitory symptoms of eclampsia. Epigastric or right upper 
quadrant pain frequently accompanies hepatocellular necrosis, ischemia, and edema that 
ostensibly stretches Glisson capsule. This characteristic pain is frequently accompanied 
by elevated serum hepatic transaminase levels. Finally, thrombocytopenia is also 
characteristic of worsening preeclampsia as it signifies platelet activation and aggregation 
as well as microangiopathic hemolysis. Other factors indicative of severe preeclampsia 
include renal or cardiac involvement and obvious fetal-growth restriction, which also 
attests to its duration. The more profound these signs and symptoms, the less likely they 
can be temporized, and the more likely delivery will be required. A caveat is that 
differentiation between non-severe and severe gestational hypertension or preeclampsia 
can be misleading because what might be apparently mild disease may progress rapidly 
to severe disease (Lindheimer et al., 2008a). 
 





In a woman with preeclampsia, a convulsion that cannot be attributed to another 
cause is termed eclampsia. The seizures are generalized and may appear before, during, 
or after labor. The proportion who do not develop seizures until after 48 hours postpartum 
approximates 10 percent (Sibai et al., 2005). In some reports, up to a fourth of eclamptic 
seizures develop beyond 48 hours postpartum (Chames et al., 2002). Experiences from 
Parkland Hospital, however, are that delayed postpartum eclampsia continues to occur in 
about 10 percent of cases (Alexander et al., 2006). This lower percentage was also found 
in 222 women with eclampsia from The Netherlands (Zwart et al., 2008). 
PREECLAMPSIA SUPERIMPOSED ON CHRONIC HYPERTENSION 
Regardless of its cause, any chronic hypertensive disorder predisposes a woman 
to develop superimposed preeclampsia syndrome. Chronic underlying hypertension is 
diagnosed in women with documented blood pressures ≥ 140/90 mm Hg before 
pregnancy or before 20 weeks’ gestation, or both. Hypertensive disorders can create 
difficult problems with diagnosis and management in women who are not first seen until 
after mid-pregnancy. This is because blood pressure normally decreases during the 
second and early third trimesters in both normotensive and chronically hypertensive 
women. Thus, a woman with previously undiagnosed chronic vascular disease who is 
seen before 20 weeks frequently has blood pressures within the normal range. During the 
third trimester, however, as blood pressures return to their originally hypertensive levels, 
it may be difficult to determine whether hypertension is chronic or induced by pregnancy. 
Even a careful search for evidence of preexisting end-organ damage may be futile, as 
many of these women have mild disease and no evidence of ventricular hypertrophy, 
retinal vascular changes, or renal dysfunction (Lawlor et al., 2005). 
In some women with chronic hypertension, their blood pressure increases to 
obviously abnormal levels, and this is typically after 24 weeks. If new-onset or worsening 
baseline hypertension is accompanied by new-onset proteinuria or other findings listed in 
Table I, then superimposed preeclampsia is diagnosed. Compared with “pure” 
preeclampsia, superimposed preeclampsia commonly develops earlier in pregnancy. It 
also tends to be more severe and often is accompanied by fetal-growth restriction. The 
same criteria shown in Table II are also used to further characterize severity of 
superimposed preeclampsia. 
INCIDENCE AND RISK FACTORS 
Preeclampsia Syndrome 
Young and nulliparous women are particularly vulnerable to developing 
preeclampsia, whereas older women are at greater risk for chronic hypertension with 
superimposed preeclampsia. The incidence is markedly influenced by race and 
ethnicity—and thus by genetic predisposition. By way of example, in nearly 2400 
nulliparas enrolled in a Maternal-Fetal Medicine Units (MFMU) Network study, the 
incidence of preeclampsia was 5 percent in white, 9 percent in Hispanic, and 11 percent 
in African-American women (Myatt et al., 2012a; 2012b). 
Other factors include environmental, socioeconomic, and even seasonal 
influences (Spencer et al., 2009). With consideration for these vicissitudes, in several 
worldwide studies reviewed by Staff and coworkers (2014), the incidence of 
preeclampsia in nulliparous populations ranged from 3 to 10 percent. The incidence of 
preeclampsia in multiparas is also variable but is less than that for nulliparas. 
Specifically, population studies from Australia, Canada, Denmark, Norway, Scotland, 
Sweden, and Massachusetts indicate an incidence of 1.4 to 4 percent (Roberts et al., 
2011). 
There are several other risk factors associated with preeclampsia. These include 
obesity, multifetal gestation, maternal age, hyperhomocysteinemia, and metabolic 
syndrome (Conde-Agudelo et al., 2000; Walker et al., 2000; Scholten et al., 2013). The 
relationship between maternal weight and the risk of preeclampsia is progressive. It 
increases from 4.3 percent for women with a body mass index (BMI) < 20 kg/m2 to 13.3 
percent in those with a BMI > 35 kg/m2 (Table III and Figure 2).  
TABLE III. Adverse Pregnancy Effects in Overweight and Obese Women: 
 
 
FIGURE 2. Incidence of selected pregnancy outcomes in 16,102 women enrolled in 
the FASTER (First- and Second-Trimester Evaluation of Risk) trial according to body 
mass index (BMI) status (Adapted from Weiss et al., 2004). 
In women with a twin gestation compared with those with singletons, the 
incidence of gestational hypertension—13 versus 6 percent, and the incidence of 
preeclampsia—13 versus 5 percent, are both significantly increased (Sibai et al., 2000). 
It is interesting that this latter incidence is unrelated to zygosity (Maxwell et al., 2001). 
Although smoking during pregnancy causes various adverse pregnancy outcomes, 
ironically, it has consistently been associated with a reduced risk for hypertension during 
pregnancy (Bainbridge et al., 2005).  
Kraus and associates (2013) posit that this is because smoking upregulates 
placental adrenomedullin expression, which regulates volume homeostasis.Women with 
preeclampsia in the first pregnancy are at greater risk in a second pregnancy compared 
with women normotensive during their first pregnancy (McDonald et al., 2009).  
And conversely, in the woman who was normotensive during her first pregnancy, 
the incidence of preeclampsia in a subsequent pregnancy is much lower than for a first 
pregnancy. In a population-based retrospective cohort analysis, Getahun and colleagues 
(2007) studied almost 137,000 second pregnancies in such women. The incidence for 
preeclampsia in secundigravida white women was 1.8 percent compared with 3 percent in 
African-American women. 
Eclampsia 
Presumably because it is somewhat preventable by adequate prenatal care, the 
incidence of eclampsia has decreased over the years in areas where health care is more 
readily available. In countries with adequate resources, its incidence averages 1 in 2000 
deliveries. Ventura and associates (2000) estimated that the incidence in the United 
States in 1998 was 1 in 3250 births. According to the Royal College of Obstetricians 
and Gynecologists (2006), it approximates 1 in 2000 in the United Kingdom. Akkawi 
and coworkers (2009) reported it to be 1 in 2500 in Dublin, Andersgaard and associates 
(2006) as 1 per 2000 for Scandinavia, and Zwart and colleagues (2008) as 1 per 1600 
for The Netherlands. 
ETIOPATHOGENESIS 
Any satisfactory theory concerning the etiology and pathogenesis of preeclampsia must 
account for the observation that gestational hypertensive disorders are more likely to 
develop in women with the following characteristics: 
• Are exposed to chorionic villi for the first time or are exposed to a 
superabundance of chorionic villi, as with twins or hydatidiform mole 
• Have preexisting conditions of endothelial cell activation or inflammation such as 
diabetes or renal or cardiovascular disease 
• Are genetically predisposed to hypertension developing during pregnancy. 
A fetus is not a requisite for preeclampsia to develop. And, although chorionic 
villi are essential, they need not be intrauterine. For example, Worley and associates 
(2008) reported a 30-percent incidence in women with an extrauterine pregnancy 
exceeding 18 weeks’ gestation. Regardless of precipitating etiology, the cascade of events 
leading to the preeclampsia syndrome is characterized by abnormalities that result in 
vascular endothelial damage with resultant vasospasm, transudation of plasma, and 
ischemic and thrombotic sequelae. 
Phenotypic Expression of Preeclampsia Syndrome 
The preeclampsia syndrome is widely variable in its clinical phenotypic 
expression. There are at least two major subtypes differentiated by whether or not 
remodeling of uterine spiral arterioles by endovascular trophoblastic invasion is 
defective. This concept has given rise to the “two-stage disorder” theory of preeclampsia 
etiopathogenesis. The two-stage disorder includes “maternal and placental preeclampsia.” 
According to Redman and coworkers (2014), stage 1 is caused by faulty endovascular 
trophoblastic remodeling that downstream causes the stage 2 clinical syndrome. 
Importantly, stage 2 is susceptible to modification by preexisting maternal conditions that 
are manifest by endothelial cell activation or inflammation. Such conditions include 
cardiovascular or renal disease, diabetes, obesity, immunological disorders, or hereditary 
influences. Such compartmentalization is artificial, and it seems logical to us that 
preeclampsia syndrome presents clinically as a spectrum of worsening disease. Moreover, 
evidence is accruing that many “isoforms” exist. Examples include differences in 
maternal and fetal characteristics, placental findings, and hemodynamic findings 




Writings describing eclampsia have been traced as far back as 2200 BC 
(Lindheimer et al., 2014). And, an imposing number of mechanisms have been proposed 
to explain its cause. Those currently considered important include: 
1. Placental implantation with abnormal trophoblastic invasion of uterine vessels 
2. Immunological maladaptive tolerance between maternal, paternal (placental), and 
fetal tissues 
3. Maternal maladaptation to cardiovascular or inflammatory changes of normal 
pregnancy 
4. Genetic factors including inherited predisposing genes and epigenetic influences. 
Abnormal Trophoblastic Invasion 
Normal implantation is characterized by extensive remodeling of the spiral 
arterioles within the decidua basalis as shown schematically in Figure 3. Endovascular 
trophoblasts replace the vascular endothelial and muscular linings to enlarge the vessel 
diameter. The veins are invaded only superficially. In some cases of preeclampsia, 
however, there may be incomplete trophoblastic invasion. With this, decidual vessels, but 
not myometrial vessels, become lined with endovascular trophoblasts. The deeper 
myometrial arterioles do not lose their endothelial lining and musculoelastic tissue, and 
their mean external diameter is only half that of corresponding vessels in normal 
placentas (Fisher et al., 2014). In general, the magnitude of defective trophoblastic 
invasion is thought to correlate with severity of the hypertensive disorder (Madazli et al., 
2000). 
 
FIGURE 3. Schematic representation of normal placental implantation shows 
proliferation of extravillous trophoblasts from an anchoring villus. These 
trophoblasts invade the decidua and extend into the walls of the spiral arteriole to replace 
the endothelium and muscular wall to create a dilated low-resistance vessel. With 
preeclampsia, there is defective implantation characterized by incomplete invasion of the 
spiral arteriolar wall by extravillous trophoblasts. This results in a small-caliber vessel 
with high resistance to flow. 
Using electron microscopy, De Wolf and coworkers (1980) examined arteries 
taken from the implantation site. They reported that early preeclamptic changes included 
endothelial damage, insudation of plasma constituents into vessel walls, proliferation of 
myointimal cells, and medial necrosis. Lipid accumulated first in myointimal cells and 
then within macrophages.  
These lipid-laden cell changes, shown in Figure 4, were referred to as atherosis. 
Nelson and colleagues (2014) completed placental examination in more than 1200 
women with preeclampsia. These investigators reported that vascular lesions including 
spiral arteriole narrowing, atherosis, and infarcts were more common in placentas from 







FIGURE 4. Atherosis in a blood vessel from a placental bed. A. Photomicrograph 
shows disruption of the endothelium that result in a narrowed lumen because of 
subendothelial accumulation of plasma proteins and foamy macrophages. Some of the 
foamy macrophages are shown by curved arrows and straight arrows highlight areas of 
endothelial disruption. B. Schematic diagram of the photomicrograph (Adapted from 
Rogers et al., 1999). 
Thus, the abnormally narrow spiral arteriolar lumen likely impairs placental blood 
flow. McMahon and colleagues (2014) have provided evidence that decreased soluble 
antiangiogenic growth factors may be involved in faulty endovascular remodeling.  
 
Diminished perfusion and a hypoxic environment eventually lead to release of 
placental debris or microparticles that incite a systemic inflammatory response (Lee et 
al., 2012; Redman et al., 2012). Fisher and Roberts (2014) have provided an elegant 
review of the molecular mechanisms involved in these interactions. 
Defective placentation is posited to further cause the susceptible (pregnant) 
woman to develop gestational hypertension, the preeclampsia syndrome, preterm 
delivery, a growth-restricted fetus, and/or placental abruption (McElrath et al., 2008; 
Kovo et al., 2010; Brosens et al., 2011; Nelson et al., 2014). In addition, Staff and 
coworkers (2013) have hypothesized that acute atherosis identifies a group of women at 
increased risk for later atherosclerosis and cardiovascular disease. 
Immunological Factors 
Loss of maternal immune tolerance to paternally derived placental and fetal 
antigens, or perhaps its dysregulation, is another theory cited to account for preeclampsia 
syndrome (Erlebacher et al., 2013). Certainly, the histological changes at the maternal-
placental interface are suggestive of acute graft rejection. Some of the factors possibly 
associated with dysregulation include “immunization” from a previous pregnancy, some 
inherited human leukocyte antigen (HLA) and natural killer (NK)-cell receptor 
haplotypes, and possibly shared susceptibility genes with diabetes and hypertension 
(Fukui et al., 2012; Ward et al., 2014). 
Inferential data also suggest preeclampsia to be an immune-mediated disorder. 
For example, the risk of preeclampsia is appreciably enhanced in circumstances in which 
formation of blocking antibodies to placental antigenic sites might be impaired. In this 
scenario, the first pregnancy would carry a higher risk. Tolerance dysregulation might 
also explain an increased risk when the paternal antigenic load is increased, that is, with 
two sets of paternal chromosomes—a “double dose” (Bdolah et al., 2006). 
Namely, women with molar pregnancies have a high incidence of early-onset 
preeclampsia. Women with a trisomy 13 fetus also have a 30- to 40-percent incidence of 
preeclampsia. These women have elevated serum levels of antiangiogenic factors, and the 
gene for one of these factors, sFlt-1, is on chromosome 13 (Bdolah et al., 2006). 
Conversely, women previously exposed to paternal antigens, such as a prior pregnancy 
with the same partner, are “immunized” against preeclampsia. This phenomenon is not as 
apparent in women with a prior abortion.  
Strickland and associates (1986) studied more than 29,000 pregnancies at 
Parkland Hospital. These investigators reported that hypertensive disorder rates were 
decreased in women who previously had miscarried compared with nulligravidas. 
However, the difference, although statistically significant, was not great—22 versus 25 
percent. Other studies have shown that multiparas impregnated by a new consort have an 
increased risk of preeclampsia (Mostello et al., 2002). 
Redman and colleagues (2014) reviewed the possible role of immune 
maladaptation in preeclampsia pathophysiology. In women destined to be preeclamptic, 
extravillous trophoblasts early in pregnancy express reduced amounts of 
immunosuppressive nonclassic HLA G. Black women more commonly have the 1597ΔC 
allele that further predisposes to preeclampsia (Loisel et al., 2013).  
Zhou and coworkers (2012b) have shown this to be associated with high levels 
of placental oxidative products. These changes may contribute to defective placental 
vascularization in stage 1 of the preeclampsia syndrome. During normal pregnancy, T-
helper (Th) lymphocytes are produced so that type 2 activity is increased in relation to 
type 1—termed type 2 bias (Redman et al., 2012; 2014).  
 
Th2 cells promote humoral immunity, whereas Th1 cells stimulate inflammatory 
cytokine secretion. Beginning in the early second trimester in women who develop 
preeclampsia, Th1 action is increased and the Th1/Th2 ratio changes. Contributors to an 
enhanced immunologically mediated inflammatory reaction are stimulated by placental 
microparticles and by adipocytes (Redman et al., 2012; 2014). 
Endothelial Cell Activation 
In many ways, inflammatory changes are believed to be a continuation of the 
stage 1 changes caused by defective placentation. In response to placental factors 
released by ischemic changes or by any other inciting cause, a cascade of events begins 
(Davidge et al., 2014). Thus, antiangiogenic and metabolic factors and other 
inflammatory mediators are thought to provoke endothelial cell injury (Davidge et al., 
2014). 
Endothelial cell dysfunction may result from an extreme activated state of 
leukocytes in the maternal circulation (Faas et al., 2000; Gervasi et al., 2001). Briefly, 
cytokines such as tumor necrosis factor-α (TNF-α) and the interleukins (IL) may 
contribute to the oxidative stress associated with preeclampsia. This is characterized by 
reactive oxygen species and free radicals that lead to formation of self-propagating lipid 
peroxides (Manten et al., 2005).  
These in turn generate highly toxic radicals that injure endothelial cells, modify 
their nitric oxide production, and interfere with prostaglandin balance. Other 
consequences of oxidative stress include production of the lipid-laden macrophage foam 
cells seen in atherosis and shown in Figure 4; activation of microvascular coagulation 
manifest by thrombocytopenia; and increased capillary permeability manifest by edema 
and proteinuria (Task Force, 2013). 
These observations on the effects of oxidative stress in preeclampsia have given 
rise to increased interest in the potential benefit of antioxidants to prevent preeclampsia. 
Unfortunately, dietary supplementation with vitamins E (α-tocopherol) and C (ascorbic 
acid) to prevent preeclampsia has thus far proven unsuccessful (Task Force, 2013).  
Nutritional Factors 
John and colleagues (2002) showed that in the general population, a diet high in 
fruits and vegetables with antioxidant activity is associated with decreased blood 
pressure. Zhang and associates (2002) reported that the incidence of preeclampsia was 
doubled in women whose daily intake of ascorbic acid was less than 85 mg. These studies 
were followed by randomized trials to study dietary supplementation.  
Villar and coworkers (2006) showed that calcium supplementation in 
populations with a low dietary calcium intake had a small effect to lower perinatal 
mortality rates but no effect on preeclampsia incidence (p. 748). According to the 2013 
Task Force, in several trials, supplementation with the antioxidant vitamins C or E 
showed no benefits. 
Genetic Factors 
From a hereditary viewpoint, preeclampsia is a multifactorial, polygenic disorder. 
In their comprehensive review, Ward and Taylor (2014) cite an incident risk for 
preeclampsia of 20 to 40 percent for daughters of preeclamptic mothers; 11 to 37 percent 
for sisters of preeclamptic women; and 22 to 47 percent for twins. In a study by Nilsson 
and colleagues (2004) that included almost 1.2 million Swedish births, there was a 
genetic component for gestational hypertension and for preeclampsia. They also reported 
60-percent concordance in monozygotic female twin pairs. 
The hereditary predisposition for preeclampsia likely is the result of interactions 
of literally hundreds of inherited genes—both maternal and paternal—that control myriad 
enzymatic and metabolic functions throughout every organ system. Plasma-derived 
factors may induce some of these genes in preeclampsia (Mackenzie et al., 2012).  
Thus, the clinical manifestation in any given woman with the preeclampsia 
syndrome will occupy a spectrum. In this regard, phenotypic expression will differ 
among similar genotypes depending on interactions with environmental factors (Yang et 
al., 2013). 
Candidate Genes 
Hundreds of genes have been studied for their possible association with 
preeclampsia (Buurma et al., 2013; Ward et al., 2014). Several of those that may have 
positive significant association with preeclampsia are listed in Table IV. Polymorphisms 
of the genes for Fas receptor, hypoxia-inducible factor-1α protein (HIF-1α), IL-1β, 
lymphotoxin-α, transforming growth factor beta 3 (TGF-β3), apolipoprotein E (ApoE), 
and TNF-α have also been studied with varying results (Hefler et al., 2001; Lachmeijer 
et al., 2001; Livingston et al., 2001; Borowski et al., 2009; Wilson et al., 2009; 
Jamalzei et al., 2013).  
Because of the heterogeneity of the preeclampsia syndrome and especially of the 
other genetic and environmental factors that interact with its complex phenotypic 
expression, it is doubtful that any one candidate gene will be found responsible. Indeed, 
Majander and associates (2013) have linked preeclampsia predisposition to fetal genes 
on chromosome 18. 
 
 
TABLE IV. Genes with Possible Associations with Preeclampsia Syndrome: 
 
Other Genetic Variables 
An extensive list of other variables affect genotypic and phenotypic expression of 
the preeclampsia syndrome. Some include maternal and paternal genotypes, associated 
disorders, genomic ethnicity, gene-gene interactions, epigenetic phenomena, and gene-
environmental interactions. Combinations of these are infinite. Ethnoracial factors are 
important as discussed regarding the high incidence of preeclampsia in African-American 
women. It may be that Latina women have a lower prevalence because of interactions of 





The concept of vasospasm with preeclampsia was advanced by Volhard (1918) 
based on his direct observations of small blood vessels in the nail beds, ocular fundi, and 
bulbar conjunctivae. It was also surmised from histological changes seen in various 
affected organs. Endothelial activation causes vascular constriction with increased 
resistance and subsequent hypertension. At the same time, endothelial cell damage causes 
interstitial leakage through which blood constituents, including platelets and fibrinogen, 
are deposited subendothelially. Wang and associates (2002) have also demonstrated 
disruption of endothelial junctional proteins. Suzuki and coworkers (2003) described 
ultrastructural changes in the subendothelial region of resistance arteries in preeclamptic 
women. The much larger venous circuit is similarly involved, and with diminished blood 
flow because of maldistribution, ischemia of the surrounding tissues can lead to necrosis, 
hemorrhage, and other end-organ disturbances characteristic of the syndrome. One 
important clinical correlate is the markedly attenuated blood volume seen in women with 
severe preeclampsia (Zeeman et al., 2009). 
Endothelial Cell Injury 
During the past two decades, endothelial cell injury has become the centerpiece in 
the contemporary understanding of preeclampsia pathogenesis. In this scheme, protein 
factor(s)—likely placental—are secreted into the maternal circulation and provoke 
activation and dysfunction of the vascular endothelium. Many of the facets of the clinical 
syndrome of preeclampsia are thought to result from these widespread endothelial cell 
changes (Davidge et al., 2014). 
 
Grundmann and associates (2008) have reported that circulating endothelial 
cell—CEC—levels are elevated fourfold in the peripheral blood of preeclamptic women. 
Similarly, Petrozella and colleagues (2012) demonstrated increased levels of circulating 
endothelial microparticles—EMPs—in preeclamptic women. 
Intact endothelium has anticoagulant properties, and endothelial cells blunt the 
response of vascular smooth muscle to agonists by releasing nitric oxide. Damaged or 
activated endothelial cells may produce less nitric oxide and secrete substances that 
promote coagulation and increase sensitivity to vasopressors. Further evidence of 
endothelial activation includes the characteristic changes in glomerular capillary 
endothelial morphology, increased capillary permeability, and elevated blood 
concentrations of substances associated with endothelial activation. These latter 
substances are transferable, and serum from women with preeclampsia stimulates some 
of these substances in greater amounts. It seems likely that multiple factors in plasma of 
preeclamptic women combine to have these vasoactive effects (Myers et al., 2007; 
Walsh et al., 2009). 
Prostaglandins/ Pressor Responses 
Pregnant women normally develop refractoriness to infused vasopressors. Women 
with early preeclampsia, however, have increased vascular reactivity to infused 
norepinephrine and angiotensin II. Moreover, increased sensitivity to angiotensin II 
clearly precedes the onset of gestational hypertension (Abdul-Karim et al., 1961). 
Several prostanoids are thought to be central to preeclampsia syndrome pathophysiology. 
Specifically, the blunted pressor response seen in normal pregnancy is at least partially 
due to decreased vascular responsiveness mediated by endothelial prostaglandin 
synthesis. For example, compared with normal pregnancy, endothelial prostacyclin 
(PGI2) production is decreased in preeclampsia. This action appears to be mediated by 
phospholipase A2 (Davidge et al., 2014).  
At the same time, thromboxane A2 secretion by platelets is increased, and the 
prostacyclin: thromboxane A2 ratio decreases. The net result favors increased sensitivity 
to infused angiotensin II and, ultimately, vasoconstriction. These changes are apparent as 
early as 22 weeks in women who later develop preeclampsia (Chavarria et al., 2003). 
Nitric Oxide 
This potent vasodilator is synthesized from L-arginine by endothelial cells. 
Withdrawal of nitric oxide results in a clinical picture similar to preeclampsia in a 
pregnant animal model. Inhibition of nitric oxide synthesis increases mean arterial 
pressure, decreases heart rate, and reverses the pregnancy-induced refractoriness to 
vasopressors. In humans, nitric oxide likely is the compound that maintains the normal 
low-pressure vasodilated state characteristic of fetoplacental perfusion. It also is 
produced by fetal endothelium, and here it is increased in response to preeclampsia, 
diabetes, and sepsis (Parra et al., 2001; von Mandach et al., 2003). 
The effects of nitric oxide production in preeclampsia are unclear (Davidge et al., 
2014). It appears that the syndrome is associated with decreased endothelial nitric oxide 
synthase expression, thus increasing nitric oxide inactivation. These responses may be 
race related, with African-American women producing more nitric oxide (Wallace et al., 
2009). 
Endothelins 
These 21-amino acid peptides are potent vasoconstrictors, and endothelin-1 (ET-
1) is the primary isoform produced by human endothelium (George et al., 2011). Plasma 
ET-1 levels are increased in normotensive pregnant women, but women with 
preeclampsia have even higher levels (Ajne et al., 2003).  
According to Taylor and Roberts (1999), the placenta is not the source of 
increased ET-1 concentrations, and they likely arise from systemic endothelial activation. 
Interestingly, treatment of preeclamptic women with magnesium sulfate lowers ET-1 
concentrations (Sagsoz et al., 2003). 
Angiogenic and Antiangiogenic Proteins 
Placental vasculogenesis is evident by 21 days after conception. There is an ever-
expanding list of pro- and antiangiogenic substances involved in placental vascular 
development. The families of vascular endothelial growth factor (VEGF) and 
angiopoietin (Ang) are most extensively studied. Angiogenic imbalance is used to 
describe excessive amounts of antiangiogenic factors that are hypothesized to be 
stimulated by worsening hypoxia at the uteroplacental interface (Karumanchi et al., 
2014). 
Trophoblast of women destined to develop preeclampsia overproduces at least 
two antiangiogenic peptides that enter the maternal circulation (Karumanchi et al., 
2014): 
1. Soluble Fms-like tyrosine kinase 1 (sFlt-1) is a variant of the Flt-1 receptor for 
placental growth factor (PlGF) and for VEGF. Increased maternal sFlt-1 levels 
inactivate and decrease circulating free PlGF and VEGF concentrations, leading 
to endothelial dysfunction (Maynard et al., 2003). As shown in Figure 5, sFlt-1 
levels begin to increase in maternal serum months before preeclampsia is evident. 
Haggerty and colleagues (2012) observed that these high levels in the second 
trimester were associated with a doubling of the risk for preeclampsia. This 
divergence from normal levels appears to occur even sooner with early-onset 
preeclampsia (Vatten et al., 2012). 
 
FIGURE 5. Angiogenic and antiangiogenic factors in normotensive (NT) and 
preeclamptic (PE) women across pregnancy. Both pairs of factors are significantly 
divergent by 23 to 26 weeks. sFlt = soluble Fms-like tyrosine kinase 1; PlGF = placental 
growth factor (Adapted from Myatt, 2013). 
2. Soluble endoglin (sEng) is a placenta-derived 65-kDa molecule that blocks endoglin, 
which is a surface coreceptor for the TGFβ family. Also called CD105, this soluble form 
of endoglin inhibits various TGFβ isoforms from binding to endothelial receptors and 
results in decreased endothelial nitric oxide-dependent vasodilatation (Levine et al., 
2006; Venkatesha et al., 2006). Serum levels of sEng also begin to increase months 
before clinical preeclampsia develops (Haggerty et al., 2012). 
The cause of placental overproduction of antiangiogenic proteins remains an 
enigma. Concentrations of the soluble forms are not increased in the fetal circulation or 
amnionic fluid, and their levels in maternal blood dissipate after delivery (Staff et al., 
2007). Research currently is focused on immunological mechanisms, oxidative stress, 
mitochondrial pathology, and hypoxia genes (Karumanchi et al., 2014).  
Clinical research is directed at use of antiangiogenic proteins in the prediction and 
diagnosis of preeclampsia. In a systematic review, Widmer and associates (2007) 
concluded that third-trimester elevation of sFlt-1 levels and decreased PlGF 
concentrations correlate with preeclampsia development after 25 weeks. These results 
require verification in prospective studies. Subsequently, Haggerty and coworkers 
(2012) reported that doubling of expressions of sFlt-1 and sEng increased the 
preeclampsia risk 39 and 74 percent, respectively. 
PATHOPHYSIOLOGY 
Although the cause of preeclampsia remains unknown, evidence for its 
manifestation begins early in pregnancy with covert pathophysiological changes that gain 
momentum across gestation and eventually become clinically apparent. Unless delivery 
supervenes, these changes ultimately result in multiorgan involvement with a clinical 
spectrum ranging from an attenuated manifestation to one of cataclysmic deterioration 
that is life threatening for both mother and fetus. These are thought to be a consequence 
of endothelial dysfunction, vasospasm, and ischemia.  
Although the many maternal consequences of the preeclampsia syndrome are 
usually described in terms of individual organ systems, they frequently are multiple, and 
they overlap clinically. 
Cardiovascular System 
Severe disturbances of normal cardiovascular function are common with 
preeclampsia syndrome. These are related to: (1) increased cardiac afterload caused by 
hypertension; (2) cardiac preload, which is affected negatively by pathologically 
diminished hypervolemia of pregnancy and is increased by intravenous crystalloid or 
oncotic solutions; and (3) endothelial activation with interendothelial extravasation of 
intravascular fluid into the extracellular space and importantly, into the lungs 
(Melchiorre et al., 2013). 
Hemodynamic Changes and Cardiac Function 
The cardiovascular aberrations of pregnancy-related hypertensive disorders vary 
depending on several modifiers. These factors include hypertension severity, underlying 
chronic disease, preeclampsia severity, and in which part of the clinical spectrum these 
are studied. In some women, these cardiovascular changes may precede hypertension 
onset (De Paco et al., 2008; Khalil et al., 2012; Melchiorre et al., 2013).  
Nevertheless, with the clinical onset of preeclampsia, cardiac output declines, due 
at least in part to increased peripheral resistance. When assessing cardiac function in 
preeclampsia, consideration is given to echocardiographic measures of myocardial 
function and to clinically relevant ventricular function. Serial echocardiographic studies 
have documented in preeclampsia evidence for ventricular remodeling that is 
accompanied by diastolic dysfunction in 40 percent of women (Melchiorre et al., 2012). 
In some of these women, functional differences persisted up to 16 months after delivery 
(Evans et al., 2011).  
Ventricular Function 
Ventricular remodeling was judged to be an adaptive response to maintain normal 
contractility with the increased after-load of preeclampsia. In the otherwise healthy 
pregnant woman, these changes are usually clinically inconsequential. But when 
combined with underlying ventricular dysfunction—for example, concentric ventricular 
hypertrophy from chronic hypertension—further diastolic dysfunction may cause 
cardiogenic pulmonary edema. Despite the relatively high frequency of diastolic 
dysfunction with preeclampsia, in most women clinical cardiac function is appropriate. 
This has been shown by several studies in which ventricular function was assessed using 
invasive hemodynamic methods (Hibbard et al., 2014).  
Importantly, both normally pregnant women and those with preeclampsia 
syndrome can have normal or slightly hyperdynamic ventricular function (Figure 6). 
Thus, both have a cardiac output that is appropriate for left-sided filling pressures. Data 
from preeclamptic women obtained by invasive hemodynamic studies are confounded 
because of the heterogeneity of populations and interventions that also may significantly 
alter these measurements. Some of these are crystalloid infusions, antihypertensive 
agents, and magnesium sulfate. Ventricular function studies of preeclamptic women from 
several investigations are shown in Figure 7. Although cardiac function was 
hyperdynamic in all women, filling pressures were dependent on the volume of 
intravenous fluids. Specifically, aggressive hydration resulted in overtly hyperdynamic 
ventricular function in most women. However, this was accompanied by elevated 
pulmonary capillary wedge pressures. In some of these women, pulmonary edema may 
develop despite normal ventricular function because of an alveolar endothelial-epithelial 
leak. This is compounded by decreased oncotic pressure from a low serum albumin 
concentration (American College of Obstetricians and Gynecologists, 2012b). 
 
FIGURE 6. Ventricular function in normally pregnant women (striped area) and in 
women with eclampsia (boxed area) is plotted on a Braunwald ventricular function 
curve. Normal values are from Clark, 1989, and those for eclampsia are from Hankins, 
1984. LVSWI = left ventricular stroke work index; PCWP = pulmonary capillary wedge 
pressure. 
 
FIGURE 7. Ventricular function in women with severe preeclampsia–eclampsia 
plotted on the Braunwald ventricular function curve. The pulmonary capillary wedge 
pressures (PCWP) are lower in those managed with restricted fluid administration 
(striped area in A) compared with women managed with aggressive fluid therapy (striped 
area in B). In those managed with aggressive fluid infusions, eight developed pulmonary 
edema despite normal to hyperdynamic ventricular function in all but one. LVSWI = left 
ventricular stroke work index (data for A adapted from Hankins et al., 1984; data for 
B adapted from Phelan et al., 1982). 
 
Thus, increased cardiac output and hyperdynamic ventricular function is largely a 
result of low wedge pressures and not a result of augmented myocardial contractility. By 
comparison, women given appreciably larger volumes of fluid commonly had filling 
pressures that exceeded normal, but their ventricular function remained hyperdynamic 
because of concomitantly increased cardiac output. From these studies, it is reasonable to 
conclude that aggressive fluid administration to otherwise normal women with severe 
preeclampsia substantially elevates normal left-sided filling pressures and increases a 
physiologically normal cardiac output to hyperdynamic levels (American College of 
Obstetricians and Gynecologists, 2012b). 
Blood Volume 
For nearly 100 years, hemoconcentration has been a hallmark of eclampsia. This 
was not precisely quantified until Zeeman and colleagues (2009) expanded the previous 
observations of Pritchard and associates (1984) and showed in eclamptic women that 
the normally expected hypervolemia is severely curtailed (Figure 8). Women of average 
size should have a blood volume of nearly 4500 mL during the last several weeks of a 
normal pregnancy. In nonpregnant women, this volume approximates only 3000 mL. 
With eclampsia, however, much or all of the anticipated normal excess 1500 mL is lost. 
Such hemoconcentration results from generalized vasoconstriction that follows 
endothelial activation and leakage of plasma into the interstitial space because of 
increased permeability. In women with preeclampsia, and depending on its severity, 
hemoconcentration is usually not as marked. Women with gestational hypertension, but 
without preeclampsia, usually have a normal blood volume (Silver et al., 1998). 
 
FIGURE 8. The two bar graphs on the left compare mean blood volumes in non-
pregnant and term normally pregnant women. On the right, graphs display values for 
a group of 29 women with eclampsia and their non-pregnant values. The red bar reflects 
values for a subset of 14 who had a subsequent normotensive pregnancy. Extensions 
above bars represent one standard deviation. Comparison between values with identical 
lowercase letters, that is, a-a, b-b, c-c, d-d, are significant p <0.001 (Adapted from 




For women with severe hemoconcentration, it was once taught that an acute fall in 
hematocrit suggested resolution of preeclampsia. In this scenario, hemodilution follows 
endothelial healing with return of interstitial fluid into the intravascular space. Although 
this is somewhat correct, it is important to recognize that a substantive cause of this fall 
in hematocrit is usually the consequence of blood loss at delivery. It may also partially 
result from increased erythrocyte destruction as subsequently described. Vasospasm and 
endothelial leakage of plasma may persist for a variable time after delivery as the 
endothelium is restored to normalcy. As this takes place, vasoconstriction reverses, and as 
the blood volume increases, the hematocrit usually falls. Thus, women with eclampsia are 
sensitive to vigorous fluid therapy administered in an attempt to expand the contracted 
blood volume to normal pregnancy levels or are sensitive to amounts of blood loss at 
delivery that are considered normal for a normotensive woman (Zeeman et al.,  2009). 
Hematological Changes 
Several hematological abnormalities are associated with the preeclampsia 
syndrome. Among those commonly identified is thrombocytopenia, which at times may 
become severe enough to be life threatening. Occasionally, the levels of some plasma 
clotting factors may be decreased, and erythrocytes display abnormal morphology and 
undergo rapid hemolysis (Heilmann et al., 2007). 
Thrombocytopenia 
Decreased platelet concentrations with eclampsia were described as early as 1922 
by Stancke. The platelet count is routinely measured in women with any form of 
gestational hypertension. The frequency and intensity of thrombocytopenia vary and are 
dependent on the severity and duration of the preeclampsia syndrome and the frequency 
with which platelet counts are performed (Hupuczi et al., 2007).  
Overt thrombocytopenia—defined by a platelet count < 100,000/μL—indicates 
severe disease (Table II). In general, the lower the platelet count, the higher the rates of 
maternal and fetal morbidity and mortality. In most cases, delivery is advisable because 
thrombocytopenia usually continues to worsen. After delivery, the platelet count may 
continue to decline for the first day or so. It then usually increases progressively to reach 
a normal level within 3 to 5 days. In some instances with HELLP syndrome, the platelet 
count continues to fall after delivery. If these do not reach a nadir until 48 to 72 hours, 
then preeclampsia syndrome may be incorrectly attributed to one of the thrombotic 
microangiopathies (George et al., 2013).  
Other Platelet Abnormalities 
In addition to thrombocytopenia, there are myriad other platelet alterations 
described with the preeclampsia syndrome. These were reviewed by Kenny and 
coworkers (2014) and include platelet activation with increased α-degranulation 
producing β-thromboglobulin, factor 4, and increased clearance. Paradoxically, in most 
studies, in vitro platelet aggregation is decreased compared with the normal increase 
characteristic of pregnancy. This likely is due to platelet “exhaustion” following in vivo 
activation. Although the cause is unknown, immunological processes or simply platelet 
deposition at sites of endothelial damage may be implicated. Platelet-bound and 
circulating platelet-bindable immunoglobulins are increased, which suggest platelet 
surface alterations. 
Neonatal Thrombocytopenia 
Severe thrombocytopenia does not develop in the fetus or infant born to 
preeclamptic women despite severe maternal thrombocytopenia. Importantly, maternal 
thrombocytopenia in hypertensive women is not a fetal indication for cesarean delivery 
(Kenny et al., 2014). 
Hemolysis 
Severe preeclampsia is frequently accompanied by evidence of hemolysis as 
manifest by elevated serum lactate dehydrogenase levels and decreased haptoglobin 
levels. Other evidence comes from schizocytosis, spherocytosis, and reticulocytosis in 
peripheral blood. These derangements result in part from microangiopathic hemolysis 
caused by endothelial disruption with platelet adherence and fibrin deposition. Sanchez-
Ramos and colleagues (1994) described increased erythrocyte membrane fluidity with 
HELLP syndrome. Cunningham and coworkers (1995) postulated that these changes 
were due to serum lipid alterations, and Mackay and associates (2012) found 
substantively decreased long-chain fatty acid content in erythrocytes of pre-eclamptic 
women. Erythrocytic membrane changes, increased adhesiveness, and aggregation may 
also promote a hypercoagulable state (Gamzu et al., 2001). 
HELLP Syndrome 
Subsequent to reports of hemolysis and thrombocytopenia with severe 
preeclampsia, descriptions followed that abnormally elevated serum liver transaminase 
levels were commonly found and were indicative of hepatocellular necrosis (Chesley et 
al., 1978). Weinstein (1982) referred to this combination of events as the HELLP 
syndrome—and this moniker now is used worldwide. Also, and as shown in Table II, 
facets of the HELLP syndrome are included in criteria that differentiate severe from non-
severe preeclampsia.  
Coagulation Changes 
Subtle changes consistent with intravascular coagulation, and less often 
erythrocyte destruction, commonly are found with preeclampsia and especially eclampsia 
(Kenny et al., 2014).  
Some of these changes include increased factor VIII consumption, increased 
levels of fibrinopeptides A and B and of D-dimers, and decreased levels of regulatory 
proteins—antithrombin III and protein C and S. Except for thrombocytopenia, 
coagulation aberrations generally are mild and are seldom clinically significant (Kenny 
et al.,  2014).  
Unless there is associated placental abruption, plasma fibrinogen levels do not 
differ remarkably from levels found in normal pregnancy. Fibrin degradation products 
such as d-dimers are elevated only occasionally. Fibronectin, a glycoprotein associated 
with vascular endothelial cell basement membrane, is elevated in women with 
preeclampsia (Brubaker et al., 1992).  
As preeclampsia worsens, so do abnormal findings with thromboelastography 
(Pisani-Conway et al., 2013). Despite these changes, routine laboratory assessments of 
coagulation, including prothrombin time, activated partial thromboplastin time, and 
plasma fibrinogen level, were found to be unnecessary in the management of pregnancy-
associated hypertensive disorders (Barron et al., 1999). 
Endocrine Changes 
Plasma levels of renin, angiotensin II, angiotensin 1–7, aldosterone, and atrial 
natriuretic peptide are substantively increased during normal pregnancy. 
Deoxycorticosterone (DOC) is a potent mineralocorticoid that is also increased 
remarkably in normal pregnancy. This compound results from conversion of plasma 
progesterone to DOC rather than increased maternal adrenal secretion. Because of this, 
DOC secretion is not reduced by sodium retention or hypertension. This may explain why 
women with preeclampsia retain sodium. In pregnancy, the mineralocorticoid receptor 
becomes less sensitive to aldosterone (Armanini et al., 2012). 
Vasopressin levels are similar in non-pregnant, normally pregnant, and 
preeclamptic women even though the metabolic clearance is increased in the latter two 
(Dürr et al., 1999). Atrial natriuretic peptide is released during atrial wall stretching from 
blood volume expansion, and it responds to cardiac contractility. Serum levels rise in 
pregnancy, and its secretion is further increased in women with preeclampsia (Borghi et 
al., 2000; Luft et al., 2009). Levels of its precursor—proatrial natriuretic peptide—are 
also increased in preeclampsia (Sugulle et al., 2012). 
Fluid/ Electrolyte Changes and Volume Homeostasis 
The normal pregnancy-induced extra- and intracellular volume increases that are 
accompanied by vasodilatation undergo further complex shifts with the preeclampsia 
syndrome. In addition to blood volume changes shown in Figure 8, there are many 
hormonal, fluid, and electrolyte aberrations. In women with severe preeclampsia, the 
volume of extracellular fluid, manifest as edema is usually much greater than that in 
normal pregnant women. The mechanism responsible for pathological fluid retention is 
thought to be endothelial injury. In addition to generalized edema and proteinuria, these 
women have reduced plasma oncotic pressure. This reduction creates a filtration 
imbalance and further displaces intravascular fluid into the surrounding interstitium 
(Davidge et al., 2014). 
Electrolyte concentrations do not differ appreciably in women with preeclampsia 
compared with those of normal pregnant women. This may not be the case if there has 
been vigorous diuretic therapy, sodium restriction, or administration of free water with 
sufficient oxytocin to produce anti-diuresis. Following an eclamptic convulsion, the 
serum pH and bicarbonate concentration are lowered due to lactic acidosis and 
compensatory respiratory loss of carbon dioxide. The intensity of acidosis relates to the 
amount of lactic acid produced—metabolic acidosis—and the rate at which carbon 
dioxide is exhaled—respiratory acidosis (Davidge et al., 2014). 
Renal Changes 
During normal pregnancy, renal blood flow and glomerular filtration rate are 
increased appreciably. With development of preeclampsia, there may be a number of 
reversible anatomical and pathophysiological changes. Of clinical importance, renal 
perfusion and glomerular filtration are reduced. Levels that are much less than normal 
nonpregnant values are infrequent and are the consequence of severe disease. A small 
degree of decreased glomerular filtration may result from reduced plasma volume. Most 
of the decrement, however, is from increased renal afferent arteriolar resistance that may 
be elevated up to fivefold (Cornelis et al., 2011; Conrad et al., 2014).  
There are also morphological changes characterized by glomerular endotheliosis 
blocking the filtration barrier. Diminished filtration causes serum creatinine levels to rise 
to values seen in non-pregnant individuals, that is, 1 mg/mL, and sometimes even higher 
(Lindheimer et al., 2008a). Abnormal values usually begin to normalize 10 days or later 
after delivery. In most pre-eclamptic women, urine sodium concentration is elevated. 
Urine osmolality, urine: plasma creatinine ratio, and fractional excretion of sodium also 
indicate that a prerenal mechanism is involved (Spaan et al., 2012a). 
Kirshon and coworkers (1988) infused dopamine intravenously into oliguric 
women with preeclampsia, and this renal vasodilator stimulated increased urine output, 
fractional sodium excretion, and free water clearance. As was shown in Figure 7, 
sodium-containing crystalloid infusion increases left ventricular filling pressure, and 
although oliguria temporarily improves, rapid infusions may cause clinically apparent 
pulmonary edema. Intensive intravenous fluid therapy is not indicated as “treatment” for 
preeclamptic women with oliguria. Exceptions are diminished urine output from 
hemorrhage or fluid loss from vomiting or fever. 
Plasma uric acid concentration is typically elevated in preeclampsia. The 
elevation exceeds the reduction in glomerular filtration rate and likely is also due to 
enhanced tubular reabsorption. At the same time, preeclampsia is associated with 
diminished urinary excretion of calcium, perhaps because of increased tubular 
reabsorption. Another possibility is from increased placental urate production 
compensatory to increased oxidative stress (Spaan et al., 2012a). 
Proteinuria 
As shown in Table I, some degree of proteinuria will establish the diagnosis of 
preeclampsia syndrome. Proteinuria may develop late, and some women may already be 
delivered or have had an eclamptic convulsion before it appears. For example, 10 to 15 
percent of women with HELLP syndrome did not have proteinuria at presentation (Sibai 
et al., 2004). In another report, 17 percent of eclamptic women did not have proteinuria 
by the time of seizures (Zwart et al., 2008). Problematically, the optimal method of 
establishing abnormal levels of either urine protein or albumin remains to be defined. 
Chen and associates (2008) have shown that clean-catch and catheterized urine 
specimens correlate well. But dipstick qualitative determinations depend on urinary 
concentration and are notorious for false-positive and -negative results.  
For a 24-hour quantitative specimen, the “consensus” threshold value used is > 
300 mg/24 h (Task Force, 2013). Tun and colleagues (2012) have shown equivalent 
efficacy using protein excretion of 165 mg in a 12-hour sample. Importantly, these values 
have not been irrefutably established. Determination of urinary protein: creatinine ratio 
may supplant the cumbersome 24-hour quantification (Kyle et al., 2008; Morris et al., 
2012; Ethridge et al., 2013).  
 
In a systematic review, Papanna and associates (2008) concluded that random 
urine protein: creatinine ratios that are below 130 to 150 mg/g, that is, 0.13 to 0.15, 
indicate a low likelihood of proteinuria exceeding 300 mg/day. Midrange ratios, that is, 
300 mg/g or 0.3 have poor sensitivity and specificity. Stout and colleagues (2013) found 
that values < 0.08 or > 1.19 had negative- or positive-predictive values of 86 and 96 
percent, respectively. At this time, most recommend that with midrange ratio values, 24-
hour protein excretion should be quantified. 
There are several methods used to measure proteinuria, and none detect all of the 
various proteins normally excreted (Nayeri et al., 2013). A more accurate method 
involves measurement of albumin excretion. Albumin filtration exceeds that of larger 
globulins, and with glomerular disease such as preeclampsia, most of the protein in urine 
is albumin. There are test kits that permit rapid measurement of urinary 
albumin:creatinine ratios in an outpatient setting (Kyle et al., 2008). 
Although worsening or nephrotic-range proteinuria has been considered by most 
to be a sign of severe disease, this does not appear to be the case (Airoldi et al., 2007). 
Certainly, this concept was not accepted by the 2013 Task Force. Finally, increasing 
proteinuria is more common in multifetal pregnancy complicated by preeclampsia 
(Zilberberg et al., 2013). 
Kidney Anatomical Changes 
Sheehan and Lynch (1973) commonly found changes identifiable at autopsy by 
light and electron microscopy in the kidneys of eclamptic women. Glomeruli are enlarged 
by approximately 20 percent, they are “bloodless,” and capillary loops variably are 
dilated and contracted. Endothelial cells are swollen—termed glomerular capillary 
endotheliosis by Spargo and associates (1959). Endothelial cells are often so swollen 
that they block or partially block the capillary lumens (Figure 9). Homogeneous 
subendothelial deposits of proteins and fibrin-like material are seen. 
 
FIGURE 9. Schematic showing glomerular capillary endotheliosis. The capillary of 
the normal glomerulus shown on the left has wide endothelial fenestrations, and the 
pedicels emanating from the podocytes are widely spaced (arrow). The illustration on the 
right is of a glomerulus with changes induced by the preeclampsia syndrome. The 
endothelial cells are swollen and their fenestrae narrowed, as are the pedicels that now 
abut each other. 
Endothelial swelling may result from angiogenic factor “withdrawal” caused by 
free angiogenic proteins complexing with the circulating antiangiogenic protein receptor 
(Eremina et al., 2007; Karumanchi et al., 2009; Conrad et al., 2014).  
The angiogenic proteins are crucial for podocyte health, and their inactivation 
leads to podocyte dysfunction and endothelial swelling. One marker of this is excretion of 
podocyte proteins such as nephrin, podocalyxin, and βig-h3 (transforming growth factor, 
β-induced) (Wang et al., 2012b).  
Also, eclampsia is characterized by increased excretion of urinary podocytes, a 
phenomenon shared by other proteinuric disorders (Garrett et al., 2013). Of interest, 
podocytes are epithelia, and thus renal pathology involves both endothelial and epithelial 
cells (Figure 9) (Wagner et al., 2012). 
Acute Kidney Injury 
Rarely is acute tubular necrosis caused by preeclampsia alone. Although mild 
degrees are encountered in neglected cases, clinically apparent renal failure is invariably 
induced by coexistent hemorrhage with hypovolemia and hypotension. This is usually 
caused by severe obstetrical hemorrhage for which adequate blood replacement is not 
given. Drakeley and coworkers (2002) described 72 women with preeclampsia and 
renal failure. Half had HELLP syndrome and a third had placental abruption. Haddad 
and colleagues (2000) reported that 5 percent of 183 women with HELLP syndrome had 
kidney injury. Half of these, however, also had a placental abruption, and most had 
postpartum hemorrhage. Rarely, irreversible renal cortical necrosis develops. 
Hepatic Changes 
Hepatic changes in women with fatal eclampsia were described in 1856 by 
Virchow. The characteristic lesions were regions of periportal hemorrhage in the liver 
periphery. In their elegant autopsy studies, Sheehan and Lynch (1973) described that 
some degree of hepatic infarction accompanied hemorrhage in almost half of women who 
died with eclampsia. These corresponded with reports that had appeared during the 1960s 
describing elevated serum hepatic transaminase levels. Along with the earlier 
observations by Pritchard and associates (1954), who described hemolysis and 
thrombocytopenia with eclampsia, this constellation of hemolysis, hepatocellular 
necrosis, and thrombocytopenia was later termed HELLP syndrome by Weinstein et al., 
(1985) to call attention to its seriousness. 
Lesions as extensive as those shown in Figure 10 are unusual, even in the autopsy 
series by Sheehan and Lynch (1973). From a pragmatic point, liver involvement with 
preeclampsia may be clinically significant in several circumstances. 
 
FIGURE 10. Gross liver specimen from a woman with preeclampsia who died from 
aspiration pneumonitis. Periportal hemorrhagic necrosis was seen microscopically 
(Adapted from Cunningham et al., 1993). 
First, symptomatic involvement is considered a sign of severe disease. It typically 
manifests by moderate to severe right-upper quadrant or midepigastric pain and 
tenderness. In many cases, such women also have elevated levels of serum 
aminotransferase, namely, aspartate aminotransferase (AST) or alanine aminotransferase 
(ALT). In some cases, however, the amount of hepatic tissue involved with infarction 
may be surprisingly extensive yet still clinically insignificant. Infarction may be 
worsened by hypotension from obstetrical hemorrhage, and it occasionally causes hepatic 
failure—so-called shock liver (Alexander et al., 2009). 
Second, asymptomatic elevations of serum hepatic transaminase levels—AST and 
ALT—are also considered markers for severe preeclampsia. Values seldom exceed 500 
U/L, but have been reported to be greater than 2000 U/L in some women. In general, 
serum levels inversely follow platelet levels, and they both usually normalize within 3 
days following delivery. In a third example of liver involvement, hemorrhagic infarction 
may extend to form a hepatic hematoma. These in turn may extend to form a subcapsular 
hematoma that may rupture. They can be identified using computed tomography (CT) 
scanning or magnetic resonance (MR) imaging as shown in Figure 11. Unruptured 
hematomas are probably more common than clinically suspected and are more likely to 
be found with HELLP syndrome (Carlson et al., 2004; Vigil-De Gracia et al., 2012).  
Although once considered a surgical condition, contemporaneous management 
usually consists of observation and conservative treatment of hematomas unless 
hemorrhage is ongoing. In some cases, however, prompt surgical intervention may be 
lifesaving. Vigil-De Gracia and coworkers (2012) reviewed 180 cases of hepatic 
hematoma or rupture. More than 90 percent had HELLP syndrome, and in 90 percent, the 
capsule had ruptured. The maternal mortality rate was 22 percent, and the perinatal 
mortality rate was 31 percent. In rare cases, liver transplant is necessary (Wicke et al., 
2004). 
Lastly, acute fatty liver of pregnancy is sometimes confused with preeclampsia. It 
too has an onset in late pregnancy, and often there is accompanying hypertension, 
elevated serum transaminase and creatinine levels, and thrombocytopenia (Sibai et al., 
2007a; Nelson et al., 2013). 
 
 
FIGURE 11. Abdominal CT imaging performed postpartum in a woman with severe 
HELLP syndrome and right-upper quadrant pain. A large subcapsular hematoma 
(asterisk) is seen confluent with intrahepatic infarction and hematoma (arrowhead). 
Numerous flame-shaped hemorrhages are seen at the hematoma interface (arrows). 
HELLP Syndrome 
There is no universally accepted strict definition of this syndrome, and thus its 
incidence varies by investigator. When it is identified, the likelihood of hepatic hematoma 
and rupture is substantially increased. In a multicenter study, Haddad and colleagues 
(2000) described 183 women with HELLP syndrome of whom 40 percent had adverse 
outcomes including two maternal deaths. The incidence of subcapsular liver hematoma 
was 1.6 percent. Other complications included eclampsia—6 percent, placental 
abruption—10 percent, acute kidney injury—5 percent, and pulmonary edema—10 
percent. Other serious complications included stroke, coagulopathy, acute respiratory 
distress syndrome, and sepsis. 
Women with preeclampsia complicated by the HELLP syndrome typically have 
worse outcomes than those without these findings (Kozic et al., 2011; Martin et al., 
2012; 2013). In their review of 693 women with HELLP syndrome, Keiser and 
coworkers (2009) reported that 10 percent had concurrent eclampsia.  
Sep and associates (2009) also described a significantly increased risk for 
complications in women with HELLP syndrome compared with those with “isolated 
preeclampsia.” These included eclampsia—15 versus 4 percent; preterm birth—93 versus 
78 percent; and perinatal mortality rate—9 versus 4 percent, respectively. Because of 
these marked clinical differences, these investigators postulate that HELLP syndrome has 
a distinct pathogenesis. Others have shown a difference in the ratio of anti-angiogenic 
and inflammatory acute-phase proteins in these two conditions and have reached similar 
conclusions (Reimer et al., 2013). Sibai and Stella (2009) have discussed some of these 
aspects under the rubric of “atypical preeclampsia-eclampsia.” 
Pancreatic Changes  
According to Sheehan and Lynch (1973), there are no convincing data that the 
pancreas has special involvement with preeclampsia syndrome. If so, the occasional case 
reports of concurrent hemorrhagic pancreatitis are likely unrelated. That said, severe 
hemoconcentration may predispose to pancreatic inflammation (Swank et al., 2012). 
Neurological Changes 
Headaches and visual symptoms are common with severe preeclampsia, and 
associated convulsions define eclampsia. The earliest anatomical descriptions of brain 
involvement came from autopsy specimens, but CT- and MR-imaging and Doppler 
studies have added many important insights into cerebrovascular involvement. 
 
Neuroanatomical Lesions 
Most gross anatomical descriptions of the brain in eclamptic women are taken 
from eras when mortality rates were high. One consistent finding was that brain 
pathology accounted for only about a third of fatal cases such as the one shown in Figure 
12. In fact, most deaths were from pulmonary edema, and brain lesions were 
coincidental. Thus, although gross intracerebral hemorrhage was seen in up to 60 percent 
of eclamptic women, it was fatal in only half of these (Sheehan et al., 1973; Richards et 
al., 1988). As shown in Figure 13, other principal lesions found at autopsy of eclamptic 
women were cortical and subcortical petechial hemorrhages. The classic microscopic 
vascular lesions consist of fibrinoid necrosis of the arterial wall and perivascular 
microinfarcts and hemorrhages. Other frequently described major lesions include 
subcortical edema, multiple non-hemorrhagic areas of “softening” throughout the brain, 
and hemorrhagic areas in the white matter. There also may be hemorrhage in the basal 
ganglia or pons, often with rupture into the ventricles. 
 
FIGURE 12. This autopsy brain slice shows a fatal hypertensive hemorrhage in a 
primigravida with eclampsia. 
 
FIGURE 13. Composite illustration showing location of cerebral hemorrhages and 
petechiae in women with eclampsia. Insert shows the level of the brain from which the 
main image was constructed (Adapted from Sheehan et al., 1973). 
Cerebrovascular Pathophysiology 
Clinical, pathological, and neuroimaging findings have led to two general theories 
to explain cerebral abnormalities with eclampsia. Importantly, endothelial cell 
dysfunction that characterizes the preeclampsia syndrome likely plays a key role in both. 
The first theory suggests that in response to acute and severe hypertension, 
cerebrovascular overregulation leads to vasospasm (Trommer et al., 1988).  
This presumption is based on the angiographic appearance of diffuse or multifocal 
segmental narrowings suggestive of vasospasm. In this scheme, diminished cerebral 
blood flow is hypothesized to result in ischemia, cytotoxic edema, and eventually tissue 
infarction. Although this theory was widely embraced for many years, there is little 
objective evidence to support it. The second theory is that sudden elevations in systemic 
blood pressure exceed the normal cerebrovascular autoregulatory capacity (Schwartz et 
al., 2000).  
Regions of forced vasodilation and vasoconstriction develop, especially in arterial 
boundary zones. At the capillary level, disruption of end-capillary pressure causes 
increased hydrostatic pressure, hyperperfusion, and extravasation of plasma and red cells 
through endothelial tight-junction openings. This leads to vasogenic edema. This theory 
is incomplete because very few eclamptic women have mean arterial pressures that 
exceed limits of autoregulation—approximately 160 mm Hg. It seems reasonable to 
conclude that the most likely mechanism is a combination of the two. Thus, a 
preeclampsia-associated interendothelial cell leak develops at blood pressure (hydraulic) 
levels much lower than those usually causing vasogenic edema and is coupled with a loss 
of upper-limit autoregulation (Zeeman et al., 2009).  
With imaging studies, these changes manifest as facets of the reversible posterior 
leukoencephalopathy syndrome. This subsequently became referred to as the posterior 
reversible encephalopathy syndrome—PRES. This term is misleading because although 
PRES lesions principally involve the posterior brain—the occipital and parietal 
cortices—in at least a third of cases, they also involve other brain areas (Zeeman et al., 
2004a; Edlow et al., 2013). The most frequently affected region is the parietooccipital 
cortex—the boundary zone of the anterior, middle, and posterior cerebral arteries. Also, 
in most cases, these lesions are reversible (Cipolla et al., 2014). 
 
Cerebral Blood Flow 
Autoregulation is the mechanism by which cerebral blood flow remains relatively 
constant despite alterations in cerebral perfusion pressure. In nonpregnant individuals, 
this mechanism protects the brain from hyperperfusion when mean arterial pressures 
increase to as high as 160 mm Hg. These are pressures far greater than those seen in all 
but a very few women with eclampsia. Thus, to explain eclamptic seizures, it was 
theorized that autoregulation must be altered by pregnancy. Although species differences 
must be considered, studies by Cipolla and colleagues (2007; 2009 and 2014) have 
convincingly shown that autoregulation is unchanged across pregnancy in rodents. That 
said, some, but not others, have provided evidence of impaired autoregulation in women 
with preeclampsia (van Veen et al., 2013; Janzarik et al., 2014). 
Zeeman and associates (2003) showed that cerebral blood flow during the first 
two trimesters of normal pregnancy is similar to nonpregnant values, but thereafter, it 
significantly decreases by 20 percent during the last trimester. These investigators also 
documented significantly increased cerebral blood flow in women with severe 
preeclampsia compared with that of normotensive pregnant women. Taken together, these 
findings suggest that eclampsia occurs when cerebral hyperperfusion forces capillary 
fluid interstitially because of endothelial damage, which leads to perivascular edema 
characteristic of the preeclampsia syndrome. In this regard, eclampsia is an example of 
the posterior reversible encephalopathy syndrome (Zeeman et al., 2004b). 
Neurological Manifestations 
There are several neurological manifestations of the preeclampsia syndrome. Each 
signifies severe involvement and requires immediate attention. First, headache and 
scotomata are thought to arise from cerebrovascular hyperperfusion that has a 
predilection for the occipital lobes (Sibai, 2005). 
According to Sibai (2005) and Zwart and coworkers (2008), 50 to 75 percent of 
women have headaches and 20 to 30 percent have visual changes preceding eclamptic 
convulsions. The headaches may be mild to severe and intermittent to constant. They are 
unique in that they do not usually respond to traditional analgesia, but they do improve 
after magnesium sulfate infusion is initiated. 
Convulsions are a second potential manifestation and are diagnostic for 
eclampsia. These are caused by excessive release of excitatory neurotransmitters—
especially glutamate; massive depolarization of network neurons; and bursts of action 
potentials (Meldrum et al., 2002). Clinical and experimental evidence suggest that 
extended seizures can cause significant brain injury and later brain dysfunction. As a third 
manifestation, blindness is rare with preeclampsia alone, but it complicates eclamptic 
convulsions in up to 15 percent of women. Blindness has been reported to develop up to a 
week or more following delivery (Chambers et al., 2004). There are at least two types of 
blindness. Last, generalized cerebral edema may develop and is usually manifest by 
mental status changes that vary from confusion to coma. This situation is particularly 
dangerous because fatal transtentorial herniation may result (Chambers et al., 2004). 
Neuroimaging Studies 
With CT imaging, localized hypodense lesions at the gray- and white-matter 
junction, primarily in the parietooccipital lobes, are typically found in eclampsia. Such 
lesions may also be seen in the frontal and inferior temporal lobes, the basal ganglia, and 
thalamus. The spectrum of brain involvement is wide, and increasing involvement can be 
identified with CT imaging. Edema of the occipital lobes or diffuse cerebral edema may 
cause symptoms such as blindness, lethargy, and confusion (Cunningham et al., 2000).  
In the latter cases, widespread edema shows as a marked compression or even 
obliteration of the cerebral ventricles. Such women may develop signs of impending life-
threatening transtentorial herniation. Several MR imaging acquisitions are used to study 
eclamptic women. Common findings are hyperintense T2 lesions—posterior reversible 
encephalopathy syndrome (PRES)—in the subcortical and cortical regions of the parietal 
and occipital lobes (Figure 14). There is also relatively common involvement of the basal 
ganglia, brainstem, and cerebellum (Zeeman et al., 2004a; Brewer et al., 2013). 
Although these PRES lesions are almost universal in women with eclampsia, their 
incidence in women with preeclampsia is less frequent. They are more likely to be found 
in women who have severe disease and who have neurological symptoms (Schwartz et 
al., 2000). And although usually reversible, a fourth of these hyperintense lesions 
represent cerebral infarctions that have persistent findings (Loureiro et al., 2003; 
Zeeman et al., 2004a). 
 
FIGURE 14. Cranial magnetic resonance imaging in a nullipara with eclampsia. 
Multilobe T2-FLAIR high-signal lesions are apparent. FLAIR = fluid-attenuated 
inversion recovery (Adapted from Zeeman et al., 2004a). 
Visual Changes and Blindness 
Scotomata, blurred vision, or diplopia are common with severe preeclampsia and 
eclampsia. These usually improve with magnesium sulfate therapy and/or lowered blood 
pressure. Blindness is less common, is usually reversible, and may arise from three 
potential areas. These are the visual cortex of the occipital lobe, the lateral geniculate 
nuclei, and the retina. In the retina, pathological lesions may be ischemia, infarction, or 
detachment. Occipital blindness is also called amaurosis—from the Greek dimming. 
Affected women usually have evidence of extensive occipital lobe vasogenic edema on 
imaging studies. Of 15 women cared for at Parkland Hospital, occipital blindness lasted 
from 4 hours to 8 days, but it resolved completely in all cases. Rarely, extensive cerebral 
infarctions may result in total or partial visual defects (Figure 15) (Roos et al., 2012). 
 
FIGURE 15. Cranial magnetic resonance imaging performed 3 days postpartum in 
a woman with eclampsia and HELLP syndrome. Neurovisual defects persisted at 1 
year, causing job disability (Adapted from Murphy et al., 2005). 
Blindness from retinal lesions is caused either by serous retinal detachment or 
rarely by retinal infarction, which is termed Purtscher retinopathy (Figure 16). Serous 
retinal detachment is usually unilateral and seldom causes total visual loss. In fact, 
asymptomatic serous retinal detachment is relatively common. In most cases of 
eclampsia-associated blindness, visual acuity subsequently improves, but if caused by 
retinal artery occlusion, vision may be permanently impaired (Lara-Torre et al., 2002; 
Roos et al., 2012). In some women, these findings are additive. Moseman and Shelton 
(2002) described a woman with permanent blindness due to a combination of retinal 








FIGURE 16. Purtscher retinopathy caused by choroidal ischemia and infarction in 
preeclampsia syndrome. A. Ophthalmoscopy shows scattered yellowish, opaque lesions 
of the retina (arrows). B. The late phase of fluorescein angiography shows areas of 
intense hyperfluorescence representing pooling of extravasated dye (Adapted from Lam 
et al., 2001). 
 
Cerebral Edema 
Clinical manifestations suggesting widespread cerebral edema are worrisome. 
During 13 years at Parkland Hospital, 10 of 175 women with eclampsia were diagnosed 
with symptomatic cerebral edema. Symptoms ranged from lethargy, confusion, and 
blurred vision to obtundation and coma. In most cases, symptoms waxed and waned. 
Mental status changes generally correlated with the degree of involvement seen with CT 
and MR imaging studies. These women are very susceptible to sudden and severe blood 
pressure elevations, which can acutely worsen the already widespread vasogenic edema. 
Thus, careful blood pressure control is essential. In the 10 women with generalized 
edema, three became comatose and had imaging findings of impending transtentorial 
herniation. One of these three died from herniation. Consideration is given for treatment 
with mannitol or dexamethasone (Cunningham et al., 2000). 
Uteroplacental Perfusion 
Of immense clinical importance, compromised uteroplacental perfusion is almost 
certainly a major culprit in the increased perinatal morbidity and mortality rates. Thus, 
measurement of uterine, intervillous, and placental blood flow would likely be 
informative. Attempts to assess these in humans have been hampered by several obstacles 
that include inaccessibility of the placenta, the complexity of its venous effluent, and the 
need for radioisotopes or invasive techniques. Measurement of uterine artery blood flow 
velocity has been used to estimate resistance to uteroplacental blood flow. Vascular 
resistance is estimated by comparing arterial systolic and diastolic velocity waveforms. 
By the completion of placentation, impedance to uterine artery blood flow is markedly 
decreased, but with abnormal placentation, abnormally high resistance persists (Ghidini 
et al., 2008; Everett et al., 2012; Napolitano et al., 2012).  
Earlier studies were done to assess this by measuring peak systolic:diastolic 
velocity ratios from uterine and umbilical arteries in preeclamptic pregnancies. The 
results were interpreted as showing that in some cases, but certainly not all, there was 
increased resistance. Another Doppler waveform—uterine artery “notching”—has been 
reported to be associated with increased risks for preeclampsia or fetal-growth restriction 
(Groom et al., 2009). In the MFMU Network study reported by Myatt and colleagues 
(2012a), however, notching had a low predictive value except for early-onset severe 
disease. 
Matijevic and Johnson (1999) measured resistance in uterine spiral arteries. 
Impedance was higher in peripheral than in central vessels—a so-called ring-like 
distribution. Mean resistance was higher in all women with preeclampsia compared with 
that in normotensive controls. Ong and associates (2003) used MR imaging and other 
techniques to assess placental perfusion ex vivo in the myometrial arteries removed from 
women with preeclampsia or fetal-growth restriction. These investigators confirmed that 
in both conditions myometrial arteries exhibited endothelium-dependent vasodilatory 
response. Moreover, other pregnancy conditions are also associated with increased 
resistance. One major adverse effect is fetal-growth restriction (Urban et al., 2007).  
Pimenta and colleagues (2013) assessed placental vascularity using a three-
dimensional power Doppler histogram. These researchers described the placental 
vascularity index, which was decreased in women with any pregnancy-associated 
hypertensive disorders—11.1 percent compared with 15.2 percent in normal controls. 
Despite these findings, evidence for compromised uteroplacental circulation is 
found in only a few women who go on to develop preeclampsia. Indeed, when 
preeclampsia develops during the third trimester, only a third of women with severe 
disease have abnormal uterine artery velocimetry (Li et al., 2005).  
In a study of 50 women with HELLP syndrome, only a third had abnormal uterine 
artery waveforms (Bush et al., 2001). In general, the extent of abnormal waveforms 
correlates with severity of fetal involvement (Ghidini et al., 2008; Groom et al., 2009). 
PREDICTION AND PREVENTION 
PREDICTION 
Measurement during early pregnancy—or across pregnancy—of various 
biological, biochemical, and biophysical markers implicated in preeclampsia syndrome 
pathophysiology has been proposed to predict its development. Attempts have been made 
to identify early markers of faulty placentation, impaired placental perfusion, endothelial 
cell activation and dysfunction, and activation of coagulation. For the most, these have 
resulted in testing strategies with poor sensitivity and with poor positive-predictive value 
for preeclampsia (Lindheimer et al., 2008b; Odibo et al., 2013; Conde-Agudelo et al., 
2014). Currently, no screening tests are predictably reliable, valid, and economical 
(Kleinrouweler et al., 2012). There are, however, combinations of tests, some yet to be 
adequately evaluated, that may be promising (Kuc et al., 2011; Olsen et al., 2012; 
Dugoff et al., 2013; Navaratnam et al., 2013). 
The list of predictive factors evaluated during the past three decades is legion. 
Although most have been evaluated in the first half of pregnancy, some have been tested 
as predictors of severity in the third trimester (Rana et al., 2012; Chaiworapongsa et 
al., 2013; Mosimann et al., 2013). Others have been used to forecast recurrent 
preeclampsia (Demers et al., 2014). Some of these tests are listed in Table V, which is by 
no means all inclusive. Conde-Agudelo and coworkers (2014) have recently provided a 
thorough review of many of these testing strategies. 
 










Vascular Resistance Testing and Placental Perfusion: 
Most of these are cumbersome, time consuming, and overall inaccurate. 
Provocative Pressor Tests 
Three tests have been extensively evaluated to assess the blood pressure rise in 
response to a stimulus. The roll-over test measures the hypertensive response in women 
at 28 to 32 weeks who are resting in the left lateral decubitus position and then roll over 
to the supine position. Increased blood pressure signifies a positive test. The isometric 
exercise test employs the same principle by squeezing a handball (Rana et al., 2012). 
The angiotensin II infusion test is performed by giving incrementally increasing 
doses intravenously, and the hypertensive response is quantified. In their updated meta-
analysis, Conde-Agudelo and associates (2014) found sensitivities of all three tests to 
range from 55 to 70 percent, and specificities approximated 85 percent. 
Uterine Artery Doppler Velocimetry  
Faulty trophoblastic invasion of the spiral arteries, which is depicted in Figure 2, 
results in diminished placental perfusion and upstream increased uterine artery resistance. 
Increased uterine artery velocimetry determined by Doppler ultrasound in the first two 
trimesters should provide indirect evidence of this process and thus serve as a predictive 
test for preeclampsia (Gebb et al., 2009a; 2009b; Groom et al., 2009).  
Increased flow resistance results in an abnormal waveform represented by an 
exaggerated diastolic notch. These have value for fetal-growth restriction but not 
preeclampsia (American College of Obstetricians and Gynecologists, 2013a). Several 
flow velocity waveforms—alone or in combination—have been investigated for 
preeclampsia prediction. In some of these, predictive values for early-onset preeclampsia 
were promising (Herraiz et al., 2012). At this time, however, none is suitable for clinical 
use (Kleinrouweler et al., 2012; Myatt et al., 2012a; Conde-Agudelo et al., 2014). 
Pulse Wave Analysis  
Like the uterine artery, finger arterial pulse “stiffness” is an indicator of 
cardiovascular risk. Investigators have preliminarily evaluated its usefulness in 
preeclampsia prediction (Vollebregt et al., 2009). 
 
 
Fetal-Placental Unit Endocrine Function 
Several serum analyses that have been proposed to help predict preeclampsia. 
Newer ones are continuously added. Many of these gained widespread use in the 1980s to 
identify fetal malformations and were also found to be associated with other pregnancy 
abnormalities such as neural-tube defects and aneuploidy. Although touted for 
hypertension prediction, in general, none of these tests has been shown to be clinically 
beneficial for that purpose (Kanasaki et al., 2008; Kenny et al., 2009; Jeyabalan et al., 
2009). 
Tests of Renal Function 
Serum Uric Acid 
One of the earliest laboratory manifestations of preeclampsia is hyperuricemia 
(Powers et al., 2006). It likely results from reduced uric acid clearance from diminished 
glomerular filtration, increased tubular reabsorption, and decreased secretion 
(Lindheimer et al., 2008a). It is used by some to define preeclampsia, but Cnossen and 
coworkers (2006) reported that its sensitivity ranged from 0 to 55 percent, and specificity 
was 77 to 95 percent. 
Microalbuminuria 
As a predictive test for preeclampsia, microalbuminuria has sensitivities ranging 
from 7 to 90 percent and specificities between 29 and 97 percent (Conde-Agudelo, 2014). 
Poon and colleagues (2008) likewise found unacceptable sensitivity and specificity for 
urine albumin:creatinine ratios. 
 
 
Endothelial Dysfunction and Oxidant Stress 
Endothelial activation and inflammation are major participants in the 
pathophysiology of the preeclampsia syndrome. As a result, compounds such as those are 
found in circulating blood of affected women, and some have been assessed for their 
predictive value. 
Fibronectins 
These high-molecular-weight glycoproteins are released from endothelial cells 
and extracellular matrix following endothelial injury (Chavarria et al., 2002). More than 
30 years ago, plasma concentrations were reported to be elevated in women with 
preeclampsia. Following their systematic review, however, Leeflang and associates 
(2007) concluded that neither cellular nor total fibronectin levels were clinically useful to 
predict preeclampsia. 
Coagulation Activation 
Thrombocytopenia and platelet dysfunction are integral features of preeclampsia. 
Platelet activation causes increased destruction and decreased concentrations, and mean 
platelet volume rises because of platelet immaturity. Although markers of coagulation 
activation are increased, the substantive overlap with levels in normotensive pregnant 
women stultifies their predictive value (Kenny et al., 2014). 
Oxidative Stress 
Increased levels of lipid peroxides coupled with decreased antioxidant activity 
have raised the possibility that markers of oxidative stress might predict preeclampsia. 
For example, malondialdehyde is a marker of lipid peroxidation. Other markers are 
various prooxidants or their potentiators.  
These include iron, transferrin, and ferritin; blood lipids, including triglycerides, 
free fatty acids, and lipoproteins; and antioxidants such as ascorbic acid and vitamin E 
(Powers et al., 2000; Bainbridge et al., 2005; Mackay et al., 2012). These have not 
been found to be predictive, and treatment to prevent preeclampsia with some of them 
has been studied (Conde-Agudelo et al., 2014). 
Hyperhomocysteinemia causes oxidative stress and endothelial cell dysfunction 
and is characteristic of preeclampsia. Although women with elevated serum 
homocysteine levels at mid-pregnancy had a three- to fourfold risk of preeclampsia, these 
tests have not been shown to be clinically useful predictors (Zeeman et al., 2003; 
D’Anna et al., 2004; Mignini et al., 2005). 
Angiogenic Factors 
Evidence has accrued that an imbalance between proangiogenic and 
antiangiogenic factors is related to preeclampsia pathogenesis. Serum levels of some 
proangiogenic factors—vascular endothelial growth factor (VEGF) and placental growth 
factor (PlGF)—begin to decrease before clinical preeclampsia develops. And, recall as 
shown in Figure 4 that at the same time levels of some antiangiogenic factors such as 
sFlt-1 and sEng become increased (Maynard et al., 2008). In one study, these 
abnormalities were identified coincidentally with rising uterine artery Doppler resistance 
(Coolman et al., 2012). 
Conde-Agudelo and colleagues (2014) reviewed the predictive accuracy of some 
of these factors for severe preeclampsia. Sensitivities for all cases of preeclampsia ranged 
from 30 to 50 percent, and specificity was about 90 percent. Their predictive accuracy 
was higher for early-onset preeclampsia. These preliminary results suggest a clinical role 
for preeclampsia prediction.  
However, until this role is better substantiated, their general clinical use is not 
currently recommended (Boucoiran et al., 2013; Kleinrouweler et al., 2012; Widmer 
et al., 2007). Automated assays are being studied, and the World Health Organization 
(WHO) began a multicenter trial in 2008 to evaluate these factors (Sunderji et al., 2009). 
Cell-Free Fetal DNA 
Cell-free fetal DNA can be detected in maternal plasma. It has been reported that 
fetal-maternal cell trafficking is increased in pregnancies complicated by preeclampsia. It 
is hypothesized that cell-free DNA is released by accelerated apoptosis of 
cytotrophoblasts. From their review, Conde-Agudelo and associates (2014) concluded 
that cell-free fetal DNA quantification is not yet useful for prediction purposes. 
Proteomic, Metabolomic, and Transcriptomic Markers 
Methods to study serum and urinary proteins and cellular metabolites have 
opened a new vista for preeclampsia prediction. Preliminary studies indicate that these 
may become useful (Bahado-Singh et al., 2013; Carty et al., 2011; Liu et al., 2013; 
Myers et al., 2013). 
PREVENTION 
Various strategies used to prevent or modify preeclampsia severity have been 
evaluated. Some are listed in Table VI. In general, none of these has been found to be 
convincingly and reproducibly effective. 
 
 
TABLE VI. Some Methods to Prevent Preeclampsia That Have Been Evaluated in 
Randomized Trials: 
Dietary manipulation— Calcium or fish oil Low-salt diet  
supplementation 




Cardiovascular drugs— Anti-hypertensive drugs Diuretics   








Modified from Staff et al. 2014. 
Dietary and Lifestyle Modifications 
A favorite of many theorists and faddists for centuries, dietary “treatment” for 
preeclampsia has produced some interesting abuses as chronicled by Chesley (1978). 
Low-Salt Diet. One of the earliest research efforts to prevent preeclampsia was salt 
restriction (De Snoo et al., 1937). This interdiction was followed by years of 
inappropriate diuretic therapy. Although these practices were discarded, it ironically was 
not until relatively recently that the first randomized trial was done and showed that a 
sodium-restricted diet was ineffective in preventing preeclampsia in 361 women (Knuist 
et al., 1998). Guidelines from the United Kingdom National Institute for Health and 
Clinical Excellence (2010) recommend against salt restrictions. 
 
Calcium Supplementation 
Studies performed in the 1980s outside the United States showed that women with 
low dietary calcium intake were at significantly increased risk for gestational 
hypertension. Calcium supplementation has been studied in several trials, including one 
by the National Institute of Child Health and Human Development (NICHD) that 
included more than 4500 nulliparous women (Levine et al., 1997). In one recent meta-
analysis, Patrelli and coworkers (2012) reported that increased calcium intake lowered 
the risk for preeclampsia in high-risk women. In aggregate, most of these trials have 
shown that unless women are calcium deficient, supplementation has no salutary effects 
(Staff et al., 2014). 
Fish Oil Supplementation  
Cardioprotective fatty acids found in some fatty fishes are plentiful in diets of 
Scandinavians and American Eskimos. The most common dietary sources are EPA—
eicosapentaenoic acid, ALA—alpha-linoleic acid, and DHA—docosahexaenoic acid. 
With proclamations that supplementation with these fatty acids would prevent 
inflammatory-mediated atherogenesis, it was not a quantum leap to posit that they might 
also prevent preeclampsia. Unfortunately, randomized trials conducted thus far have 
shown no such benefits (Olsen et al., 2000; Makrides et al., 2006; Olafsdottir et al., 
2006; Zhou et al., 2012a). 
Exercise 
There are a few studies done to assess the protective effects of physical activity on 
preeclampsia. In their systematic review, Kasawara and associates (2012) reported a 
trend toward risk reduction with exercise. More research is needed in this area (Staff et 
al., 2014). 
Anti-hypertensive Drugs 
Because of the putative effects of sodium restriction, diuretic therapy became 
popular with the introduction of chlorothiazide. In their meta-analysis, Churchill and 
colleagues (2007) summarized nine randomized trials that included more than 7000 
pregnancies. They found that women given diuretics had a decreased incidence of edema 
and hypertension but not of preeclampsia. Because women with chronic hypertension are 
at high risk for preeclampsia, several randomized trials—only a few placebo-controlled—
have been done to evaluate various antihypertensive drugs to reduce the incidence of 
superimposed preeclampsia. A critical analysis of these trials by Staff and coworkers 
(2014) failed to demonstrate salutary effects. 
Anti-oxidants 
There are inferential data that an imbalance between oxidant and antioxidant 
activity may play an important role in the pathogenesis of preeclampsia. Thus, naturally 
occurring antioxidants—vitamins C, D, and E—might decrease such oxidation. Indeed, 
women who developed preeclampsia were found to have reduced plasma levels of these 
antioxidants (Raijmakers et al., 2004; De-Regil et al., 2012).  
There have now been several randomized studies to evaluate vitamin 
supplementation for women at high risk for preeclampsia (Poston et al., 2006; Rumbold 
et al., 2006; Villar et al., 2007). The one by the MFMU Network included almost 10,000 
low-risk nulliparas (Roberts et al., 2009). None of these studies showed reduced 
preeclampsia rates in women given vitamins C and E compared with those given placebo. 
The recent meta-analysis by De-Regil and colleagues (2012) likewise showed no 
benefits of vitamin D supplementation. 
 
The rationale for the use of statins to prevent preeclampsia is that they stimulate 
hemoxygenase-1 expression that inhibits sFlt-1 release. There are preliminary animal data 
that statins may prevent hypertensive disorders of pregnancy. The MFMU Network plans 
a randomized trial to test pravastatin for this purpose (Costantine et al., 2013). 
Anti-thrombotic Agents 
There are sound theoretical reasons that antithrombotic agents might reduce the 
incidence of preeclampsia. The syndrome is characterized by vasospasm, endothelial cell 
dysfunction, and inflammation, as well as activation of platelets and the coagulation-
hemostasis system. Moreover, prostaglandin imbalance(s) may be operative, and other 
sequelae include placental infarction and spiral artery thrombosis (Nelson et al., 2014). 
Low-Dose Aspirin 
In oral doses of 50 to 150 mg daily, aspirin effectively inhibits platelet 
thromboxane A2 biosynthesis but has minimal effects on vascular prostacyclin 
production. However, clinical trials have shown limited benefits. For example, results in 
Table VII are from the MFMU Network, and none of the outcomes shown were 
significantly improved. Some reports are more favorable. For example, the Paris 
Collaborative Group performed a meta-analysis that included 31 randomized trials 
involving 32,217 women (Askie et al., 2007).  
For women assigned to receive anti-platelet agents, the relative risk for 
development of preeclampsia, superimposed preeclampsia, preterm delivery, or any 
adverse pregnancy outcome was significantly decreased by 10 percent. Another review 
and meta-analysis reported marginal benefits for low-dose aspirin and severe 
preeclampsia (Roberge et al., 2012).  
A recent small Finnish multicenter trial included 152 women at high risk for 
preeclampsia (Villa et al., 2013). Although there were no benefits to low-dose aspirin, 
the accompanying meta-analysis reported a lowering of risk. The 2013 Task Force 
recommended the use of low-dose aspirin in some high-risk women to prevent 
preeclampsia. 
TABLE VII. Maternal-Fetal Medicine Units Network Trial of Low-Dose Aspirin in 
Women at High Risk for Preeclampsia: 
 
Low-Dose Aspirin plus Heparin 
In women with lupus anticoagulant, treatment with low-dose aspirin and heparin 
mitigates thrombotic sequelae. Because of the high prevalence of placental thrombotic 
lesions found with severe preeclampsia, observational trials have been done to evaluate 
such treatments for affected women (Staff et al., 2014).  
 
Sergis and associates (2006) reviewed effects of prophylaxis with low-
molecular-weight heparin plus low-dose aspirin on pregnancy outcomes in women with a 
history of severe early-onset preeclampsia and low-birth weight neonates. They reported 
better pregnancy outcomes in women given low-molecular-weight heparin plus low-dose 
aspirin compared with those given low-dose aspirin alone. Similar findings were reported 
in a trial that included 139 women with thrombophilia and a history of early-onset 
preeclampsia (de Vries et al., 2012). Despite these small trials, evidence is insufficient to 
recommend these regimens to prevent preeclampsia (National Institute for Health and 
Clinical Excellence, 2010). 
MANAGEMENT 
Pregnancy complicated by gestational hypertension is managed based on severity, 
gestational age, and presence of preeclampsia. With preeclampsia, management varies 
with the severity of endothelial cell injury and multi-organ dysfunction. Preeclampsia 
cannot always be diagnosed definitively. Thus, the Task Force of the American College 
of Obstetricians and Gynecologists (2013b) recommends more frequent prenatal visits 
if preeclampsia is “suspected.” Increases in systolic and diastolic blood pressure can be 
either normal physiological changes or signs of developing pathology. Increased 
surveillance permits more prompt recognition of ominous changes in blood pressure, 
critical laboratory findings, and clinical signs and symptoms. 
The basic management objectives for any pregnancy complicated by preeclampsia 
are: (1) termination of pregnancy with the least possible trauma to mother and fetus, (2) 
birth of an infant who subsequently thrives, and (3) complete restoration of health to the 
mother. In many women with preeclampsia, especially those at or near term, all three 
objectives are served equally well by induction of labor. One of the most important 
clinical questions for successful management is precise knowledge of fetal age 
(Macdonald-Wallis et al., 2012). 
Early Diagnosis of Preeclampsia 
Traditionally, the frequency of prenatal visits is increased during the third 
trimester, and this aids early detection of preeclampsia. Women without overt 
hypertension, but in whom early developing preeclampsia is suspected during routine 
prenatal visits, are seen more frequently. The protocol used successfully for many years at 
Parkland Hospital for women with new-onset diastolic blood pressures > 80 mm Hg but 
< 90 mm Hg or with sudden abnormal weight gain of more than 2 pounds per week 
includes, at minimum, return visits at 7-day intervals. Outpatient surveillance is 
continued unless overt hypertension, proteinuria, headache, visual disturbances, or 
epigastric discomfort supervene. Women with overt new-onset hypertension—either 
diastolic pressures ≥ 90 mm Hg or systolic pressures ≥ 140 mm Hg—are admitted to 
determine if the increase is due to preeclampsia, and if so, to evaluate its severity. Women 
with persistent severe disease are generally delivered. Conversely, women with 
apparently mild disease can often be managed as outpatients, although there should be a 
low threshold for continued hospitalization for the nullipara, especially if there is 
proteinuria (Conde-Agudelo et al., 2014). 
Evaluation 
Hospitalization is considered at least initially for women with new-onset 
hypertension, especially if there is persistent or worsening hypertension or development 
of proteinuria. A systematic evaluation is instituted to include the following (Macdonald-
Wallis et al., 2012): 
 Detailed examination, which is followed by daily scrutiny for clinical findings 
such as headache, visual disturbances, epigastric pain, and rapid weight gain 
 Weight determined daily. 
 Analysis for proteinuria or urine protein: creatinine ratio on admittance and at 
least every 2 days thereafter. 
 Blood pressure readings in the sitting position with an appropriate-size cuff every 
4 hours, except between 2400 and 0600 unless previous readings had become 
elevated (Cnossen et al., 2006). 
 Measurements of plasma or serum creatinine and hepatic aminotransferase levels 
and a hemogram that includes platelet quantification. The frequency of testing is 
determined by hypertension severity. Some recommend measurement of serum 
uric acid and lactic acid dehydrogenase levels and coagulation studies. However, 
the value of these tests has been called into question (Thangaratinam et al., 
2006). 
 Evaluation of fetal size and well-being and amnionic fluid volume, with either 
physical examination or sonography (Conde-Agudelo et al., 2014). 
Goals of management include early identification of worsening preeclampsia and 
development of a management plan for timely delivery. If any of these observations lead 
to a diagnosis of severe preeclampsia as previously defined by the criteria in Table II, 
further management is subsequently described. Reduced physical activity throughout 
much of the day is likely beneficial, but as the 2013 Task Force concluded, absolute bed 
rest is not desirable. Ample protein and calories should be included in the diet, and 
sodium and fluid intake should not be limited or forced. Further management depends on: 
(1) preeclampsia severity, (2) gestational age, and (3) condition of the cervix. Fortunately, 
many cases are sufficiently mild and near enough to term that they can be managed 
conservatively until labor commences spontaneously or until the cervix becomes 
favorable for labor induction. Complete abatement of all signs and symptoms, however, 
is uncommon until after delivery. Almost certainly, the underlying disease persists until 
delivery is accomplished (Conde-Agudelo et al., 2014). 
 
Consideration for Delivery 
Termination of pregnancy is the only cure for preeclampsia. Headache, visual 
disturbances, or epigastric pain are indicative that convulsions may be imminent, and 
oliguria is another ominous sign. Severe preeclampsia demands anticonvulsant and 
frequently antihypertensive therapy, followed by delivery. Treatment is identical to that 
described subsequently for eclampsia. The prime objectives are to forestall convulsions, 
to prevent intracranial hemorrhage and serious damage to other vital organs, and to 
deliver a healthy newborn. When the fetus is preterm, the tendency is to temporize in the 
hope that a few more weeks in utero will reduce the risk of neonatal death or serious 
morbidity from prematurity. Such a policy certainly is justified in milder cases. 
Assessments of fetal well-being and placental function are performed, especially when 
the fetus is immature. Most recommend frequent performance of various tests to assess 
fetal well-being as described by the American College of Obstetricians and 
Gynecologists (2012a). These include the nonstress test or the biophysical profile. 
Measurement of the lecithin-sphingomyelin (L/S) ratio in amnionic fluid may provide 
evidence of lung maturity. 
With moderate or severe preeclampsia that does not improve after hospitalization, 
delivery is usually advisable for the welfare of both mother and fetus. This is true even 
when the cervix is unfavorable (Tajik et al., 2012).  
Labor induction is carried out, usually with preinduction cervical ripening from a 
prostaglandin or osmotic dilator. Whenever it appears that induction almost certainly will 
not succeed or attempts have failed, then cesarean delivery is indicated. For a woman 
near term, with a soft, partially effaced cervix, even milder degrees of preeclampsia 
probably carry more risk to the mother and her fetus-infant than does induction of labor 
(Tajik et al., 2012).  
The decision to deliver late-preterm fetuses is not clear. Barton and coworkers 
(2009) reported excessive neonatal morbidity in women delivered before 38 weeks 
despite having stable, mild, non-proteinuric hypertension. The Netherlands study of 4316 
newborns delivered between 340/7 and 366/7 weeks also described substantive neonatal 
morbidity in these cases (Langenveld et al., 2011). Most of these deliveries were before 
36 weeks, and the higher cesarean delivery rates were associated with more respiratory 
complications. Conversely, one randomized trial of 756 women with mild preeclampsia 
supported delivery after 37 weeks (Koopmans et al., 2009). 
Elective Cesarean Delivery 
Once severe preeclampsia is diagnosed, labor induction and vaginal delivery have 
traditionally been considered ideal. Temporization with an immature fetus is considered 
subsequently. Several concerns, including an unfavorable cervix, a perceived sense of 
urgency because of preeclampsia severity, and a need to coordinate neonatal intensive 
care, have led some to advocate cesarean delivery. Alexander and colleagues (1999) 
reviewed 278 singleton liveborn neonates weighing 750 to 1500 g delivered of women 
with severe preeclampsia at Parkland Hospital. In half of the women, labor was induced, 
and the remainder underwent cesarean delivery without labor. Induction was successful in 
accomplishing vaginal delivery in a third, and it was not harmful to the very- low-
birthweight infants. Alanis and associates (2008) reported similar observations. The 
results of a systematic review also confirmed these conclusions (Le Ray et al., 2009). 
Hospitalization versus Outpatient Management 
For women with mild to moderate stable hypertension—whether or not 
preeclampsia has been confirmed—surveillance is continued in the hospital, at home for 
some reliable patients, or in a day-care unit. At least intuitively, reduced physical activity 
throughout much of the day seems beneficial.  
Several observational studies and randomized trials have addressed the benefits of 
inpatient care and outpatient management. Somewhat related, Abenhaim and coworkers 
(2008) reported a retrospective cohort study of 677 non-hypertensive women hospitalized 
for bed rest because of threatened preterm delivery. When outcomes of these women 
were compared with those of the general obstetrical population, bed rest was associated 
with a significantly reduced relative risk—RR 0.27—of developing preeclampsia.  
In a review of two small randomized trials totaling 106 women at high risk for 
preeclampsia, prophylactic bed rest for 4 to 6 hours daily at home was successful in 
significantly lowering the incidence of preeclampsia but not gestational hypertension 
(Meher et al., 2006). 
These and other observations support the claim that restricted activity alters the 
underlying pathophysiology of the preeclampsia syndrome. That said, complete bed rest 
is not recommended by the 2013 Task Force. First, this is pragmatically unachievable 
because of the severe restrictions it places on otherwise well women. Also, it likely also 
predisposes to thromboembolism (Knight et al., 2007). 
High-Risk Pregnancy Unit 
Most hospitalized women have a beneficial response characterized by 
amelioration or improvement of hypertension. These women are not “cured,” and nearly 
90 percent have recurrent hypertension before or during labor. By 2013, more than 
10,000 nulliparas with mild to moderate early-onset hypertension during pregnancy had 
been managed successfully in this unit. Provider costs—not charges—for this relatively 
simple physical facility, modest nursing care, no drugs other than iron and folate 
supplements, and few essential laboratory tests are minimal compared with the cost of 
neonatal intensive care for a preterm infant. None of these women have suffered 
thromboembolic disease. 
Home Health Care 
Many clinicians believe that further hospitalization is not warranted if 
hypertension abates within a few days, and this has legitimized third-party payers to deny 
hospitalization reimbursement. Consequently, many women with mild to moderate 
hypertension are managed at home. Outpatient management may continue as long as 
preeclampsia syndrome does not worsen and fetal jeopardy is not suspected. Sedentary 
activity throughout the greater part of the day is recommended. These women are 
instructed in detail to report symptoms. Home blood pressure and urine protein 
monitoring or frequent evaluations by a visiting nurse may prove beneficial. Caution is 
exercised regarding use of certain automated home blood pressure monitors (Lo et al., 
2002; Ostchega et al., 2012). 
In an observational study by Barton and associates (2002), 1182 nulliparas with 
mild gestational hypertension—20 percent had proteinuria—were managed with home 
health care. Their mean gestational ages were 32 to 33 weeks at enrollment and 36 to 37 
weeks at delivery. Severe preeclampsia developed in approximately 20 percent, about 3 
percent developed HELLP syndrome, and two women had eclampsia. Perinatal outcomes 
were generally good. In approximately 20 percent, there was fetal-growth restriction, and 
the perinatal mortality rate was 4.2 per 1000. 
Several prospective studies have been designed to compare continued 
hospitalization with either home health care or a day-care unit. In a pilot study from 
Parkland Hospital, Horsager and colleagues (1995) randomly assigned 72 nulliparas 
with new-onset hypertension from 27 to 37 weeks either to continued hospitalization or 
to outpatient care. In all of these women, proteinuria had receded to less than 500 mg per 
day when they were randomized. Outpatient management included daily blood pressure 
monitoring by the patient or her family. Weight and dipstick spot urine protein 
determinations were evaluated three times weekly.  
A home health nurse visited twice weekly, and the women were seen weekly in 
the clinic. Perinatal outcomes were similar in each group. The only significant difference 
was that women in the home care group developed severe preeclampsia significantly 
more frequently than hospitalized women—42 versus 25 percent. A larger randomized 
trial reported by Crowther and coworkers (1992) included 218 women with mild 
gestational non-proteinuric hypertension. After evaluation, half remained hospitalized, 
whereas the other half was managed as outpatients. As shown in Table VIII, the mean 
duration of hospitalization was 22.2 days for women with inpatient management 
compared with only 6.5 days in the home-care group. Preterm delivery before 34 and 
before 37 weeks was increased twofold in the outpatient group, but maternal and infant 
outcomes otherwise were similar. 
TABLE VIII. Randomized Clinical Trials Comparing Hospitalization versus 









Another approach, popular in European countries, is day care (Milne et al., 
2009). This approach has been evaluated by several investigators. In the study by 
Tuffnell and associates (1992), 54 women with hypertension after 26 weeks’ gestation 
were assigned to either day care or routine outpatient management (Table VIII). 
Progression to overt preeclampsia and labor inductions were significantly increased in the 
routine management group. Turnbull and coworkers (2004) enrolled 395 women who 
were randomly assigned to either day care or inpatient management (Table VIII). Almost 
95 percent had mild to moderate hypertension. Of enrolled women, 288 were without 
proteinuria, and 86 had ≥ 1+ proteinuria. There were no perinatal deaths, and none of the 
women developed eclampsia or HELLP syndrome. Surprisingly, costs for either scheme 
were not significantly different. Perhaps not surprisingly, general satisfaction favored day 
care. 
Anti-hypertensive Therapy for Mild to Moderate Hypertension 
The use of antihypertensive drugs in attempts to prolong pregnancy or modify 
perinatal outcomes in pregnancies complicated by various types and severities of 
hypertensive disorders has been of considerable interest. Drug treatment for early mild 
preeclampsia has been disappointing as shown in representative randomized trials listed 
in Table IX. Sibai and colleagues (1987a) evaluated the effectiveness of labetalol and 
hospitalization compared with hospitalization alone in 200 nulliparas with gestational 
hypertension from 26 to 35 weeks’ gestation. Although women given labetalol had 
significantly lower mean blood pressures, there were no differences between the groups 
in terms of mean pregnancy prolongation, gestational age at delivery, or birthweight. The 
cesarean delivery rates were similar, as were the number of infants admitted to special-
care nurseries. The frequency of growth-restricted infants was doubled in women given 
labetalol—19 versus 9 percent.  
The three other studies listed in Table IX were performed to compare labetalol or 
the calcium-channel blockers, nifedipine and isradipine, with placebo. Except for fewer 
episodes of severe hypertension, none of these studies showed any benefits of 
antihypertensive treatment. Moreover, there may have been treatment-induced adverse 
fetal growth (Von Dadelszen et al., 2002). 
TABLE IX. Randomized Placebo-Controlled Trials of Antihypertensive Therapy for 












Abalos and associates (2007) reviewed 46 randomized trials of active 
antihypertensive therapy compared with either no treatment or placebo given to women 
with mild to moderate gestational hypertension. Except for a halving of the risk for 
developing severe hypertension, active antihypertensive therapy had no beneficial effects. 
They further reported that fetal-growth restriction was not increased in treated women. In 
this vein, it is also controversial whether β-blocking agents cause fetal-growth restriction 
if given for chronic hypertension. Thus, any salutary or adverse effects of 
antihypertensive therapy seem minimal at most (August et al., 2014; Umans et al., 
2014). 
Delayed Delivery 
Up through the early 1990s, it was the practice that all women with severe 
preeclampsia were delivered without delay. During the past 25 years, however, another 
approach for women with preterm severe preeclampsia has been advocated. This 
approach calls for “conservative” or “expectant” management with the aim of improving 
neonatal outcome without compromising maternal safety. Aspects of such management 
always include careful daily—and usually more frequent—inpatient monitoring of the 
mother and her fetus. 
Expectant Management of Preterm Severe Preeclampsia 
Theoretically, antihypertensive therapy has potential application when severe 
preeclampsia develops before intact neonatal survival is likely. Such management is 
controversial, and it may be dangerous. In one of the first studies, Sibai and the 
Memphis group (1985) attempted to prolong pregnancy because of fetal immaturity in 
60 women with severe preeclampsia between 18 and 27 weeks. The results were 
disastrous.  
The perinatal mortality rate was 87 percent. Although no mothers died, 13 
suffered placental abruption, 10 had eclampsia, three developed renal failure, two had 
hypertensive encephalopathy, and one each had an intracerebral hemorrhage and a 
ruptured hepatic hematoma. Because of these catastrophic outcomes, the Memphis group 
redefined their study criteria and performed a randomized trial of expectant versus 
aggressive management for 95 women who had severe preeclampsia but with more 
advanced gestations of 28 to 32 weeks (Sibai et al., 1994).  
Women with HELLP syndrome were excluded from this trial. Aggressive 
management included glucocorticoid administration for fetal lung maturation followed by 
delivery in 48 hours. Expectantly managed women were observed at bed rest and given 
either labetalol or nifedipine orally if there was severe hypertension. In this study, 
pregnancy was prolonged for a mean of 15.4 days in the expectant management group. 
An overall improvement in neonatal outcomes was also reported. Following these 
experiences, expectant management became more commonly practiced, but with the 
caveat that women with HELLP syndrome or growth-restricted fetuses were usually 
excluded. But in a subsequent follow-up observational study, the Memphis group 
compared outcomes in 133 preeclamptic women with and 136 without HELLP syndrome 
who presented between 24 and 36 weeks (Abramovici et al., 1999).  
Women were subdivided into three study groups. The first group included those 
with complete HELLP syndrome. The second group included women with partial HELLP 
syndrome—defined as either one or two but not all three of the defining laboratory 
findings. The third group included women who had severe preeclampsia without HELLP 
syndrome laboratory findings. Perinatal outcomes were similar in each group, and 
importantly, outcomes were not improved with procrastination. Despite this, the 
investigators concluded that women with partial HELLP syndrome and those with severe 
preeclampsia alone could be managed expectantly. 
Sibai and Barton (2007b) reviewed expectant management of severe 
preeclampsia from 24 to 34 weeks. More than 1200 women were included, and although 
the average time gained ranged from 5 to 10 days, the maternal morbidity rates were 
formidable. As shown in Table X, serious complications in some of these and in later 
studies included placental abruption, HELLP syndrome, pulmonary edema, renal failure, 
and eclampsia. Moreover, perinatal mortality rates averaged 90 per 1000.  
Fetal-growth restriction was common, and in the study from The Netherlands by 
Ganzevoort and associates (2005a; 2005b), it was an astounding 94 percent. Perinatal 
mortality rates are disproportionately high in these growth-restricted infants, but maternal 
outcomes were not appreciably different from pregnancies in women without growth-
restricted fetuses (Haddad et al., 2007; Shear et al., 2005). 
TABLE X. Maternal and Perinatal Outcomes Reported Since 2005 with Expectant 









The MEXPRE Latin Study was a multicenter trial that randomly assigned 267 
women with severe preeclampsia at 28 to 32 weeks to prompt delivery or to expectant 
management (Vigil-De Gracia et al., 2013). The perinatal mortality rate approximated 9 
percent in each group, and these investigators found no improvements in composite 
neonatal morbidity with expectant management. On the other hand, fetal-growth 
restriction—22 versus 9 percent—and placental abruption—7.6 versus 1.5 percent—were 
significantly higher in the group managed expectantly. 
Barber and associates (2009) conducted a 10-year review of 3408 women with 
severe preeclampsia from 24 to 32 weeks. They found that increasing lengths of 
antepartum hospital stays were associated with slight but significantly increased rates of 
maternal and neonatal morbidity. 
Expectant Management of Mid-trimester Severe Preeclampsia 
Several small studies have focused on expectant management of severe 
preeclampsia syndrome before 28 weeks. In their review, Bombrys and coworkers 
(2008) found eight such studies that included nearly 200 women with severe 
preeclampsia with an onset < 26 completed weeks. Maternal complications were 
common.  
Because there were no neonatal survivors in women presenting before 23 weeks, 
the Task Force of the American College of Obstetricians and Gynecologists (2013b) 
recommends pregnancy termination. For women with slightly more advanced 
pregnancies, however, the decision is less clear. For example, at 23 weeks’ gestation, the 
perinatal survival rate was 18 percent, but long-term perinatal morbidity is yet unknown. 
For women with pregnancies at 24 to 26 weeks, perinatal survival approached 60 percent, 
and it averaged almost 90 percent for those at 26 weeks. 
There have been at least five studies published since 2005 of women with severe 
mid-trimester preeclampsia who were managed expectantly. Maternal complications 
developed in 60 percent, and there was one death. Perinatal mortality was 65 percent. At 
this time, there are no comparative studies attesting to the perinatal benefits of such 
expectant treatment versus early delivery in the face of serious maternal complications 
that approach 50 percent (Budden et al., 2006; Gaugler-Senden et al., 2006; Bombrys 
et al., 2008; Abdel-Hady et al., 2010; Belghiti et al., 2011). 
Glucocorticoids for Lung Maturation 
In attempts to enhance fetal lung maturation, glucocorticoids have been 
administered to women with severe hypertension who are remote from term. Treatment 
does not seem to worsen maternal hypertension, and a decrease in the incidence of 
respiratory distress and improved fetal survival has been cited. That said, there is only 
one randomized trial of corticosteroids given to hypertensive women for fetal lung 
maturation. This trial, by Amorim and colleagues (1999), included 218 women with 
severe preeclampsia between 26 and 34 weeks who were randomly assigned to 
betamethasone or placebo administration. Neonatal complications, including respiratory 
distress, intraventricular hemorrhage, and death, were decreased significantly when 
betamethasone was given compared with placebo. On the heavily weighted negative side, 
there were two maternal deaths and 18 stillbirths (Bloom et al., 2003; Alexander et al., 
2014). 
Corticosteroids to Ameliorate HELLP Syndrome 
Almost 30 years ago, Thiagarajah and associates (1984) suggested that 
glucocorticoids might aid treatment of the laboratory abnormalities associated with 
HELLP syndrome.  
Subsequently, Tompkins and Thiagarajah (1999) and O’Brien et al. (2002) and 
their colleagues reported less than salutary effects. Martin and coworkers (2003) 
reviewed observational outcomes of almost 500 such women treated at their institution 
and reported salutary results with treatment. Unfortunately, their subsequent randomized 
trial compared two corticosteroids and did not include a non-treated group (Isler et al., 
2001). 
Since these observational studies, at least two prospective randomized trials have 
addressed this question. Fonseca and associates (2005) randomly assigned 132 women 
with HELLP syndrome to either dexamethasone or placebo administration. Outcomes 
assessed included duration of hospitalization, recovery time of abnormal laboratory test 
results, resolution of clinical parameters, and complications that included acute renal 
failure, pulmonary edema, eclampsia, and death. None of these was significantly different 
between the two groups.  
In another randomized study, Katz and coworkers (2008) assigned 105 
postpartum women with HELLP syndrome to treatment with dexamethasone or placebo. 
They analyzed outcomes similar to the Fonseca study and found no advantage to 
dexamethasone. Shown in Figure 17 are recovery times for platelet counts and serum 
aspartate aminotransferase (AST) levels. These times were almost identical in the two 
groups.  
For these reasons, the 2013 Task Force does not recommend corticosteroid 
treatment for thrombocytopenia with HELLP syndrome. A caveat is that in women with 
dangerously low platelet counts, corticosteroids might serve to increase platelets. 
 
FIGURE 17. Recovery times for platelet counts and serum aspartate 
aminotransferase (AST) levels in women with HELLP syndrome assigned to receive 
treatment with dexamethasone or placebo (Data from Katz et al., 2008). 
Expectant Management—Risks versus Benefits—Recommendations 
These studies do not show overwhelming benefits compared with risks for 
expectant management of severe preeclampsia in those with gestations from 24 to 32 
weeks. The Society for Maternal-Fetal Medicine (2011) has determined that such 
management is a reasonable alternative in selected women with severe preeclampsia 
before 34 weeks (Figure 18).  
 
FIGURE 18. Schematic clinical management algorithm for suspected severe 
preeclampsia at < 34 weeks. HELLP = hemolysis, elevated liver enzyme levels, low 
platelet count; L&D = labor and delivery; MgSO4 = magnesium sulfate; UOP = urine 
output (Adapted from the Society for Maternal-Fetal Medicine, 2011). 
The Task Force of the American College of Obstetricians and Gynecologists 
(2013b) supports this recommendation. As shown in Figure 18, such management calls 
for in-hospital maternal and fetal surveillance with delivery prompted by evidence for 
worsening severe preeclampsia or maternal or fetal compromise. Although attempts are 
made for vaginal delivery in most cases, the likelihood of cesarean delivery increases 
with decreasing gestational age. 
Undoubtedly, the overriding reason to terminate pregnancies with severe 
preeclampsia is maternal safety. There are no data to suggest that expectant management 
is beneficial for the mother. Indeed, it seems obvious that a delay to prolong gestation in 
women with severe preeclampsia may have serious maternal consequences. Notably, 
placental abruption develops in up to 20 percent, and pulmonary edema in as many as 4 
percent. Moreover, there are substantive risks for eclampsia, cerebrovascular hemorrhage, 
and especially maternal death. These observations are even more pertinent when 
considered with the absence of convincing evidence that perinatal outcomes are markedly 
improved by the average prolongation of pregnancy of about 1 week. If undertaken, the 
caveats that mandate delivery shown in Table XI should be strictly heeded. 
ECLAMPSIA 
Preeclampsia complicated by generalized tonic-clonic convulsions appreciably 
increases the risk to both mother and fetus. Mattar and Sibai (2000) described outcomes 
in 399 consecutive women with eclampsia from 1977 through 1998. Major maternal 
complications included placental abruption—10 percent, neurological deficits—7 
percent, aspiration pneumonia—7 percent, pulmonary edema—5 percent, 
cardiopulmonary arrest—4 percent, and acute renal failure—4 percent. Moreover, 1 
percent of these women died. 
TABLE XI. Indications for Delivery in Women < 34 Weeks’ Gestation Managed 
Expectantly: 
Corticosteroid Therapy for Lung Maturation a and Delivery after Maternal 
Stabilization: 
    Uncontrolled severe hypertension 
    Eclampsia 
    Pulmonary edema 
    Placental abruption 
    Disseminated intravascular coagulation 
    Non-reassuring fetal status 
    Fetal demise 
Corticosteroid Therapy for Lung Maturation—Delay Delivery 48 hr If Possible: 
    Preterm ruptured membranes or labor 
    Thrombocytopenia < 100,000/μL 
    Hepatic transaminase levels twice upper limit of normal 
    Fetal-growth restriction 
    Oligohydramnios 
    Reversed end-diastolic Doppler flow in umbilical artery 
    Worsening renal dysfunction 
a Initial dose only, do not delay delivery. From the Society for Maternal-Fetal Medicine, 
2011, and the Task Force of the American College of Obstetricians and Gynecologists, 
2013b. 
European maternity units also report excessive maternal and perinatal morbidity 
and mortality rates with eclampsia. In a report from Scandinavia, Andersgaard and 
associates (2006) described 232 women with eclampsia.  
Although there was but a single maternal death, a third of the women experienced 
major complications that included HELLP syndrome, renal failure, pulmonary edema, 
pulmonary embolism, and stroke. The United Kingdom Obstetric Surveillance System 
(UKOSS) audit reported by Knight (2007) described no maternal deaths in 214 
eclamptic women, but five women experienced cerebral hemorrhage.  
In The Netherlands, there were three maternal deaths among 222 eclamptic 
women (Zwart et al., 2008). From Dublin, Akkawi and coworkers (2009) reported four 
maternal deaths among 247 eclamptic women (Akkawi et al., 2009). Data from Australia 
are similar (Thornton et al., 2013).  
Thus, in developed countries, the maternal mortality rate approximates 1 percent 
in women with eclampsia. In perspective, this is a thousand-fold increase above the 
overall maternal death rates for these countries. Almost without exception—but at times 
unnoticed—preeclampsia precedes the onset of eclamptic convulsions. Depending on 
whether convulsions appear before, during, or after labor, eclampsia is designated as 
antepartum, intrapartum, or postpartum. Eclampsia is most common in the last trimester 
and becomes increasingly frequent as term approaches. In more recent years, the 
incidence of postpartum eclampsia has risen. This is presumably related to improved 
access to prenatal care, earlier detection of preeclampsia, and prophylactic use of 
magnesium sulfate (Chames et al., 2002).  
Importantly, other diagnoses should be considered in women with convulsions 
more than 48 hours postpartum or in women with focal neurological deficits, prolonged 
coma, or atypical eclampsia (Sibai et al., 2009; 2012). 
 
 
Immediate Management of Seizure 
Eclamptic seizures may be violent, and the woman must be protected, especially 
her airway. So forceful are the muscular movements that the woman may throw herself 
out of her bed, and if not protected, her tongue is bitten by the violent action of the jaws. 
This phase, in which the muscles alternately contract and relax, may last approximately a 
minute. Gradually, the muscular movements become smaller and less frequent, and 
finally the woman lies motionless. After a seizure, the woman is postictal, but in some, a 
coma of variable duration ensues. When the convulsions are infrequent, the woman 
usually recovers some degree of consciousness after each attack. As the woman arouses, 
a semiconscious combative state may ensue. In severe cases, coma persists from one 
convulsion to another, and death may result. In rare instances, a single convulsion may be 
followed by coma from which the woman may never emerge. As a rule, however, death 
does not occur until after frequent convulsions. Finally and also rarely, convulsions 
continue unabated—status epilepticus—and require deep sedation and even general 
anesthesia to obviate anoxic encephalopathy. Respirations after an eclamptic convulsion 
are usually increased in rate and may reach 50 or more per minute in response to 
hypercarbia, lactic acidemia, and transient hypoxia. Cyanosis may be observed in severe 
cases. High fever is a grave sign as it likely emanates from cerebrovascular hemorrhage 
(Podymow et al., 2010).  
Proteinuria is usually, but not always, present. Urine output may be diminished 
appreciably, and occasionally anuria develops. There may be hemoglobinuria, but 
hemoglobinemia is observed rarely. Often, peripheral and facial edema is pronounced, 
but it may also be absent. As with severe preeclampsia, an increase in urinary output after 
delivery is usually an early sign of improvement. If there is renal dysfunction, serum 
creatinine levels should be monitored. Proteinuria and edema ordinarily disappear within 
a week postpartum. In most cases, blood pressure returns to normal within a few days to 
2 weeks after delivery (Berks et al., 2009).  
The longer hypertension persists postpartum and the more severe it is, the more 
likely it is that the woman also has chronic vascular disease (Podymow et al., 2010). In 
antepartum eclampsia, labor may begin spontaneously shortly after convulsions ensue 
and may progress rapidly. If the convulsions occur during labor, contractions may 
increase in frequency and intensity, and the duration of labor may be shortened. Because 
of maternal hypoxemia and lactic acidemia caused by convulsions, it is not unusual for 
fetal bradycardia to follow a seizure. Bradycardia usually recovers within 3 to 5 minutes. 
If it persists more than about 10 minutes, however, then another cause such as placental 
abruption or imminent delivery must be considered. Pulmonary edema may follow 
shortly after eclamptic convulsions or up to several hours later. This usually is caused by 
aspiration pneumonitis from gastric-content inhalation during vomiting that frequently 
accompanies convulsions. In some women, pulmonary edema may be caused by 
ventricular failure from increased afterload that may result from severe hypertension and 
further aggravated by vigorous intravenous fluid administration (Dennis et al., 2012b).  
Such pulmonary edema from ventricular failure is more common in morbidly 
obese women and in those with previously unappreciated chronic hypertension. 
Occasionally, sudden death occurs synchronously with an eclamptic convulsion, or it 
follows shortly thereafter. Most often in these cases, death results from a massive cerebral 
hemorrhage (Figure 11). Hemiplegia may result from sublethal hemorrhage. Cerebral 
hemorrhages are more likely in older women with underlying chronic hypertension. 
Rarely, they may be due to a ruptured cerebral berry aneurysm or arteriovenous 
malformation (Witlin et al., 1997a). 
In approximately 10 percent of women, some degree of blindness follows a 
seizure. Blindness with severe preeclampsia without convulsions is usually due to retinal 
detachment (Vigil-De Gracia et al., 2011).  
Conversely, blindness with eclampsia is almost always due to occipital lobe 
edema (Cunningham et al., 1995). In both instances, however, the prognosis for return 
to normal function is good and is usually complete within 1 to 2 weeks postpartum. Up to 
5 percent of women with eclampsia have substantively altered consciousness, including 
persistent coma, following a seizure. This is due to extensive cerebral edema, and 
transtentorial herniation may cause death. Rarely, eclampsia is followed by psychosis, 
and the woman becomes violent. This may last for several days to 2 weeks, but the 
prognosis for return to normal function is good, provided there was no preexisting mental 
illness. It is presumed to be similar to postpartum psychosis. Antipsychotic medications 
have proved effective in the few cases of posteclampsia psychosis (Cunningham et al., 
2000). 
Differential Diagnosis 
Generally, eclampsia is more likely to be diagnosed too frequently rather than 
overlooked. Epilepsy, encephalitis, meningitis, brain tumor, neurocysticercosis, amnionic 
fluid embolism, postdural puncture cephalgia, and ruptured cerebral aneurysm during late 
pregnancy and the puerperium may simulate eclampsia. Until other such causes are 
excluded, however, all pregnant women with convulsions should be considered to have 
eclampsia (Cunningham et al., 2000). 
Management of Eclampsia 
It has been long recognized that magnesium sulfate is highly effective in 
preventing convulsions in women with preeclampsia and in stopping them in those with 
eclampsia. Most eclampsia old regimens used in the United States adhered to a similar 
philosophy still in use today, the tenets of which include the following (Jana et al., 
2013): 
1. Control of convulsions using an intravenously administered loading dose of 
magnesium sulfate that is followed by a maintenance dose, usually intravenous, of 
magnesium sulfate 
2. Intermittent administration of an antihypertensive medication to lower blood 
pressure whenever it is considered dangerously high 
3. Avoidance of diuretics unless there is obvious pulmonary edema, limitation of 
intravenous fluid administration unless fluid loss is excessive, and avoidance of 
hyperosmotic agents 
4. Delivery of the fetus to achieve a remission of preeclampsia. 
Magnesium Sulfate to Control Convulsions 
In more severe cases of preeclampsia and in eclampsia, magnesium sulfate 
administered parenterally is an effective anticonvulsant that avoids producing central 
nervous system depression in either the mother or the infant. It may be given 
intravenously by continuous infusion or intramuscularly by intermittent injection (Table 
XII). The dosages for severe preeclampsia are the same as for eclampsia. Because labor 
and delivery is a more likely time for convulsions to develop, women with preeclampsia-
eclampsia usually are given magnesium sulfate during labor and for 24 hours postpartum 
(Salinger et al., 2013). 
Magnesium sulfate is almost universally administered intravenously. In most 
units, the intramuscular route has been abandoned. Of concern, magnesium sulfate 
solutions, although inexpensive to prepare, are not readily available in all parts of the 
developing world. And even when the solutions are available, the technology to infuse 
them may not be. It should not be overlooked that the drug can be administered 
intramuscularly and that this route is as effective as intravenous administration. In two 
reports from India, intramuscular regimens were nearly equivalent in preventing recurrent 
convulsions and maternal deaths in women with eclampsia (Chowdhury et al., 2009).  
TABLE XII. Magnesium Sulfate Dosage Schedule for Severe Preeclampsia and 
Eclampsia: 
Continuous Intravenous (IV) Infusion 
Give 4- to 6-g loading dose of magnesium sulfate diluted in 100 mL of IV fluid 
administered over 15–20 min 
Begin 2 g/hr in 100 mL of IV maintenance infusion. Some recommend 1 g/hr 
Monitor for magnesium toxicity: 
    Assess deep tendon reflexes periodically 
    Some measure serum magnesium level at 4–6 hr and adjust infusion to maintain levels 
between 4 and 7 mEq/L (4.8 to 8.4 mg/dL) 
    Measure serum magnesium levels if serum creatinine ≥ 1.0 mg/dL 
Magnesium sulfate is discontinued 24 hr after delivery 
Intermittent Intramuscular Injections 
Give 4 g of magnesium sulfate (MgSO4·7H2O USP) as a 20% solution intravenously 
at a rate not to exceed 1 g/min 
Follow promptly with 10 g of 50% magnesium sulfate solution, one half (5 g) injected 
deeply in the upper outer quadrant of each buttock through a 3-inch-long 20-gauge 
needle. (Addition of 1.0 mL of 2% lidocaine minimizes discomfort.) If convulsions 
persist after 15 min, give up to 2 g more intravenously as a 20% solution at a rate not to 
exceed 1 g/min. If the woman is large, up to 4 g may be given slowly 
Every 4 hr thereafter, give 5 g of a 50% solution of magnesium sulfate injected deeply in 
the upper outer quadrant of alternate buttocks, but only after ensuring that: 
    The patellar reflex is present, 
    Respirations are not depressed, and 
    Urine output the previous 4 hr exceeded 100 mL 
Magnesium sulfate is not given to treat hypertension. Based on several studies 
cited subsequently and extensive clinical observations, magnesium most likely exerts a 
specific anticonvulsant action on the cerebral cortex. Typically, the mother stops 
convulsing after the initial 4-g loading dose. By an hour or two, she regains 
consciousness sufficiently to be oriented to place and time. The magnesium sulfate 
dosages presented in Table XII usually result in plasma magnesium levels illustrated in 
Figure 19. When magnesium sulfate is given to arrest eclamptic seizures, 10 to 15 
percent of women will have a subsequent convulsion. If so, an additional 2-g dose of 
magnesium sulfate in a 20-percent solution is slowly administered intravenously. In a 
small woman, this additional 2-g dose may be used once, but it can be given twice if 
needed in a larger woman. In only 5 of 245 women with eclampsia at Parkland Hospital 
was it necessary to use supplementary anticonvulsant medication to control convulsions 
(Pritchard et al., 1984). For these, an intravenous barbiturate is given slowly. 
Midazolam or lorazepam may be given in a small single dose, but prolonged use is 
avoided because it is associated with a higher mortality rate (Royal College of 
Obstetricians and Gynecologists, 2006). 
Maintenance magnesium sulfate therapy is continued for 24 hours after delivery. 
For eclampsia that develops postpartum, magnesium sulfate is administered for 24 hours 
after the onset of convulsions. Ehrenberg and Mercer (2006) studied abbreviated 
postpartum magnesium administration in 200 women with mild preeclampsia. Of 101 
women randomized to 12-hour treatment, seven had worsening preeclampsia, and 
treatment was extended to 24 hours. None of these 101 women and none of the other 
cohort of 95 given the 24-hour magnesium infusion developed eclampsia. This 
abbreviated regimen needs further study before being routinely administered for severe 
preeclampsia or eclampsia. 
 
 
FIGURE 19. Comparison of serum magnesium levels in mEq/L following a 4-g 
intravenous loading dose of magnesium sulfate and then maintained by either an 
intramuscular or continuing infusion. Multiply by 1.2 to convert mEq/L to mg/dL 
(Data from Sibai et al., 1984). 
Pharmacology and Toxicology 
Magnesium sulfate USP is MgSO4·7H2O and not simple MgSO4. It contains 
8.12 mEq per 1 g. Parenterally administered magnesium is cleared almost totally by renal 
excretion, and magnesium intoxication is unusual when the glomerular filtration rate is 
normal or only slightly decreased.  
Adequate urine output usually correlates with preserved glomerular filtration 
rates. That said, magnesium excretion is not urine flow dependent, and urinary volume 
per unit time does not, per se, predict renal function. Thus, serum creatinine levels must 
be measured to detect a decreased glomerular filtration rate. Eclamptic convulsions are 
almost always prevented or arrested by plasma magnesium levels maintained at 4 to 7 
mEq/L, 4.8 to 8.4 mg/dL, or 2.0 to 3.5 mmol/L. Although laboratories typically report 
total magnesium levels, free or ionized magnesium is the active moiety for suppressing 
neuronal excitability. Taber and associates (2002) found poor correlation between total 
and ionized levels. Further studies are necessary to determine if either measurement 
provides a superior method for surveillance. 
After a 4-g intravenous loading dose in nonobese women, magnesium levels 
observed with the intramuscular regimen and those observed with the maintenance 
infusion of 2 g/hr are similar (Figure 19). The obesity epidemic has affected these 
observations. Tudela and colleagues (2013) reported observations from Parkland 
Hospital with magnesium administration to obese women. More than 60 percent of 
women whose body mass index (BMI) exceeded 30 kg/m2 and who were receiving the 2-
g/hr dose had subtherapeutic levels at 4 hours. Thus, 40 percent of obese women would 
require 3 g/hr to maintain effective plasma levels. That said, currently most do not 
recommend routine magnesium level measurements (American College of 
Obstetricians and Gynecologists, 2013b). 
Patellar reflexes disappear when the plasma magnesium level reaches 10 
mEq/L—about 12 mg/dL—presumably because of a curariform action. This sign serves 
to warn of impending magnesium toxicity. When plasma levels rise above 10 mEq/L, 
breathing becomes weakened. At 12 mEq/L or higher levels, respiratory paralysis and 
respiratory arrest follow (Royal College of Obstetricians and Gynaecologists, 2006).  
Somjen and coworkers (1966) induced marked hypermagnesemia in themselves 
by intravenous infusion and achieved plasma levels up to 15 mEq/L. Predictably, at such 
high plasma levels, respiratory depression developed that necessitated mechanical 
ventilation, but depression of the sensorium was not dramatic as long as hypoxia was 
prevented. 
Treatment with calcium gluconate or calcium chloride, 1 g intravenously, along 
with withholding further magnesium sulfate, usually reverses mild to moderate 
respiratory depression. One of these agents should be readily available whenever 
magnesium is being infused. Unfortunately, the effects of intravenously administered 
calcium may be short-lived if there is a steady-state toxic level. For severe respiratory 
depression and arrest, prompt tracheal intubation and mechanical ventilation are 
lifesaving. Direct toxic effects on the myocardium from high levels of magnesium are 
uncommon. It appears that cardiac dysfunction associated with magnesium is due to 
respiratory arrest and hypoxia. With appropriate ventilation, cardiac action is satisfactory 
even when plasma magnesium levels are exceedingly high (Morisaki et al., 2000). 
Because magnesium is cleared almost exclusively by renal excretion, the dosages 
described will become excessive if glomerular filtration is substantially decreased. The 
initial 4-g loading dose of magnesium sulfate can be safely administered regardless of 
renal function. It is important to administer the standard loading dose and not to reduce it 
under the mistaken conception that diminished renal function requires it. This is because 
after distribution, a loading dose achieves the desired therapeutic level, and the infusion 
maintains the steady-state level. Thus, only the maintenance infusion rate should be 
altered with diminished glomerular filtration rate. Renal function is estimated by 
measuring plasma creatinine. Whenever plasma creatinine levels are > 1.0 mg/mL, serum 
magnesium levels are measured to guide the infusion rate. With severe renal dysfunction, 
only the loading dose of magnesium sulfate is required to produce a steady-state 
therapeutic level (Arango et al., 2006). 
Acute cardiovascular effects of parenteral magnesium in women with severe 
preeclampsia have been studied using data obtained by pulmonary and radial artery 
catheterization. After a 4-g intravenous dose administered over 15 minutes, mean arterial 
pressure fell slightly, accompanied by a 13-percent increase in cardiac index (Cotton et 
al., 1986b).  
Thus, magnesium decreased systemic vascular resistance and mean arterial 
pressure. At the same time, it increased cardiac output without evidence of myocardial 
depression. These findings were coincidental with transient nausea and flushing, and the 
cardiovascular effects persisted for only 15 minutes despite continued magnesium 
infusion. Thurnau and associates (1987) showed that there was a small but highly 
significant increase in total magnesium concentration in the cerebrospinal fluid with 
magnesium therapy. The magnitude of the increase was directly proportional to the 
corresponding serum concentration. 
Magnesium is anticonvulsant and neuroprotective in several animal models. Some 
proposed mechanisms of action include: (1) reduced presynaptic release of the 
neurotransmitter glutamate, (2) blockade of glutamatergic N-methyl-D-aspartate 
(NMDA) receptors, (3) potentiation of adenosine action, (4) improved calcium buffering 
by mitochondria, and (5) blockage of calcium entry via voltage-gated channels (Wang et 
al., 2012a). 
Uterine Effects 
Relatively high serum magnesium concentrations depress myometrial contractility 
both in vivo and in vitro. With the regimen described and the plasma levels that result, no 
evidence of myometrial depression has been observed beyond a transient decrease in 
activity during and immediately after the initial intravenous loading dose (Atkinson et 
al., 1995). 
Leveno and associates (1998) compared outcomes in 480 nulliparous women 
given phenytoin for preeclampsia with outcomes in 425 preeclamptic women given 
magnesium sulfate. Magnesium did not significantly alter the need for oxytocin 
stimulation of labor, admission-to-delivery intervals, or route of delivery. Similar results 
have been reported by others (Witlin et al., 1997b; Szal et al., 1999). 
The mechanisms by which magnesium might inhibit uterine contractility are not 
established. It is generally assumed, however, that these depend on its effects on 
intracellular calcium. Inhibition of uterine contractility is magnesium dose dependent, 
and serum levels of at least 8 to 10 mEq/L are necessary to inhibit uterine contractions. 
This likely explains why there are few if any uterine effects seen clinically when 
magnesium sulfate is given for preeclampsia. Magnesium is also not considered to be an 
effective tocolytic agent (Watt-Morse et al., 1995). 
Fetal and Neonatal Effects  
Magnesium administered parenterally promptly crosses the placenta to achieve 
equilibrium in fetal serum and less so in amnionic fluid (Hallak et al., 1993). Levels in 
amnionic fluid increase with duration of maternal infusion (Gortzak-Uzen et al., 2005). 
Current evidence supports the view that magnesium sulfate has small but significant 
effects on the fetal heart rate pattern—specifically beat-to-beat variability. Hallak and 
coworkers (1999) compared an infusion of magnesium sulfate with a saline infusion. 
These investigators reported that magnesium was associated with a small and clinically 
insignificant decrease in variability.  
Similarly, in a retrospective study, Duffy and associates (2012) reported a lower 
heart rate baseline that was within the normal range; decreased variability; and fewer 
prolonged decelerations. They noted no adverse outcomes. 
Overall, maternal magnesium therapy appears safe for perinates. For example, a 
recent MFMU Network study of more than 1500 exposed preterm neonates found no 
association between the need for neonatal resuscitation and cord blood magnesium levels 
(Johnson et al., 2012). Still, there are a few neonatal adverse events associated with its 
use. In a Parkland Hospital study of 6654 mostly term exposed newborns, 6 percent had 
hypotonia (Abbassi-Ghanavati et al., 2012). In addition, exposed neonates had lower 1- 
and 5-minute Apgar scores, a higher intubation rate, and more admissions to the special 
care nursery. The study showed that neonatal depression occurs only if there is severe 
hypermagnesemia at delivery. 
Observational studies have suggested a protective effect of magnesium against the 
development of cerebral palsy in very-low-birthweight infants (Nelson et al., 1995; 
Schendel et al., 1996). At least five randomized trials have also assessed neuroprotective 
effects in preterm newborns. Nguyen and colleagues (2013) expanded this possibility to 
include term newborn neuroprotection. They performed a Cochrane Database review to 
compare term neonatal outcomes with and without exposure to peripartum magnesium 
therapy and reported that there were insufficient data to draw conclusions. 
Finally, long-term use of magnesium, given for several days for tocolysis, has 
been associated with neonatal osteopenia (American College of Obstetricians and 
Gynecologists, 2013c). 
Maternal Safety and Efficacy of Magnesium Sulfate  
The multinational Eclampsia Trial Collaborative Group study (1995) 
involved 1687 women with eclampsia randomly allocated to different anticonvulsant 
regimens. In one cohort, 453 women were randomly assigned to be given magnesium 
sulfate and compared with 452 given diazepam.  
In a second cohort, 388 eclamptic women were randomly assigned to be given 
magnesium sulfate and compared with 387 women given phenytoin. The results of these 
and other comparative studies that each enrolled at least 50 women are summarized in 
Table XIII. In aggregate, magnesium sulfate therapy was associated with a significantly 
lower incidence of recurrent seizures compared with women given an alternative 
anticonvulsant—9.7 versus 23 percent. Importantly, the maternal death rate of 3.1 percent 
with magnesium sulfate was significantly lower than that of 4.9 percent for the other 
regimens. 
TABLE XIII. Randomized Comparative Trials of Magnesium Sulfate with Another 








Magnesium safety and toxicity was recently reviewed by Smith and coworkers 
(2013). In more than 9500 treated women, the overall rate of absent patellar tendon 
reflexes was 1.6 percent; respiratory depression 1.3 percent; and calcium gluconate 
administration 0.2 percent. They reported only one maternal death due to magnesium 
toxicity (Pritchard et al., 1984). 
Management of Severe Hypertension 
Dangerous hypertension can cause cerebrovascular hemorrhage and hypertensive 
encephalopathy, and it can trigger eclamptic convulsions in women with preeclampsia. 
Other complications include hypertensive afterload congestive heart failure and placental 
abruption (Clark et al., 2012). 
Because of these sequelae, the National High Blood Pressure Education 
Program Working Group (2000) and the 2013 Task Force recommend treatment to 
lower systolic pressures to or below 160 mm Hg and diastolic pressures to or below 110 
mm Hg.  
Martin and associates (2005) reported provocative observations that highlight 
the importance of treating systolic hypertension. They described 28 selected women with 
severe preeclampsia who suffered an associated stroke. Most of these were hemorrhagic 
strokes—93 percent—and all women had systolic pressures > 160 mm Hg before 
suffering their stroke.  
By contrast, only 20 percent of these same women had diastolic pressures > 110 
mm Hg. It seems likely that at least half of serious hemorrhagic strokes associated with 
preeclampsia are in women with chronic hypertension. Long-standing hypertension 
results in development of Charcot-Bouchard aneurysms in the deep penetrating arteries of 
the lenticulostriate branch of the middle cerebral arteries. These vessels supply the basal 
ganglia, putamen, thalamus, and adjacent deep white matter, as well as the pons and deep 
cerebellum. These unique aneurysmal weakening predisposes these small arteries to 




Several drugs are available to rapidly lower dangerously elevated blood pressure 
in women with the gestational hypertensive disorders. The three most commonly 
employed are hydralazine, labetalol, and nifedipine. For years, parenteral hydralazine was 
the only one of these three available. But when parenteral labetalol was later introduced, 
it was considered to be equally effective for obstetrical use. Orally administered 
nifedipine has since then gained some popularity as first-line treatment for severe 
gestational hypertension. 
Hydralazine 
This is probably still the most commonly used antihypertensive agent in the 
United States for treatment of women with severe gestational hypertension. Hydralazine 
is administered intravenously with a 5-mg initial dose, and this is followed by 5- to 10-
mg doses at 15- to 20-minute intervals until a satisfactory response is achieved 
(American College of Obstetricians and Gynecologists, 2012b). Some limit the total 
dose to 30 mg per treatment cycle (Sibai et al., 2003).  
The target response antepartum or intrapartum is a decrease in diastolic blood 
pressure to 90 to 110 mm Hg. Lower diastolic pressures risk compromised placental 
perfusion. Hydralazine has proven remarkably effective to prevent cerebral hemorrhage. 
Its onset of action can be as rapid as 10 minutes. Although repeated administration every 
15 to 20 minutes may theoretically lead to undesirable hypotension, this has not been 
occurred when given in these 5- to 10-mg increments. Between 5 and 10 percent of all 
women with intrapartum hypertensive disorders are given a parenteral antihypertensive 
agent. The total dose is not limited and seldom has a second antihypertensive agent been 
needed. Although less popular in Europe, hydralazine is used in some centers, according 
to the Royal College of Obstetricians and Gynaecologists (2006).  
A dissenting opinion for first-line intrapartum use of hydralazine was voiced by 
the Vancouver group after a systematic review (Magee et al., 2009). At the same time, 
however, Umans and coworkers (2014) concluded that objective outcome data did not 
support the use of one drug over another. As with any antihypertensive agent, the 
tendency to give a larger initial dose of hydralazine if the blood pressure is higher must 
be avoided. The response to even 5- to 10-mg doses cannot be predicted by hypertension 
severity. Thus, the protocol is to always administer 5 mg as the initial dose. An adverse 
response to exceeding this initial dose is shown in Figure 20.  
 
FIGURE 20. Woman with chronic hypertension complicated by severe 
superimposed preeclampsia, and hydralazine was injected more frequently than 
recommended. Her mean arterial pressure (MAP) decreased in less than 1 hour from 
240–270/130–150 mm Hg to 110/80 mm Hg, and fetal heart rate decelerations 
characteristic of uteroplacental insufficiency. Decelerations persisted until her blood 
pressure was increased with rapid crystalloid infusion. Hydralazine was given at 5-minute 
instead of 15-minute intervals. MAP decreased from 180 to 90 mm Hg within 1 hour and 
was associated with fetal bradycardia. Rapid crystalloid infusion raised MAP to 115 mm 
Hg, and the fetus recovered. 
In some cases, this fetal response to diminished uterine perfusion may be 
confused with placental abruption and may result in unnecessary and potentially 
dangerous emergent cesarean delivery (Umans et al., 2014). 
Labetalol 
This effective intravenous antihypertensive agent is an α1- and nonselective β-
blocker. Some prefer its use over hydralazine because of fewer side effects (Sibai, 2003). 
At Parkland Hospital, we give 10 mg intravenously initially. If the blood pressure has not 
decreased to the desirable level in 10 minutes, then 20 mg is given. The next 10-minute 
incremental dose is 40 mg and is followed by another 40 mg if needed. If a salutary 
response is not achieved, then an 80-mg dose is given. Sibai (2003) recommends 20 to 40 
mg every 10 to 15 minutes as needed and a maximum dose of 220 mg per treatment 
cycle. The American College of Obstetricians and Gynecologists (2012b) recommends 
starting with a 20-mg intravenous bolus. If not effective within 10 minutes, this is 
followed by 40 mg, then 80 mg every 10 minutes. Administration should not exceed a 
220-mg total dose per treatment cycle. 
Hydralazine versus Labetalol 
Comparative studies of these two antihypertensive agents show equivalent results 
(Umans et al., 2014). In an older trial, Mabie and colleagues (1987) compared 
intravenous hydralazine with labetalol for blood pressure control in 60 peripartum 
women. Labetalol lowered blood pressure more rapidly, and associated tachycardia was 
minimal. However, hydralazine lowered mean arterial pressures to safe levels more 
effectively.  
 
In a later trial, Vigil-De Gracia and associates (2007) randomly assigned 200 
severely hypertensive women intrapartum to be given either: (1) intravenous 
hydralazine—5 mg, which could be given every 20 minutes and repeated to a maximum 
of five doses, or (2) intravenous labetalol—20 mg initially, followed by 40 mg in 20 
minutes and then 80 mg every 20 minutes if needed up to a maximum 300-mg dose. 
Maternal and neonatal outcomes were similar. Hydralazine caused significantly more 
maternal tachycardia and palpitations, whereas labetalol more frequently caused maternal 
hypotension and bradycardia. Both drugs have been associated with a reduced frequency 
of fetal heart rate accelerations (Cahill et al., 2013). 
Nifedipine 
This calcium-channel blocking agent has become popular because of its efficacy 
for control of acute pregnancy-related hypertension. The NHBPEP Working Group 
(2000) and the Royal College of Obstetricians and Gynaecologists (2006) recommend 
a 10-mg initial oral dose to be repeated in 30 minutes if necessary. Nifedipine given 
sublingually is no longer recommended. Randomized trials that compared nifedipine with 
labetalol found neither drug definitively superior to the other. However, nifedipine 
lowered blood pressure more quickly (Scardo et al., 1999; Vermillion et al., 1999; 
Shekhar et al., 2013). 
Other Antihypertensive Agents 
A few other generally available antihypertensive agents have been tested in 
clinical trials but are not widely used (Umans et al., 2014). Belfort and associates 
(1990) administered the calcium antagonist verapamil by intravenous infusion at 5 to 10 
mg per hour. Mean arterial pressure was lowered by 20 percent. Belfort and coworkers 
(1996, 2003) reported that nimodipine given either by continuous infusion or orally was 
effective to lower blood pressure in women with severe preeclampsia.  
Bolte and colleagues (1998, 2001) reported good results in preeclamptic women 
given intravenous ketanserin, a selective serotonergic (5HT2A) receptor blocker. 
Nitroprusside or nitroglycerine is recommended by some if there is not optimal response 
to first-line agents. With these latter two agents, fetal cyanide toxicity may develop after 
4 hours.  
There are experimental antihypertensive drugs that may become useful for 
preeclampsia treatment. One is calcitonin gene related peptide (CGRP), a 37-amino acid 
potent vasodilator. Another is antidigoxin antibody Fab (DIF) directed against 
endogenous digitalis-like factors, also called cardiotonic steroids (Bagrov, 2008; Lam, 
2013). 
Diuretics 
Potent loop diuretics can further compromise placental perfusion. Immediate 
effects include depletion of intravascular volume, which most often is already reduced 
compared with that of normal pregnancy. Therefore, before delivery, diuretics are not 
used to lower blood pressure (Zeeman, 2009).  
FLUID THERAPY 
Lactated Ringer solution is administered routinely at the rate of 60 mL to no more 
than 125 mL per hour unless there is unusual fluid loss from vomiting, diarrhea, or 
diaphoresis, or, more likely, excessive blood loss with delivery. Oliguria is common with 
severe preeclampsia. Thus, coupled with the knowledge that maternal blood volume is 
likely constricted compared with that of normal pregnancy, it is tempting to administer 
intravenous fluids more vigorously. But controlled, conservative fluid administration is 
preferred for the typical woman with severe preeclampsia who already has excessive 
extracellular fluid that is inappropriately distributed between intravascular and 
extravascular spaces (Sciscione et al., 2003).  
Infusion of large fluid volumes enhances the mal-distribution of extravascular 
fluid and thereby appreciably increases the risk of pulmonary and cerebral edema. For 
labor analgesia with neuraxial analgesia, crystalloid solutions are infused slowly in 
graded amounts (Dennis et al., 2012a). 
PULMONARY EDEMA 
Women with severe preeclampsia-eclampsia who develop pulmonary edema most 
often do so postpartum. With pulmonary edema in the eclamptic woman, aspiration of 
gastric contents, which may be the result of convulsions, anesthesia, or oversedation, 
should be excluded. There are three common causes of pulmonary edema in women with 
severe preeclampsia syndrome—pulmonary capillary permeability edema, cardiogenic 
edema, or a combination of the two (Cunningham et al., 2012). 
Some women with severe preeclampsia—especially if given vigorous fluid 
replacement—will have mild pulmonary congestion from permeability edema. This is 
caused by normal pregnancy changes magnified by the preeclampsia syndrome. 
Importantly, plasma oncotic pressure decreases appreciably in normal term pregnancy 
because of decreased serum albumin concentration, and oncotic pressure falls even more 
with preeclampsia. And both increased extravascular fluid oncotic pressure and increased 
capillary permeability have been described in women with preeclampsia (Brown et al., 
1989). 
Invasive Hemodynamic Monitoring 
Knowledge concerning cardiovascular and hemodynamic pathophysiological 
alterations associated with severe preeclampsia-eclampsia has accrued from studies done 
using invasive monitoring and a flow-directed pulmonary artery catheter (Clark and 
Dildy, 2010).  
Two conditions frequently cited as indications are preeclampsia associated with 
either oliguria or pulmonary edema. Somewhat ironically, it is usually vigorous treatment 
of the former that results in most cases of the latter. The American College of 
Obstetricians and Gynecologists (2013a) recommends against routine invasive 
monitoring. The College notes that such monitoring should be reserved for severely 
preeclamptic women with accompanying severe cardiac disease, renal disease, or both or 
in cases of refractory hypertension, oliguria, and pulmonary edema. An alternative 
noninvasive hemodynamic monitoring strategy has been evaluated in preliminary studies 
(Moroz et al., 2013). 
PLASMA VOLUME EXPANSION 
Because the preeclampsia syndrome is associated with hemoconcentration, 
attempts to expand blood volume seem intuitively reasonable (Ganzevoort et al., 2004). 
This has led some to infuse various fluids, starch polymers, albumin concentrates, or 
combinations thereof to expand blood volume. There are, however, older observational 
studies that describe serious complications—especially pulmonary edema—with volume 
expansion. In general, these studies were not controlled or even comparative (Habek et 
al., 2006). 
The Amsterdam randomized study reported by Ganzevoort and coworkers 
(2005a; 2005b) was a well-designed investigation done to evaluate volume expansion. A 
total of 216 women with severe preeclampsia were enrolled between 24 and 34 weeks’ 
gestation. The study included women whose preeclampsia was complicated by HELLP 
syndrome, eclampsia, or fetal-growth restriction. All women were given magnesium 
sulfate to prevent eclampsia, betamethasone to promote fetal pulmonary maturity, 
ketanserine to control dangerous hypertension, and normal saline infusions restricted only 
to deliver medications.  
In the group randomly assigned to volume expansion, each woman was given 250 
mL of 6-percent hydroxyethyl starch infused over 4 hours twice daily. Their maternal and 
perinatal outcomes were compared with a control group and are shown in Table XIV. 
None of these outcomes was significantly different between the two groups. Importantly, 
serious maternal morbidity and a substantive perinatal mortality rate accompanied their 
“expectant” management (Ganzevoort et al., 2005a; 2005b). 
TABLE XIV. Maternal and Perinatal Outcomes in a Randomized Trial of Plasma 
Volume Expansion versus Saline Infusion in 216 Women with Severe Preeclampsia 
between 24 and 34 Weeks: 
 
Neuro-prophylaxis—Prevention of Seizures 
There have been several randomized trials designed to test the efficacy of seizure 
prophylaxis for women with gestational hypertension, with or without proteinuria. In 
most of these, magnesium sulfate was compared with another anticonvulsant or with a 
placebo. In all studies, magnesium sulfate was reported to be superior to the comparator 
agent to prevent eclampsia. Four of the larger studies are summarized in Table XV. 
Lucas and colleagues (1995) reported that magnesium sulfate therapy was superior to 
phenytoin to prevent eclamptic seizures in women with gestational hypertension and 
preeclampsia. Belfort and coworkers (2003) compared magnesium sulfate and 
nimodipine—a calcium-channel blocker with specific cerebral vasodilator activity—for 
eclampsia prevention. In this unblinded randomized trial involving 1650 women with 
severe preeclampsia, the rate of eclampsia was more than threefold higher for women 
allocated to the nimodipine group—2.6 versus 0.8 percent. 
TABLE XV. Randomized Trials of Prophylaxis with Magnesium Sulfate and Placebo 
or Another Anticonvulsant in Women with Gestational Hypertension: 
 
The largest comparative study was the entitled MAGnesium Sulfate for 
Prevention of Eclampsia and reported by the Magpie Trial Collaboration Group 
(2002). More than 10,000 women with severe preeclampsia from 33 countries were 
randomly allocated to treatment with magnesium sulfate or placebo. Women given 
magnesium had a 58-percent significantly lower risk of eclampsia than those given 
placebo. Smyth and associates (2009) provided follow-up data of infants born to these 
mothers given magnesium sulfate. At approximately 18 months, child behavior did not 
differ in those exposed compared with those not exposed to magnesium sulfate. 
Who Should Be Given Magnesium Sulfate? 
Magnesium will prevent proportionately more seizures in women with 
correspondingly worse disease. However, severity is difficult to quantify, and thus it is 
difficult to decide which individual woman might benefit most from neuro-prophylaxis. 
The 2013 Task Force recommends that women with either eclampsia or severe 
preeclampsia should be given magnesium sulfate prophylaxis. Again, criteria that 
establish “severity” are not totally uniform. At the same time, however, the 2013 Task 
Force suggests that all women with “mild” preeclampsia do not need magnesium sulfate 
neuro-prophylaxis. The conundrum is whether or not to give neuro-prophylaxis to any of 
these women with “non-severe” gestational hypertension or preeclampsia (Alexander et 
al., 2006). 
In many other countries, and principally following dissemination of the Magpie 
Trial Collaboration Group (2002) study results, magnesium sulfate is now 
recommended for women with severe preeclampsia. In some, however, debate continues 
concerning whether therapy should be reserved for women who have an eclamptic 
seizure. Eclamptic seizures are dangerous. Maternal mortality rates of up to 5 percent 
have been reported even in recent studies (Andersgaard et al.,  2006; Schutte et al.,  
2008; Zwart et al.,  2008; Benhamou et al.,  2009; Moodley et al., 2010).  
Moreover, there are substantially increased perinatal mortality rates in both 
industrialized countries and underdeveloped ones (Knight et al., 2007; Schutte et al., 
2008; Abd El Aal et al., 2012; Ndaboine et al., 2012; von Dadelszen et al., 2012). 
Finally, the possibility of adverse long-term neuropsychological and vision-related 
sequelae of eclampsia described by Aukes et al. (2009; 2012), Postma et al. (2009), 
Wiegman et al. (2012), and their coworkers, have raised additional concerns that 
eclamptic seizures are not “benign.” 
Selective versus Universal Magnesium Sulfate Prophylaxis 
There is uncertainty around which women with non-severe gestational 
hypertension should be given magnesium sulfate neuro-prophylaxis. Lucas and 
associates (1995) had found that the risk of eclampsia without magnesium prophylaxis 
was approximately 1 in 100 for women with mild preeclampsia. Up until 2000, all 
women with gestational hypertension were given magnesium prophylaxis intramuscularly 
as first described by Pritchard in 1955. After 2000, a standardized protocol for 
intravenously administered magnesium sulfate was instituted (Alexander et al., 2006).  
At the same time, practice of universal seizure prophylaxis for all women with 
gestational hypertension has changed to one of selective prophylaxis given only to 
women who met Parkland Hospital Criteria for severe gestational hypertension. These 
criteria, shown in Table XVI, included women with ≥ 2+ proteinuria measured by 
dipstick in a catheterized urine specimen. Following this protocol change, 60 percent of 
6518 women with gestational hypertension during a 4½-year period were given 
magnesium sulfate neuro-prophylaxis (Table XVII). The remaining 40 percent with non-
severe hypertension were not treated, and of these, 27 women developed eclamptic 
seizures—1 in 92 (American College of Obstetricians and Gynecologists, 2013d). 
 
TABLE XVI. Selective versus Universal Magnesium Sulfate Prophylaxis: Parkland 
Hospital Criteria to Define Severity of Gestational Hypertension: 
In a woman with new-onset proteinuric hypertension, at least one of the following 
criteria is required: 
 Systolic BP ≥ 160 or diastolic BP ≥ 110 mm Hg 
 Proteinuria ≥ 2+ by dipstick in a catheterized urine specimen 
 Serum creatinine > 1.2 mg/dL 
 Platelet count < 100,000/μL 
 Aspartate aminotransferase (AST) elevated two times above upper limit of normal 
range 
 Persistent headache or scotomata 
 Persistent midepigastric or right-upper quadrant pain 
BP = blood pressure. (Criteria based on those from National High Blood Pressure 
Education Program Working Group, 2000; American College of Obstetricians and 
Gynecologists, 2012b; cited by Alexander et al., 2006). 
The seizure rate was only 1 in 358 for 3935 women with criteria for severe 
disease who were given magnesium sulfate, and thus these cases were treatment failures. 
To assess morbidity, outcomes in 87 eclamptic women were compared with outcomes in 
all 6431 non-eclamptic hypertensive women. Although most maternal outcomes were 
similar, almost a fourth of women with eclampsia who underwent emergent cesarean 
delivery required general anesthesia. This is a great concern because eclamptic women 
have laryngo-tracheal edema and are at a higher risk for failed intubation, gastric acid 
aspiration, and death (American College of Obstetricians and Gynecologists, 2013d).  
Neonatal outcomes were also a concern because the composite morbidity defined 
in Table XVII was significantly increased tenfold in eclamptic compared with non-
eclamptic women—12 versus 1 percent, respectively. 
TABLE XVII. Selected Pregnancy Outcomes in 6518 Women with Gestational 
Hypertension According to Whether They Developed Eclampsia: 
 
Thus, if one uses the Parkland criteria for non-severe gestational hypertension, 
about 1 of 100 such women who are not given magnesium sulfate prophylaxis can be 
expected to have an eclamptic seizure. A fourth of these women likely will require 
emergent cesarean delivery with attendant maternal and perinatal morbidity and mortality 
from general anesthesia. From this, the major question regarding management of non-
severe gestational hypertension remains—whether it is acceptable to avoid unnecessary 
treatment of 99 women to risk eclampsia in one? The answer appears to be yes as 
suggested by the 2013 Task Force. 
DELIVERY 
To avoid maternal risks from cesarean delivery, steps to effect vaginal delivery are 
used initially in women with eclampsia. Following a seizure, labor often ensues 
spontaneously or can be induced successfully even in women remote from term. An 
immediate cure does not promptly follow delivery by any route, but serious morbidity is 
less common during the puerperium in women delivered vaginally (Alanis et al., 2008). 
Blood Loss at Delivery 
Hemoconcentration or lack of normal pregnancy-induced hypervolemia is an 
almost predictable feature of severe preeclampsia-eclampsia as quantified by Zeeman 
and associates (2009). These women, who consequently lack normal pregnancy 
hypervolemia, are much less tolerant of even normal blood loss than are normotensive 
pregnant women. It is of great importance to recognize that an appreciable fall in blood 
pressure soon after delivery most often means excessive blood loss and not sudden 
resolution of vasospasm and endothelial damage. When oliguria follows delivery, the 
hematocrit should be evaluated frequently to help detect excessive blood loss. If 
identified, hemorrhage should be treated appropriately by careful crystalloid and blood 
transfusion. 
Analgesia and Anesthesia 
During the past 20 years, the use of conduction analgesia for women with 
preeclampsia syndrome has proven ideal. Initial problems with this method included 
hypotension and diminished uterine perfusion caused by sympathetic blockade in these 
women with attenuated hypervolemia. But pulmonary edema was mitigated by 
techniques that used slow induction of epidural analgesia with dilute solutions of 
anesthetic agents to counter the need for rapid infusion of large volumes of crystalloid or 
colloid to correct maternal hypotension (Wallace et al., 1995; Hogg et al., 1999).  
Moreover, epidural blockade avoids general anesthesia, in which the stimulation 
of tracheal intubation may cause sudden severe hypertension. Such blood pressure 
increases, in turn, can cause pulmonary edema, cerebral edema, or intracranial 
hemorrhage. Finally, tracheal intubation may be particularly difficult and thus hazardous 
in women with airway edema due to preeclampsia (American College of Obstetricians 
and Gynecologists, 2013d). 
At least three randomized studies have been performed to evaluate these methods 
of analgesia and anesthesia. Wallace and colleagues (1995) studied 80 women at 
Parkland Hospital with severe preeclampsia who were to undergo cesarean delivery. They 
had not been given labor epidural analgesia and were randomized to receive general 
anesthesia, epidural analgesia, or combined spinal-epidural analgesia. Their average 
preoperative blood pressures approximated 170/110 mm Hg, and all had proteinuria. 
Anesthetic and obstetrical management included antihypertensive drug therapy and 
limited intravenous fluids as previously described. Perinatal outcomes in each group were 
similar. Maternal hypotension resulting from regional analgesia was managed with 
judicious intravenous fluid administration. In women undergoing general anesthesia, 
maternal blood pressure was managed to avoid severe hypertension (Figure 21). There 
were no serious maternal or fetal complications attributable to any of the three anesthetic 
methods. It was concluded that all three are acceptable for use in women with 
pregnancies complicated by severe preeclampsia if steps are taken to ensure a careful 
approach to the selected method. 
Another randomized study included 70 women with severe preeclampsia 
receiving spinal analgesia versus general anesthesia (Dyer et al., 2003). All had a 
nonreassuring fetal heart rate tracing as the indication for cesarean delivery, and 
outcomes were equivalent. Dyer and coworkers (2008) later showed that decreased 
mean arterial blood pressure induced by epidural blockade could be effectively 
counteracted by phenylephrine infusion to maintain cardiac output. 
 
FIGURE 21. Blood pressure effects of general anesthesia versus epidural or spinal–
epidural analgesia for cesarean delivery in 80 women with severe preeclampsia. 
MAP = mean arterial pressure. Time posts (T): OR = operating room; IN = induction of 
anesthesia; T = tracheal intubation; IN5 = induction + 5 min; IN10 = induction + 10 min; 
IN20 = induction + 20 min; SKI = skin incision; D = delivery; SKC = skin closure; O = 
extubation (From Wallace et al., 1995). 
In a study from the University of Alabama at Birmingham, Head and colleagues 
(2002) randomly assigned 116 women with severe preeclampsia to receive either epidural 
or patient-controlled intravenous meperidine analgesia during labor. A standardized 
protocol limited intravenous fluids to 100 mL/hr. More women—9 percent—from the 
group assigned to epidural analgesia required ephedrine for hypotension. As expected, 
pain relief was superior in the epidural group, but maternal and neonatal complications 
were similar between groups. One woman in each group developed pulmonary edema. 
It is important to emphasize that epidural analgesia is not to be considered 
treatment of preeclampsia. Lucas and associates (2001) studied 738 laboring women at 
Parkland Hospital who were 36 weeks or more and who had gestational hypertension of 
varying severity. Patients were randomly assigned to receive either epidural analgesia or 
patient-controlled intravenous meperidine analgesia. Maternal and neonatal outcomes 
were similar in the two study groups. However, as shown in Table XVIII, epidural 
analgesia resulted in a greater decrement of mean maternal arterial pressure compared 
with meperidine, but it was not superior in preventing recurrent severe hypertension later 
in labor. 
TABLE XVIII. Comparison of Cardiovascular Effects of Epidural versus Patient-
Controlled Meperidine Analgesia During Labor in Women with Gestational 
Hypertension: 
 
For these reasons, judicious fluid administration is essential in severely 
preeclamptic women who receive regional analgesia. Newsome and coworkers (1986) 
showed that vigorous crystalloid infusion with epidural blockade in women with severe 
preeclampsia caused elevation of pulmonary capillary wedge pressures.  
Aggressive volume replacement in these women increases their risk for 
pulmonary edema, especially in the first 72 hours postpartum (Clark et al., 1985; Cotton 
et al., 1986a). When pulmonary edema develops, there is also concern for development 
of cerebral edema. Finally, Heller and associates (1983) demonstrated that most cases of 
pharyngo-laryngeal edema were related to aggressive volume therapy. 
Persistent Severe Postpartum Hypertension 
The potential problem of antihypertensive agents causing serious compromise of 
uteroplacental perfusion and thus of fetal well-being is obviated by delivery. Postpartum, 
if difficulty arises in controlling severe hypertension or if intravenous hydralazine or 
labetalol are being used repeatedly, then oral regimens can be given. Examples include 
labetalol or another β-blocker, nifedipine or another calcium-channel blocker, and 
possible addition of a thiazide diuretic. Persistent or refractory hypertension is likely due 
to mobilization of pathological interstitial fluid and redistribution into the intravenous 
compartment, underlying chronic hypertension, or usually both (Tan et al., 2002; Sibai, 
2012). In women with chronic hypertension and left-ventricular hypertrophy, severe 
postpartum hypertension can cause pulmonary edema from cardiac failure (Cunningham 
et al., 2012). 
Furosemide 
Because persistence of severe hypertension corresponds to the onset and length of 
diuresis and extracellular fluid mobilization, it seems logical that furosemide-augmented 
diuresis might serve to hasten blood pressure control. To study this, Ascarelli and 
coworkers (2005) designed a randomized trial that included 264 postpartum 
preeclamptic women. After onset of spontaneous diuresis, patients were assigned to 20-
mg oral furosemide given daily or no therapy. Women with mild disease had similar 
blood pressure control regardless of whether they received treatment or placebo.  
However, women with severe preeclampsia who were treated, compared with 
those receiving placebo, had a lower mean systolic blood pressure at 2 days—142 versus 
153 mm Hg. They also required less frequently administered antihypertensive therapy 
during the remainder of hospitalization—14 versus 26 percent, respectively. A simple 
method to estimate excessive extracellular/interstitial fluid was used. The postpartum 
weight is compared with the most recent prenatal weight, either from the last clinic visit 
or on admission for delivery. On average, soon after delivery, maternal weight should be 
reduced by at least 10 to 15 pounds depending on infant and placental weight, amnionic 
fluid volume, and blood loss. Because of various interventions, especially intravenous 
crystalloid infusions given during operative vaginal or cesarean delivery, women with 
severe preeclampsia often have an immediate postpartum weight in excess of their last 
prenatal weight. If this weight increase is associated with severe persistent postpartum 
hypertension, then diuresis with intravenous furosemide is usually helpful in controlling 
blood pressure. 
Plasma Exchange 
Martin and colleagues (1995) have described an atypical syndrome in which 
severe preeclampsia-eclampsia persists despite delivery. These investigators described 18 
such women whom they encountered during a 10-year period. They advocate single or 
multiple plasma exchange for these women. In some cases, 3 L of plasma was exchanged 
three times—a 36- to 45-donor unit exposure for each patient—before a response was 
forthcoming. Others have described plasma exchange performed in postpartum women 
with HELLP syndrome. In all of these cases, however, the distinction between HELLP 
syndrome and thrombotic thrombocytopenic purpura or hemolytic uremic syndrome was 
not clear (Förster et al., 2002; Obeidat et al., 2002). 
 
Experiences with more than 50,000 women with gestational hypertension among 
nearly 450,000 pregnancies cared for, it has been encountered very few women with 
persistent postpartum hypertension, thrombocytopenia, and renal dysfunction who were 
diagnosed as having a thrombotic microangiopathy (Dashe et al., 1998). These latter 
syndromes complicating pregnancy were reviewed by Martin et al. (2008) and George 
et al. (2013) and their colleagues, who conclude that a rapid diagnostic test for 
ADAMTS-13 enzyme activity might be helpful to differentiate most of these syndromes. 
Reversible Cerebral Vasoconstriction Syndrome 
This is another cause of persistent hypertension, “thunderclap” headaches, 
seizures, and central nervous system findings. It is a form of postpartum angiopathy. As 
shown in Figure 22, it is characterized by diffuse segmental constriction of cerebral 
arteries and may be associated with ischemic and hemorrhagic strokes. The reversible 
cerebral vasoconstriction syndrome has several inciting causes that include pregnancy, 
and particularly preeclampsia (Ducros et al., 2012). It is more common in women, and in 
some cases, vasoconstriction may be so severe as to cause cerebral ischemia and 
infarction. The appropriate management is not known at this time (Edlow et al., 2013). 
COUNSELING FOR FUTURE PREGNANCIES 
Defective remodeling of the spiral arteries in some placentations has been posited 
as the cause of at least one preeclampsia phenotype. Lack of deep placentation has been 
associated with preeclampsia, placental abruption, fetal-growth restriction, and preterm 
birth (Wikström et al., 2011). With this type of “overlap syndrome,” hypertensive 
disorders may serve as markers for subsequent preterm labor and fetal-growth restriction. 
For example, even in subsequent non-hypertensive pregnancies, women who had preterm 
preeclampsia are at increased risk for preterm birth (Connealy et al., 2013). 
 
 
FIGURE 22. Reversible cerebral vasoconstriction syndrome. Magnetic resonance 
angiography shows generalized vasoconstriction of the anterior and posterior cerebral 
circulation (arrows) (From Garcia-Reitboeck et al., 2013). 
In addition, women who have had either gestational hypertension or preeclampsia 
are at higher risk to develop hypertension in future pregnancies. Generally, the earlier 
preeclampsia is diagnosed during the index pregnancy, the greater the likelihood of 
recurrence. Sibai and colleagues (1986, 1991) found that nulliparas diagnosed with 
preeclampsia before 30 weeks have a recurrence risk as high as 40 percent during a 
subsequent pregnancy.  
In a prospective study of 500 women previously delivered for preeclampsia at 37 
weeks, the recurrence rate in a subsequent gestation was 23 percent. These investigators 
found an increased risk during subsequent pregnancies for preterm delivery and fetal-
growth restriction even if these women remained normotensive (Bramham et al., 2011). 
In a study from the Denmark Birth Registry, Lykke and coworkers (2009b) 
analyzed singleton births in more than 535,000 women who had a first and second 
delivery. Women whose first pregnancy was complicated by preeclampsia between 32 
and 36 weeks had a significant twofold increased incidence of preeclampsia in their 
second pregnancy—25 versus 14 percent—compared with women who were 
normotensive during the first pregnancy. Analyzed from another view, they also found 
that preterm delivery and fetal-growth restriction in the first pregnancy significantly 
increased the risk for preeclampsia in the second pregnancy. 
As probably expected, women with HELLP syndrome have a substantive risk for 
recurrence in subsequent pregnancies. In two studies the risk ranged from 5 to 26 percent, 
but the true recurrence risk likely lies between these two extremes (Habli et al., 2009). 
Even if HELLP syndrome does not recur with subsequent pregnancies, there is a high 
incidence of preterm delivery, fetal-growth restriction, placental abruption, and cesarean 
delivery (Hnat et al., 2002; Habli et al., 2009). 
LONG-TERM CONSEQUENCES 
Over the past 20 years, evidence has accrued that preeclampsia, like fetal-growth 
disorders and preterm birth, is a marker for subsequent cardiovascular morbidity and 
mortality. Women with hypertension identified during pregnancy should be evaluated 
during the first several months postpartum and counseled regarding long-term risks. The 
Working Group concluded that hypertension attributable to pregnancy should resolve 
within 12 weeks of delivery (National High Blood Pressure Education Program, 
2000).  
Persistence beyond this time is considered to be chronic hypertension. The 
Magpie Trial Follow-Up Collaborative Group (2007) reported that 20 percent of 3375 
preeclamptic women seen at a median of 26 months postpartum had hypertension. 
Importantly, even if hypertension does not persist in the short term, convincing evidence 
suggests that the risk for long-term cardiovascular morbidity is significantly increased in 
preeclamptic women. 
Cardiovascular and Neurovascular Morbidity 
With the advent of national databases, several studies confirm that any 
hypertension during pregnancy is a marker for an increased risk for morbidity and 
mortality in later life (American College of Obstetricians and Gynecologists, 2013c).  
In a case-control study from Iceland, Arnadottir and associates (2005) analyzed 
outcomes for 325 women who had hypertension complicating pregnancy and who were 
delivered from 1931 through 1947. At a median follow-up of 50 years, 60 percent of 
women with pregnancy-related hypertension compared with only 53 percent of controls 
had died. Compared with 629 normotensive pregnant controls, the prevalences of 
ischemic heart disease—24 versus 15 percent, and stroke—9.5 versus 6.5 percent, were 
significantly increased in the women who had gestational hypertension.  
In a Swedish population study of more than 400,000 nulliparas delivered between 
1973 and 1982, Wikström and coworkers (2005) also found an increased incidence of 
ischemic heart disease in women with prior pregnancy-associated hypertension. 
Lykke and associates (2009a) cited findings from a Danish registry of more than 
780,000 nulliparous women. After a mean follow-up of almost 15 years, the incidence of 
chronic hypertension was significantly increased 5.2-fold in those who had gestational 
hypertension, 3.5-fold after mild preeclampsia, and 6.4-fold after severe preeclampsia.  
After two hypertensive pregnancies, there was a 5.9-fold increase in the 
incidence. Importantly, these investigators also reported a significant 3.5-fold increased 
risk for type 2 diabetes (Lykke et al., 2009a). 
Bellamy and coworkers (2007) performed a systematic review and meta-analysis 
of long-term risks for cardiovascular disease in women with preeclampsia. As shown in 
Figure 23, the risks in later life were increased for hypertension, ischemic heart disease, 
stroke, venous thromboembolism, and all-cause mortality.  
 
FIGURE 23. Long-term cardiovascular consequences of preeclampsia. All 
differences p ≤ .001 (Data from Bellamy et al., 2007). 
As emphasized by several investigators, other cofactors or comorbidities are 
related to acquisition of these long-term adverse outcomes (Harskamp et al., 2007; 
Gastrich et al., 2012; Hermes et al., 2012; Spaan et al., 2012b).  
These include but are not limited to the metabolic syndrome, diabetes, obesity, 
dyslipidemia, and atherosclerosis. These conclusions are underscored by the findings of 
Berends and colleagues (2008), who confirmed shared constitutional risks for long-term 
vascular-related disorders in preeclamptic women and in their parents. Similar 
preliminary observations were reported by Smith (2009; 2012) and Stekkinger (2013) 
and their associates. 
At least in some of these women, their hypertensive cardiovascular pathologies 
appear to have begun near the time of their own births. For example, individuals who are 
born preterm have increased ventricular mass later in life (Lewandowski et al., 2013).  
Women who have preeclampsia and who develop chronic hypertension later in 
life have an increased ventricular mass index before they become hypertensive. A similar 
phenomenon is associated with preterm birth and with fetal-growth disorders (Ghossein-
Doha et al., 2013). 
RENAL SEQUELAE 
Preeclampsia appears to also be a marker for subsequent renal disease. In a 
preliminary study, the possibility was raised that persistent podocyturia might be a 
marker for such disease (Garrett et al., 2013). In a 40-year study of Norwegian birth and 
end-stage renal disease linked registries, although the absolute risk of renal failure was 
small, preeclampsia was associated with a fourfold increased risk (Vikse et al., 2008). 
Women with recurrent preeclampsia had an even greater risk. These data need to be 
considered in light of the findings that 15 to 20 percent of women with preeclampsia who 
undergo renal biopsy have evidence of chronic renal disease (Chesley et al., 1978).  
In another long-term follow-up study, Spaan and coworkers (2009) compared 
formerly preeclamptic women with a cohort of women who were normotensive at 
delivery. At 20 years following delivery, preeclamptic women were significantly more 
likely to be chronically hypertensive—55 versus 7 percent—compared with control 
women. They also had higher peripheral vascular and renovascular resistance and 
decreased renal blood flow. These data do not permit conclusions as to cause versus 
effect. 
NEUROLOGICAL SEQUELAE 
Until recently, eclamptic seizures were believed to have no significant long-term 
sequelae. Findings have now accrued, however, that this is not always the case. Recall 
that almost all eclamptic women have multifocal areas of perivascular edema, and about a 
fourth also have areas of cerebral infarction (Zeeman et al., 2004a). 
A Dutch group has reported several long-term follow-up studies in women with 
severe preeclampsia and eclampsia (Aukes et al., 2007; 2009; 2012). These investigators 
found long-term persistence of brain white-matter lesions that were incurred during 
eclamptic convulsions (Aukes et al., 2009). When studied with MR imaging at a mean of 
7 years, 40 percent of formerly eclamptic women had more numerous and larger 
aggregate white matter lesions compared with 17 percent of normotensive control 
women. These investigators later also observed these white-matter lesions in 
preeclamptic women without convulsions (Aukes et al., 2012).  
In studies designed to assess clinical relevance, Aukes and colleagues (2007) 
reported that formerly eclamptic women had subjectively impaired cognitive functioning. 
They also reported that women with multiple seizures had impaired sustained attention 
compared with normotensive controls (Postma et al., 2009).  
Recently, Wiegman and associates (2012) described that formerly eclamptic 
women at approximately 10 years had lower vision-related quality of life compared with 
control subjects. Because there were no studies done before these women suffered from 
preeclampsia or eclampsia, the investigators appropriately concluded that cause versus 











Organized prenatal care in the United States was introduced largely by social 
reformers and nurses. In 1901, Mrs. William Lowell Putnam of the Boston Infant Social 
Service Department began a program of nurse visits to women enrolled in the home 
delivery service of the Boston Lying-in Hospital (Merkatz et al., 1990). 
It was so successful that a prenatal clinic was established in 1911. In 1915, J. Whit 
ridge Williams reviewed 10,000 consecutive deliveries at Johns Hopkins Hospital and 
concluded that 40 percent of 705 perinatal deaths could have been prevented by prenatal 
care. In 1954, Nicholas J. Eastman credited organized prenatal care with having "done 
more to save mothers' lives in our time than any other single factor." In the 1960s, Dr. 
Jack Pritchard established a network of university-operated prenatal clinics located in the 
most underserved communities in Dallas County. In large part because of increased 
accessibility, currently more than 95 percent of medically indigent women delivering at 
Parkland Hospital receive prenatal care. Importantly and related, the perinatal mortality 
rate of women in this system is less than that of the United States overall. Antenatal care 
is the clinical assessment of mother and fetus during pregnancy, for the purpose of 
obtaining the best possible outcome for the mother and child (Duckitt and Harrington, 
2011). 
The concept of the unbooked mothers has traditionally associated with women in 
developing countries who are unable or unwilling to access healthcare facilities. In 
studies of unbooked deliveries in African countries, older women of lower socioeconomic 
status and high parity have been identified as the groups most likely not to book for 
antenatal care and therefore more likely to have preterm babies and incur maternal 
mortality (Filmer and Pritchett, 2001). 
 
Experiences from different countries have shown that reducing maternal mortality 
may depend in part on the availability and use of a professional attendant at labor and a 
referral mechanism for obstetric care for managing complications, or use of basic 
essential obstetric care facilities for all deliveries (Ronsmans and Graham, 2006). 
In many developing countries however, the majority of births occur at home, 
frequently without the help of a skilled assistant (midwife, nurse trained as midwife or a 
doctor) (Abou Zahr and Wardlaw, 2001). The effect of antenatal care on maternal 
mortality is unclear (Bullough et al., 2005). However, there is broad agreement that 
antenatal care interventions can lead to improved maternal and newborn health, which 
can also impact on the survival and health of the infant (World Health Organization-
United Nations Children's Fund [WHO-UNICEF], 2003). 
A global evaluation of antenatal care has resulted in the recommendation to 
deliver antenatal services in 4 focused visits (Focused antenatal care; FANC), one within 
the first trimester and 3 after quickening, and this schedule is now endorsed by WHO 
(van Eijk et al., 2008). Proven effective antenatal interventions include serologic 
screening for syphilis, provision of malaria prevention, anti-tetanus immunization, and 
prevention of mother-to-child transmission of Human Immunodeficiency Virus (HIV) 
(Khan et al., 2006). To fully benefit from these interventions, it is important that women 
start visiting the antenatal clinic (ANC) early in pregnancy (Freedman et al., 2005). 
MATERNAL HEALTH 
Maternal health refers to the health of women during pregnancy, childbirth and 
the postpartum period. While motherhood is often a positive and fulfilling experience, it 
is associated with suffering, ill-health and even death for to many women. There is little 
information about maternal health and morbidity in many countries and, therefore, 
maternal mortality is often used as a proxy indicator for maternal health (Filippi et al., 
2005). 
Every minute, at least one woman dies from complications related to pregnancy 
or childbirth i.e. 529,000 women per year. In addition, for every woman who dies in 
childbirth, around 20 more suffer injury, infection or disease – approximately10 million 
women each year (WHO, 2009). Five direct complications that account for more than 
70% of maternal deaths are: hemorrhage, infection, unsafe abortion, eclampsia and 
obstructed labor. This did not change during the 12 year period from 1988 to 2000 (Khan 
et al, 2006) and even during the last decade (WHO, 2009). 
Unavailable, inaccessible, unaffordable, and/or poor quality care are 
fundamentally responsible for maternal deaths worldwide. These deaths are detrimental 
to social development and well-being, as some one million children are left motherless 
each year. These children are 10 times more likely to die within two years of their 
mothers’ death (WHO, 2005). 
Importance of Antenatal Care in reduction of Maternal Morbidity and Mortality 
In developing countries, the major causes of maternal mortality remain 
hemorrhage(21%), eclampsia (18.6%), sepsis (13.3%), abortion (11%), obstructed labor 
(8.7%) and others(27.4%) (Society of Obstetricians and Gynecologists, 1990). 
Good antenatal care, its provision and accessibility can mostly prevent all the 
above causes that require emergency obstetrical care. In 1994, the International 
Conference on Population and development (ICPD) held in Cairo, emphasized the 
importance and need for maternal health care services that will enable women to go 
safely through pregnancy and childbirth to produce a healthy baby. One of the 
cornerstone of provision of good maternal health service is antenatal care that not only 
identifies risks and detects complications like hypertension and mal-presentations, but 
also provides information on: i-recognition of danger signs and symptoms, ii- where to 
going case of emergency and iii- transportation to referral site (Matthews et al., 2001). 
         Antenatal visits can play a critical role in establishing confidence between the 
woman, the family and the health care provider. In developing countries only 65% 
women receive antenatal care compared to 97% in developed countries. In urban Sindh 
63% women avail antenatal care as opposed to only 15% in the rural areas. According to 
the Maternal and Infant Mortality Survey (MIMS)- Sindh of 3998 women, the three main 
reasons cited for not availing antenatal care were women’s perception of no complaints 
(44%), services not available (21.4%) and costs too much (14%). The article published in 
this issue indicates that social status and economic conditions were important 
determinants of utilization of antenatal services (MIMS- Sindh, 1994). 
A study from Rajasthan, India also observed that socio-economic status and 
literacy levels influenced utilization of antenatal service (Mondal, 1997). The importance 
of quality antenatal care cannot be questioned. But without availability of transport and 
efficient round the clock Emergency Obstetric Care (EmOC) facilities, it is not possible 
to reduce maternal morbidity and mortality. It is estimated that in Pakistan 1 in 20 women 
who suffer from complications of pregnancy reach a health facility where EmOC is 
available. This is due to three types of delays: delay in seeking care, delay in reaching to 
an EmOC and delay in starting treatment due to non-availability of trained health care 
personnel, blood, life saving drugs and equipment. In a survey of 48 health facility in 4 
districts of Sindh almost none were providing quality EmOC (Women’s Health in 
Pakistan, 1997). 
MATERNAL HEALTH SERVICES IN DEVELOPED COUNTRIES 
The importance of maternal health care is acknowledged nationally and 
internationally and listed among one of the Millennium development goals (WHO, 
2004). 
 
For last few decades, maternal health care became one of the key points in the 
health care service delivered in developed countries and because of that, these countries 
achieved significant results in terms of reduction of maternal mortality and morbidity. For 
example in Australia, the Western Australian Department of Health developed integrated 
and responsive maternal health care services that can be adapted according to the 
individual need of the patients in their own settings (Western-Australian Department 
of Health, 2007). In the United Kingdom, maternal care is available to all women (The 
House of Commons, 2003). 
MATERNAL HEALTH SERVICES IN DEVELOPING COUNTRIES 
The situation is different in developing countries. In these countries, maternal 
mortality and morbidity remain high. However, many countries have taken important 
steps to address this problem. In Tanzania, Jahn et al. (1996) reported that despite 
pursuing the risk approach and good antenatal coverage, antenatal care in Tanzania has 
only limited effect on extending obstetric care to high-risk mothers. 
In Zambia, the Department of Health has taken necessary steps to provide a 
patient-centered family orientated maternal health care services based on “Making 
pregnancy safer initiative’ of WHO (Maimbolwa, 2004).  
In Mozambique, the Department of Health introduced a patient friendly 
community participation approach by involving the patients, their families and 
communities (Sundby et al., 2002). 
Although the effect of these newer initiatives on maternal mortality and morbidity 
is yet to be seen, there are some evidences emerging. For example, in Ghana, utilization 
of maternal health services was found to be directly associated with reduction in maternal 
and neonatal mortality (Ansong-Tomui et al., 2007). 
In Botswana, the numbers of syphilis cases were declining because of compulsory 
checking of Rapid Plasma Reagin (RPR) test during antenatal attendance (Creek et al., 
2005). 
MATERNAL HEALTH SERVICES IN SOUTH AFRICA 
In South Africa, maternal and child care always remained as key priority areas for 
the Government. The South African government also introduced free maternal care in 
1994 (Republic of South Africa, 1994). The Maternal, child and women’s health is 
currently one of the strategic goals for the current strategic plan (Department of Health, 
2009). As a part of that process, the Minister of Health established National Committee 
for Confidential Enquiries into Maternal Deaths. This Committee has produced four 
reports till date. These reports critically analyze the maternal mortality in South Africa 
and provide valuable recommendations. However, most of these recommendations 
remained same for the last decade and not much progress has been made for 
implementation of these recommendations at the facility level. Poor record-keeping, 
inadequate supervision, poor levels of clinical knowledge and under-utilisation of 
midwife obstetric units were some of the challenges identified for maternal health 
services in South Africa (Thomas et al., 2007). 
Maternity cases in South Africa are managed in different levels of health care 
(primary, secondary or tertiary) according to the risk category of patients. Patients are 
classified into no risk, low risk, medium risk and high risk. Based on the classifications, 
the cases are managed at appropriate level of care. This risk classification is expected to 
guide the management of cases at the health facilities. This arrangement is expected to 
improve maternal services and maternal and perinatal outcomes (Farrell and Pattinson, 
2005). However, a similar study done in Zimbabwe did not find the usefulness of risk 
scores (Majoko et al. 2002). 
Recently, the Perinatal Mother to Child Transmission (PMTCT) Programme 
became an integral part of maternal health services. Adequate management of HIV in 
pregnancy is key to the successful implementation of maternal health services due to a 
high prevalence of HIV in this country (Hoque et al., 2008). 
ANTENATAL CARE 
Antenatal care is identified as one of the key programmes for improvement of 
maternal health not only in South Africa but also rest of the world. Antenatal care is an 
intervention aimed at pregnant women to ensure the best possible outcome for both the 
mother and the baby. The WHO recommends antenatal care to be one of the interventions 
aimed at decreasing maternal and perinatal mortality and it recommends at least four 
visits for an adequate level of antenatal care (WHO, 2009).  
Women should book as soon as pregnancy is detected which could be as early as six 
weeks of gestation in order to be screened for any pregnancy related problems, to review 
the risk of the pregnancy and to make provision for medications that may improve the 
pregnancy outcome. A woman is generally considered to be booked if she has had at least 
two clinic visits at least two weeks before giving birth and had booking bloods taken at 
the first visit (Cronje and Grobler, 2003; WHO, 2009).   
Despite all the advantages of regular antenatal care, late bookings and missed visits 
still occur in South Africa. There are still some pregnant women who present to the health 
facility to deliver without ever attending any antenatal care. Some of the reasons for late 
bookings include the following: young age, primigravidae, multigravidae, being a single 
parent, low socio-economic status, unemployment, and time constraints and for some 
women, the distance away from the health care facility contributes to being un-booked 
(Blondel et al, 1993; Mutihir and Nyiputen, 2007). 
 
Booked women are found to get early, ongoing monitoring and a continuous risk 
assessment (Fiscella, 1995). This includes health education, information about self-care 
in pregnancy, danger signs and symptoms of pregnancy. The antenatal care could address 
a delivery plan with an estimated date, place and mode of delivery for the current 
pregnancy and allow for planning of future pregnancies and contraception use. If 
indicated, additional tests, nutritional supplements and treatment of medical problems 
could be commenced. Antenatal care also has the additional advantage of ensuring that a 
woman is attended to by a skilled healthcare professional during pregnancy and labor 
which is an important point of entry in the prevention of mother to child transmission of 
HIV (Abou-Zahr and Wardlaw, 2003). On the other hand, unbooked pregnant women 
were found to be twice at risk of operative delivery, four times more likely to suffer 
delivery complications and twice likely to have low birth weight babies when compared 
to booked patients (Okunlola et al., 2008). 
      With regards to universal access to reproductive health, the provision of antenatal 
care is used as an indicator of access. The 2003 South African Demographic Health 
Survey (SADHS) reported antenatal attendance to be in the region of 92% for the 
pregnant population, which was slightly lower (94%) than the 1998 survey. About 5.3% 
of pregnant women never attended antenatal care and the remaining 2.7% had no 
knowledge of any antenatal care service provision. The majority (60%) of first antenatal 
visits occurred within the first 6 months of pregnancy. Approximately one quarter of 
women attended for the first time at between 6 and 7 months and almost 3% attended for 
the first time in their 8th month of pregnancy (Department of Health, 2007). 
           The 2006 District Health Information System (DHIS) data reported antenatal 
coverage of 100% but some provinces (such as Gauteng, Kwa-Zulu Natal, Mpumalanga 
and Northern Cape) reported antenatal coverage of more than 100%, raising concerns 
about the quality of data. The same report described the average number of antenatal 
visits was 3.4 (Health Systems Trust, 2009). 
Briggs (1988) studied a cohort of 10,665 deliveries in a hospital in Nigeria and 
found booking status was significantly associated with ante-partum and postpartum 
hemorrhage, severe anemia, and undiagnosed medical and surgical complications. The 
author stressed the importance of antenatal care as one of the key factors to a large-scale 
reduction in maternal mortality. 
Subsequently, another Nigerian study in a different hospital found 29% unbooked 
mother among a cohort of 1,154 deliveries. The study also found a significant association 
between booking status and occurrence of maternal complications (such as anemia and 
ante-partum hemorrhage) and perinatal outcomes (such as preterm babies) (Owalabi et 
al., 2008). 
However, a South African study found no difference in the perinatal mortality 
between booked and unbooked mothers, although there were higher rates of low birth 
weight and prematurity among the unbooked mothers (Ndiweni and Buchmann, 1998). 
ANTENATAL CARE BOOKING AND PROFILE OF PATIENTS 
It is important to identify profile of unbooked patients and develop an 
understanding of the factors that might influence their inability to book during pregnancy.       
Almost thirty years ago, Larsen and van Middelkoop (1982) conducted a study at the 
King Edward VIII Hospital, Durban and found that the unbooked mother was found to 
come more frequently from a background of unstable relationships, financial and 
emotional support and geographical inaccessibility. Unwanted babies and inadequate 
parenting arrangements were more frequent in this group. Previous operative deliveries 
were found to have no influence on booking status.  
A recent study done in Azerbaijan found women's education, socio-economic 
status, gravidity and desirability of the current pregnancy have a significant effect on 
antenatal care utilization (Habibov, 2010). 
This was similar to findings of a study done in Brussels, where researchers found 
women’s education, higher socio-economic status, and low gravidity had a significant 
effect on higher antenatal care utilization. They also found ethnicity, and previous 
medical history played some role (Beeckman et al., 2010). 
In addition to the patient related factors, assessing health care facilities may also 
play a role in antenatal care utilization. This is influenced by various factors such as 
transport from home, poor quality of services, and attitude of health care providers. 
Therefore, it is important to study both patient and health system related factors in a local 
setting to develop an understanding of antenatal care utilization in that area (Gaunt, 
2010). 
Overview of Prenatal Care 
Almost a century after its introduction, prenatal care has become one of the most 
frequently used health services in the United States. In 2006, more than 4.2 million births 
were registered in the United States (Martin et al., 2009).  
In 2001, there were approximately 50 million prenatal visits—the median was 
12.3 visits per pregnancy—and as shown in Figure 24, many women had 17 or more 
visits. 
Since the early 1990s, the largest gains in timely prenatal care have been among 
minority groups. As shown in Figure 25, however, disparity continues. In 2006, African 
American and Hispanic women were more than twice as likely as non-Hispanic white 
women to begin prenatal care after the first trimester (Martin et al., 2009).  
 
 
FIGURE 24. Frequency distribution of the number of prenatal visits for the United 
States in 2001 (Adapted from Martin et al., 2002b). 
 
Figure 25. Percentage of women in the United States with prenatal care beginning in 
the first trimester by ethnicity in 1989, 2001, and 2006 (Adapted from Martin et al., 
2002b; 2009.) 
Obstetrical and medical risk factors or complications identifiable during prenatal 
care are summarized in Table XIX. Importantly, many of these complications are 
treatable  
TABLE XIX. Obstetrical and Medical Risk Factors Detected during Prenatal Care 
in the United States in 2001 (Data from Martin et al., 2002b): 
Risk Factor Births Percent 
Total live births 4,025,933 100 
Gestational hypertension 150,329 3.7 
Diabetes 124,242 3.1 
Anemia 99,558 2.5 
Hydramnios/oligohydramnios 54,694 1.4 
Lung disease 48,246 1.2 
Genital herpes 33,560 0.8 
Chronic hypertension 32,232 0.8 
D (Rh) sensitization 26,933 0.7 
Cardiac disease 20,698 0.5 
Renal disease 12,045 0.3 
Incompetent cervix 11,251 0.3 
Hemoglobinopathy 3,141 0.1 
  Total 616,929 15.3 
Assessing Adequacy of Prenatal Care 
A commonly employed system for measuring prenatal care adequacy is the index 
of Kessner et al. (1973). As shown in Table XX, this Kessner Index incorporates three 
items from the birth certificate: length of gestation, timing of the first prenatal visit, and 
number of visits.  
Table XX. Kessner Index Criteria: 
Adequate Prenatal Care 
Initial visit in first trimester and: 
Weeks  Attended Prenatal Visits 
17 and 2 or more 
18–21 and 3 or more 
22–25 and 4 or more 
26–29 and 5 or more 
30–31 and 6 or more 
32–33 and 7 or more 
34–35 and 8 or more 
36 or more and 9 or more 
Inadequate Prenatal Care 
Initial visit in third trimester or: 
Weeks   Attended Prenatal Visits 
17–21 and None 
22–29 and 1 or fewer 
30–31 and 2 or fewer 
32–33 and 3 or fewer 
34 or more and 4 or fewer 
Intermediate Care 
All other combinations 
It does not, however, measure the quality of care, nor does it consider the relative 
risk of complications for the mother. Still, the index remains a useful measure of prenatal 
care adequacy. Using this index, the National Center for Health Statistics concluded that 
12 percent of American women who were delivered in 2000 received inadequate prenatal 
care (Martin et al., 2002a). 
The Centers for Disease Control and Prevention (CDC) (2000) analyzed birth 
certificate data for the years 1989 to 1997 and found that half of women with delayed or 
no prenatal care wanted to begin care earlier. Reasons for inadequate prenatal care are 
varied by social and ethnic group, age, and method of payment. The most common reason 
cited was late identification of pregnancy by the patient. The second most commonly 
cited barrier was lack of money or insurance for such care. The third was inability to 
obtain an appointment. 
Effectiveness of Prenatal Care 
Prenatal care designed during the early 1900s was focused on lowering the 
extremely high maternal mortality rates. Such care undoubtedly contributed to the 
dramatic decline in maternal mortality rates from 690 per 100,000 births in 1920 to 50 
per 100,000 by 1955 (Loudon, 1992). Maternal Mortality, the current low maternal 
mortality rate of approximately 8 per 100,000 is likely associated with the high utilization 
of prenatal care. Indeed, in a population-based study from North Carolina, Harper et al. 
(2003) found that the risk of pregnancy-related maternal death was decreased fivefold 
among recipients of prenatal care. 
There are other studies that attest to the efficacy of prenatal care. Herbst et al. 
(2003) found that no prenatal care was associated with more than a twofold increased risk 
of preterm birth. Schramm (1992) compared the costs and benefits of prenatal care in 
1988 for more than 12,000 Medicaid patients in Missouri. For each $1 spent for prenatal 
care, there were estimated savings of $1.49 in newborn and postpartum costs.  
Vintzileos et al. (2002a) analyzed National Center for Health Statistics data for 
1995 to 1997. They reported that women with prenatal care had an overall stillbirth rate 
of 2.7 per 1000 compared with 14.1 per 1000 for women without prenatal care—an 
adjusted relative risk of 3.3 for fetal death.  
Vintzileos et al. (2002b; 2003) later reported that prenatal care was associated 
with significantly lower rates of preterm births as well as neonatal death associated with 
several high-risk conditions that included placenta previa, fetal-growth restriction, and 
post-term pregnancy. 
Component of Prenatal Care 
The essence of prenatal care is described by the American Academy of 
Pediatrics and the American College of Obstetricians and Gynecologists (2007) as: 
"A comprehensive antepartum care program involves a coordinated approach to medical 
care and psychosocial support that optimally begins before conception and extends 
throughout the antepartum period." This comprehensive program includes: (1) pre-
conceptional care, (2) prompt diagnosis of pregnancy, (3) initial prenatal evaluation, and 
(4) follow-up prenatal visits. 
Pre-conceptional Care 
Because health during pregnancy depends on health before pregnancy, pre-
conceptional care should logically be an integral prelude to prenatal care. A 
comprehensive pre-conceptional care program has the potential to assist women by 
reducing risks, promoting healthy lifestyles, and improving readiness for pregnancy. 
Diagnosis of pregnancy 
The diagnosis of pregnancy usually begins when a woman presents with 
symptoms, and possibly a positive home urine pregnancy test result. Typically, such 
women receive confirmatory testing of urine or blood for human chorionic gonadotropin 
(hCG). There may be presumptive or diagnostic findings of pregnancy on examination. 
Sonography is often used, particularly in those cases in which there is question about 
pregnancy viability or location (Cole et al., 2004). 
Initial Prenatal Evaluation 
According to American Academy of Pediatrics and American College of 
Obstetricians and Gynecologists (2007), prenatal care should be initiated as soon as 
there is a reasonable likelihood of pregnancy. The major goals are to: 
1. Define the health status of the mother and fetus. 
2. Estimate the gestational age. 
3. Initiate a plan for continuing obstetrical care. 
Typical components of the initial visit are summarized in Table XXI. Initial plan 
for subsequent care may range from relatively infrequent routine visits to prompt 
hospitalization because of serious maternal or fetal disease. 
PRENATAL RECORD 
Use of a standardized record within a perinatal healthcare system greatly aids 
antepartum and intrapartum management. Standardizing documentation may allow 
communication and continuity of care between providers and enable objective measures 
of care quality to be evaluated over time and across different clinical settings (Gregory et 
al., 2006). A prototype is provided by the American Academy of Pediatrics and 






TABLE XXI. Typical Components of Routine Prenatal Care (Data from Martin et 
al., 2008): 
  Weeks  
  First Visit 15–20 24–28 29–41 
History  
  Complete *    
  Updated  * * * 
Physical examination  
  Complete *    
  Blood pressure * * * * 
  Maternal weight * * * * 
  Pelvic/cervical examination *    
  Fundal height * * * * 
  Fetal heart rate/position * * * * 
Laboratory tests  
  Hematocrit or hemoglobin *  *  
  Blood type and Rh factor *    
  Antibody screen *  A  
  Pap smear screening *    
  Glucose tolerance test     
 
Continue TABLE XXI. Typical Components of Routine Prenatal Care (Data from 
Martin et al., 2008): 
  Weeks  
  First Visit 15–20 24–28 29–41 
  Fetal aneuploidy screening Ba and/or B   
  Neural-tube defect screening  B   
  Cystic fibrosis screening B or B   
  Urine protein assessment *    
  Urine culture *    
  Rubella serology *    
  Syphilis serology *   C 
  Gonococcal culture D   D 
  Chlamydial culture *   C 
  Hepatitis B serology *    
  HIV serology B    
  Group B streptococcus culture    E 
 a First-trimester aneuploidy screening may be offered between 11 and 14 weeks. 
 HIV = human immunodeficiency virus. 
 A Performed at 28 weeks, if indicated. 
 B Test should be offered. 
 C High-risk women should be retested at the beginning of the third trimester. 
 D High-risk women should be screened at the first prenatal visit and again in the 
third trimester. 




There are several definitions pertinent to establishment of an accurate prenatal 
record. 
 Nulligravida: a woman who currently is not pregnant, nor has she ever been 
pregnant.  
 Gravida: a woman who currently is pregnant or she has been in the past, 
irrespective of the pregnancy outcome. With the establishment of the first 
pregnancy, she becomes a primigravida, and with successive pregnancies, a 
multigravida.  
 Nullipara: a woman who has never completed a pregnancy beyond 20 weeks' 
gestation. She may or may not have been pregnant or may have had a 
spontaneous or elective abortion(s) or an ectopic pregnancy.  
 Primipara: a woman who has been delivered only once of a fetus or fetuses 
born alive or dead with an estimated length of gestation of 20 or more weeks. 
 Multipara: a woman who has completed two or more pregnancies to 20 weeks 
or more. Parity is determined by the number of pregnancies reaching 20 
weeks and not by the number of fetuses delivered. Parity is the same (para 1) 
for a singleton or multifetal delivery or delivery of a live or stillborn infant. 
In the past, a 500-g birth weight threshold was used to define parity. This threshold is no 
longer as pertinent because of the survival of infants with birth weights less than 500 g.  
In some locales, the obstetrical history is summarized by a series of digits 
connected by dashes. These refer to the number of term infants, preterm infants, 
abortuses less than 20 weeks, and children currently alive. For example, a woman who is 
para 2–1–0–3 has had two term deliveries, one preterm delivery, and no abortuses, and 
has three living children. Because these are non-conventional, it is helpful to specify the 
outcome of any pregnancy that did not end normally (Merkatz et al., 1990). 
HISTORY 
For the most part, the same essentials go into appropriate history-taking from the 
pregnant woman as elsewhere in medicine. Detailed information concerning past 
obstetrical history is crucial because many prior pregnancy complications tend to recur in 
subsequent pregnancies. The menstrual history is extremely important. The woman who 
spontaneously menstruates regularly every 28 days or so is most likely to ovulate at 
midcycle. Thus, gestational or menstrual age is the number of weeks since the onset of 
the last menstrual period. If her menstrual cycles were significantly longer than 28 to 30 
days, ovulation more likely occurred well beyond 14 days. If the intervals were much 
longer and irregular, chronic anovulation is likely to have preceded some of the episodes 
identified as menses. Without a history of regular, predictable, cyclic, spontaneous 
menses that suggest ovulatory cycles, accurate dating of pregnancy by history and 
physical examination is difficult. It is also important to be sure whether or not steroidal 
contraceptives were used before the pregnancy. Because ovulation may not have resumed 
2 weeks after the onset of the last withdrawal bleeding and instead may have occurred at 
an appreciably later and highly variable date, using the time of ovulation for predicting 
the time of conception in this circumstance may be erroneous. Use of sonography in early 
pregnancy will clarify gestational age in these situations (Merkatz et al., 1990). 
Psychosocial Screening 
The American College of Obstetricians and Gynecologists (2006) defines 
psychosocial risk factors as non biomedical factors that affect mental and physical well-
being. The College advocates psychosocial screening at least once each trimester to 
increase the likelihood of identifying important issues and reducing adverse pregnancy 
outcomes. Screening for barriers to care includes lack of transportation, child care, or 
family support; unstable housing; unintended pregnancy; communication barriers; 
nutritional problems; cigarette smoking; substance abuse; depression; and safety concerns 
that include domestic violence.  
Such screening is performed regardless of social status, education level, or race 
and ethnicity, shown in Table XXII is one recommended screening tool. 
TABLE XXII. Psychosocial Screening Tool (American College of Obstetricians and 
Gynecologists, 2006): 
1. Do you have any problems (job, transportation, etc.) that prevent you from 
keeping your healthcare appointments? Yes No  
2. Do you feel unsafe where you live? Yes No  
3. In the past 2 months, have you used any form of tobacco? Yes No  
4. In the past 2 months, have you used drugs or alcohol? Yes No  
5. In the past year, have you been threatened, hit, slapped, or kicked by anyone 
you know? Yes No  
6. Has anyone forced you to perform any sexual act that you did not want to do? 
Yes No  
7. On a 1-to-5 scale, how do you rate your current stress level? 1 2 3 4 5  
8. How many times have you moved in the past 12 months? _______ 
low           high 
9. If you could change the timing of this pregnancy, would you want it: __ earlier; 
__ later; __not at all; __ no change. 
Cigarette Smoking 
Smoking results in unequivocal adverse sequelae for pregnant women and their 
fetuses (United States Department of Health and Human Services, 2000). Maternal 
smoking data has been included on the birth certificate since 1989. The number of 
pregnant women who smoke continues to decline, and from 1990 to 2003, the reported 
rate decreased from 18 to 13 percent (American College of Obstetricians and 
Gynecologists, 2005b; Martin et al., 2009). 
According to the CDC (2007), 13 percent of women admitted to smoking during 
the last 3 months of pregnancy. Those most likely to smoke were younger and had less 
education. 
Numerous adverse outcomes have been linked to smoking during pregnancy. 
Tobacco had potential teratogenic effects. There is a twofold risk of placenta previa, 
placental abruption, and premature membrane rupture compared with nonsmokers. 
Further, babies born to women who smoke are approximately 30 percent more likely to 
be born preterm, weigh on average a half pound less, and are up to three times more 
likely to die of sudden infant death syndrome (SIDS) than infants born to nonsmokers 
(CDC, 2007). 
In 2001, the incidence of low-birthweight infants born to American women who 
smoked during pregnancy was 11.9 percent compared with 7.3 percent born to 
nonsmokers (Martin et al., 2002b). Finally, risks for spontaneous abortion, fetal death, 
and fetal digital anomalies are also increased (Man and Chang, 2006). 
A number of pathophysiological mechanisms have been proposed to explain these 
adverse outcomes. They include fetal hypoxia from increased carboxyhemoglobin, 
reduced uteroplacental blood flow, and direct toxic effects of nicotine and other 
compounds in smoke (ACOG, 2005b). 
 Nicotine transfer is so efficient that fetal nicotine exposure is greater than that of 
the mother. Exposed fetuses have decreased heart rate variability, due to impaired 
autonomic regulation (Luck et al., 1985). 
According to the American Academy of Pediatrics and American College of 
Obstetricians and Gynecologists (2007), perinatal mortality rates would be reduced by 
5 percent if maternal smoking was eliminated. 
 
Smoking Cessation 
The most successful efforts for smoking cessation during pregnancy involve 
interventions that emphasize how to stop. One example is a 5-step session lasting 15 
minutes or less in which the provider: (1) Asks about smoking status; (2) Advises those 
who smoke to stop; (3) Assesses the willingness to quit within the next 30 days; (4) 
Assists interested patients by providing pregnancy-specific self-help materials; and (5) 
Arranges follow-up visits to track progress (American College of Obstetricians and 
Gynecologists, 2005b). 
Nicotine replacement products have not been sufficiently evaluated to determine 
their effectiveness and safety in pregnancy. Interdiction is optimal-but not always 
pragmatic-before conception. Thus, the American College of Obstetricians and 
Gynecologists (2005b) has concluded that it is reasonable to use nicotine medications 
during pregnancy if prior non pharmacological attempts have failed.  
Wisborg et al. (2000) randomly assigned 250 women who smoked at least 10 
cigarettes per day to receive nicotine or a placebo patch beginning after the first trimester. 
Overall, 26 percent of these women stopped smoking, but there were no significant 
differences in smoking cessation, birth weight, or preterm delivery between the two 
groups. Importantly, no serious adverse effects from the patches were reported, but 
compliance with either treatment was low. 
Alcohol Use during Pregnancy 
Ethanol is a potent teratogen and can cause fetal alcohol syndrome characterized 
by growth restriction, facial abnormalities, and central nervous system dysfunction. 
Women who are pregnant or considering pregnancy should abstain from using any 
alcoholic beverages. Such use is substantively underreported on the birth certificate—less 
than 1 percent of women reported any alcohol use during pregnancy in 2001 (Martin et 
al., 2002b).  
But, according to the CDC, (2002a), approximately 13 percent of pregnant 
women used alcohol in 1999. Although this was down from 16 percent in 1995, it is 
unfortunate that rates of binge and frequent drinking during pregnancy have not declined. 
Illicit Drug Use 
It is estimated that 10 percent of fetuses are exposed to one or more illicit drugs 
(American Academy of Pediatrics and American College of Obstetricians and 
Gynecologists, 2007). Agents may include heroin and other opiates, cocaine, 
amphetamines, barbiturates, and marijuana. Chronic use of large quantities is harmful to 
the fetus.  
Well-documented sequelae include fetal distress, low birth weight, and drug 
withdrawal soon after birth. Women who use such drugs frequently do not seek prenatal 
care or if they do, they may not admit to the use of such substances. El-Mohandes et al. 
(2003) reported that when women who use illicit drugs receive prenatal care, the risks for 
preterm birth and low birth weight are reduced. 
The American College of Obstetricians and Gynecologists, (1999) has 
reviewed methods for screening women during pregnancy for use of illicit drugs and for 
alcohol abuse. 
Domestic Violence Screening 
The term domestic violence usually refers to violence against adolescent and adult 
females within the context of family or intimate relationships. Such violence has been 
increasingly recognized as a major public health problem. Unfortunately, most abused 
women continue to be victimized during pregnancy. With the possible exception of 
preeclampsia, domestic violence is more prevalent than any major medical condition 
detectable through routine prenatal screening (American Academy of Pediatrics and 
American College of Obstetricians and Gynecologists 2007).  
The prevalence during pregnancy is estimated to be between 4 and 8 percent. 
Physical Abuse—Intimate Partner Violence, intimate partner violence is associated with 
an increased risk of a number of adverse perinatal outcomes including preterm delivery, 
fetal-growth restriction, and perinatal death. The American College of Obstetricians 
and Gynecologists (2006) has provided methods for screening for domestic violence and 
recommends their use at the first prenatal visit, then again at least once per trimester, and 
again at the postpartum visit.  
PHYSICAL EXAMINATION 
A thorough, general physical examination should be completed at the initial 
prenatal encounter.  
Pelvic Examination 
The cervix is visualized employing a speculum lubricated with warm water or 
water-based lubricant gel. Bluish-red passive hyperemia of the cervix is characteristic, 
but not of itself diagnostic, of pregnancy. Dilated, occluded cervical glands bulging 
beneath the ectocervical mucosa—nabothian cysts—may be prominent. The cervix is not 
normally dilated except at the external os. To identify cytological abnormalities, a Pap 
smear is performed, and specimens for identification of Chlamydia trachomatis and 
Neisseria gonorrhea are obtained. Bimanual examination is completed by palpation, with 
special attention given to the consistency, length, and dilatation of the cervix; to uterine 
size and any adnexal masses; to the fetal presentation later in pregnancy; to the bony 
architecture of the pelvis; and to any anomalies of the vagina and perineum. All cervical, 
vaginal, and vulvar lesions are evaluated further by appropriate use of colposcopy, 
biopsy, culture, or dark-field examination. The perianal region should be visualized and 
digital rectal examination performed (CDC, 2002b). 
 
LABORATORY TESTS 
The Institute of Medicine recommends universal HIV testing, with patient 
notification and right of refusal, as a routine part of prenatal care. The CDC (2006b) as 
well as the American Academy of Pediatrics and American College of Obstetricians 
and Gynecologists (2007) supports this recommendation. If a woman declines testing, 
this should be recorded in the prenatal record. Pregnant women should also be screened 
for hepatitis B virus.  
Based on their prospective investigation of 1000 women, Murray et al. (2002) 
concluded that in the absence of hypertension, routine urinalysis beyond the initial 
prenatal visit was not necessary. 
Chlamydial Infection 
Chlamydia trachomatis is isolated from the cervix in 2 to 13 percent of pregnant 
women. The American Academy of Pediatrics and American College of 
Obstetricians and Gynecologists (2007) recommend that all women be screened during 
the first prenatal visit, with additional third-trimester testing for those at increased risk. 
Risk factors include unmarried status, recent change in sexual partner or multiple 
concurrent partners; age less than 25 years, inner-city residence, history or presence of 
other sexually transmitted diseases, and little or no prenatal care. Following treatment, 
repeat testing is recommended in 3 weeks. A negative prenatal test for chlamydia or 
gonorrhea should not preclude postpartum screening (Mahon et al., 2002). 
HIGH-RISK PREGNANCIES 
There are many risk factors that can be identified and given appropriate 
consideration in pregnancy management. Examples of common risk factors proposed by 
the American Academy of Pediatrics and American College of Obstetricians and 
Gynecologists (2007) are shown in Table XXIII.  
TABLE XXIII. Recommended Consultation for Risk Factors Identified in Early 
Pregnancy a (American Academy of Pediatrics and American College of 
Obstetricians and Gynecologists, 2007): 
Medical History and Conditions 
Asthma  
  Symptomatic on medication OBG 
  Severe (multiple hospitalizations) MFM 
Cardiac disease  
  Cyanotic, prior myocardial infarction, aortic stenosis, pulmonary hypertension, 
Marfan syndrome, prosthetic valve, American Heart Association class II or 
greater  
MFM 
  Other OBG 
Diabetes mellitus  
  Class A–C OBG 
  Class D or greater MFM 
Drug and alcohol use OBG 
Epilepsy (on medication) OBG 
Family history of genetic problems (Down syndrome, Tay-Sachs disease, 
phenylketonuria) 
MFM 
Hemoglobinopathy (SS, SC, S-thalassemia) MFM 
Hypertension  
  Chronic, with renal or heart disease MFM 
  Chronic, without renal or heart disease OBG 
Prior pulmonary embolus or deep vein thrombosis OBG 
 
 
Continue TABLE XXIII. Recommended Consultation for Risk Factors Identified in 
Early Pregnancy a (American Academy of Pediatrics and American College of 
Obstetricians and Gynecologists, 2007): 
Obstetrical History and Conditions 
Psychiatric illness OBG 
Pulmonary disease  
  Severe obstructive or restrictive MFM 
  Moderate OBG 
Renal disease  
  Chronic, creatinine ≥3 mg/dL, ± hypertension MFM 
  Chronic, other OBG 
  Requirement for prolonged anticoagulation MFM 
  Severe systemic disease MFM 
Age ≥35 years at delivery OBG 
Cesarean delivery, prior classical or vertical incision OBG 
Incompetent cervix OBG 
Prior fetal structural or chromosomal abnormality MFM 
Prior neonatal death OBG 
Prior fetal death OBG 
Prior preterm delivery or preterm ruptured membranes OBG 
Prior low birthweight (<2500 g) OBG 
Second-trimester pregnancy loss OBG 
Uterine leiomyomas or malformation OBG 
 
Continue TABLE XXIII. Recommended Consultation for Risk Factors Identified in 
Early Pregnancy a (American Academy of Pediatrics and American College of 
Obstetricians and Gynecologists, 2007): 
Initial Laboratory Tests 
Human immunodeficiency virus (HIV)   
  Symptomatic or low CD4 count MFM 
  Other OBG 
CDE (Rh) of other blood group isoimmunization (excluding ABO, Lewis) MFM 
Initial examination condylomata (extensive, covering vulva or vaginal opening) OBG 
 a At the time of consultation, continued patient care should be determined by 
collaboration with the referring care provider or by transfer of care. 
 OBG = obstetrician-gynecologist; MFM = Maternal-fetal medicine specialist. 
In addition, Table XXIV lists ongoing risk factors for which consultation may be 
indicated. Some conditions may require the involvement of a maternal-fetal medicine 
sub-specialist, geneticist, pediatrician, anesthesiologist, or other medical specialist in the 
evaluation, counseling, and care of the woman and her fetus. 
SUBSEQUENT PRENATAL VISITS 
Subsequent prenatal visits have been traditionally scheduled at intervals of 4 
weeks until 28 weeks, and then every 2 weeks until 36 weeks and weekly thereafter. 
Women with complicated pregnancies often require return visits at 1- to 2-week intervals. 
For example, Luke et al. (2003) found that a specialized prenatal care program that 
emphasized nutrition and education and that required return visits every 2 weeks resulted 
in improved outcomes in twin pregnancies. 
TABLE XXIV. Recommended Consultation for Ongoing Risk Factors Identified 
during Pregnancy a (American Academy of Pediatrics and American College of 
Obstetricians and Gynecologists, 2007): 
Medical History and Conditions 
Drugs/alcohol use OBG 
Proteinuria (≥2+ on catheterized sample, unexplained by urinary infection) OBG 
Pyelonephritis OBG 
Severe systemic disease that adversely affects pregnancy OBG 
Obstetrical History and Conditions 
Blood pressure elevation (diastolic BP ≥90 mm Hg), no proteinuria OBG 
Fetal-growth restriction suspected OBG 
Fetal abnormality suspected by sonography  
  Anencephaly OBG 
  Other MFM 
Fetal demise OBG 
Gestational age 41 weeks OBG 
Herpes, active lesion at 36 weeks OBG 
Hydramnios or oligohydramnios by sonography OBG 
Hyperemesis, persistent, beyond first trimester OBG 
Multifetal gestation OBG 
Preterm labor, threatened OBG 
Premature rupture of membranes OBG 
Vaginal bleeding ≥14 weeks OBG 
 
 
Continue TABLE XXIV. Recommended Consultation for Ongoing Risk Factors 
Identified during Pregnancy a (American Academy of Pediatrics and American 
College of Obstetricians and Gynecologists, 2007): 
Examination and Laboratory Findings 
Abnormal MSAFP (high or low) OBG 
Abnormal Pap smear result OBG 
Anemia (hematocrit <28 percent, unresponsive to iron therapy) OBG 
Condylomata (extensive, covering labia and vaginal opening) OBG 
HIV   
  Symptomatic or low CD4 count MFM 
  Other OBG 
CDE (Rh) or other blood group isoimmunization (excluding ABO, Lewis) MFM 
 a At the time of consultation, continued patient care should be determined by 
collaboration with the referring care provider or by transfer of care.  
 OBG = obstetrician-gynecologist; MFM = Maternal-fetal medicine specialist. 
WHO conducted a multicenter randomized trial with almost 25,000 women 
comparing routine prenatal care with an experimental model designed to minimize visits. 
In the new model, women were seen once in the first trimester and screened for certain 
risk factors. Those without any anticipated complications—80 percent of the women 
screened—were seen again at 26, 32, and 38 weeks. Compared with routine prenatal care, 
which required a median of eight visits, the new model required a median of only five 
visits (Villar et al., 2001). No disadvantages were found in women with fewer visits, and 
these findings were consistent with other randomized trials (McDuffie et al., 1996; 
Clement et al., 1999). 
 
Prenatal Surveillance 
At each return visit, steps are taken to determine the well-being of mother and 
fetus (Table XXV). Certain information is considered especially important-an example is 
assessment of gestational age and accurate measurement of blood pressure (Jones et al., 
2003).  
TABLE XXV. Evaluation of maternal and fetal well-being typically includes: 
Fetal  
 Heart rate(s)  
 Size—current and rate of change  
 Amount of amnionic fluid  
 Presenting part and station (late in pregnancy)  
 Activity 
Maternal  
 Blood pressure—current and extent of change  
 Weight—current and amount of change  
 Symptoms—including headache, altered vision, abdominal pain, nausea and 
vomiting, bleeding, vaginal fluid leakage, and dysuria  
 Height in centimeters of uterine fundus from symphysis 
 Vaginal examination late in pregnancy often provides valuable information to 
include:  
1. Confirmation of the presenting part and its station. 
2. Clinical estimation of pelvic capacity and its general configuration. 





ASSESSMENT OF GESTATIONAL AGE 
This is one of the most important determinations at prenatal examinations. Precise 
knowledge of gestational age is important because a number of pregnancy complications 
may develop for which optimal treatment will depend on fetal age. Fortunately, it is 
possible to identify gestational age with considerable precision through an appropriately 
timed, carefully performed clinical examination, coupled with knowledge of the time of 
onset of the last menstrual period (Worthen and Bustillo, 1980). 
Fundal Height 
Between 20 and 34 weeks, the height of the uterine fundus measured in 
centimeters correlates closely with gestational age in weeks. The fundal height should be 
measured as the distance over the abdominal wall from the top of the symphysis pubis to 
the top of the fundus. The bladder must be emptied before making the measurement 
(Jimenez al., 1983; Quaranta al., 1981). 
For example, Worthen and Bustillo (1980) demonstrated that at 17 to 20 weeks, 
fundal height was 3 cm higher with a full bladder. Obesity may also distort this 
relationship. Unfortunately, using fundal height alone, fetal-growth restriction may be 
undiagnosed in up to a third of cases (American College of Obstetricians and 
Gynecologists, 2000). 
Fetal Heart Sounds 
The fetal heart can first be heard in most women between 16 and 19 weeks when 
carefully auscultated with a standard non-amplified stethoscope. The ability to hear 
unamplified fetal heart sounds will depend on factors such as patient size and hearing 
acuity of the examiner (American College of Obstetricians and Gynecologists, 2004c). 
 
Herbert et al. (1987) reported that the fetal heart was audible by 20 weeks in 80 
percent of women. By 21 weeks, audible fetal heart sounds were present in 95 percent, 
and by 22 weeks they were heard in all. The fetal heart rate now ranges from 110 to 160 
bpm and is heard as a double sound resembling the tick of a watch under a pillow. 
Because the fetus moves freely in amnionic fluid, the site on the maternal abdomen 
where fetal heart sounds can be heard best will vary. 
Instruments incorporating Doppler ultrasound instruments are often used to easily 
detect fetal heart action, almost always by 10 weeks. Using real-time sonography with a 
vaginal transducer, fetal cardiac activity can be seen as early as 5 menstrual weeks 
(American College of Obstetricians and Gynecologists, 2004c). 
Sonography 
In the United States, about two thirds of women have at least one prenatal 
sonographic examination (Martin et al., 2005). And within the past decade, many 
women have an initial sonographic evaluation as part of first-trimester aneuploidy 
screening, followed by a standard examination in the second trimester to evaluate fetal 
anatomy (American College of Obstetricians and Gynecologists, 2009). 
The American College of Obstetricians and Gynecologists, (2009) has 
concluded that a physician is not obligated to perform sonography without a specific 
indication in a low-risk patient, but that if she requests sonography, it is reasonable to 
honor her request.  
SUBSEQUENT LABORATORY TESTS 
If initial results in (Table XXV) were normal, most tests need not be repeated. 
Fetal aneuploidy screening may be performed at 11 to 14 weeks and/or at 15 to 20 weeks, 
depending on the protocol selected. Serum screening for neural-tube defects is offered at 
15 to 20 weeks (Hollier et al., 2003). 
Hematocrit or hemoglobin determination, along with syphilis serology if it is 
prevalent in the population, should be repeated at 28 to 32 weeks. Women who are D 
(Rh) negative and are unsensitized should have an antibody screening test repeated at 28 
to 29 weeks, with administration of anti-D immune globulin if they remain unsensitized 
(Hollier et al., 2003). 
Cystic fibrosis carrier screening should be offered to couples with a family history 
of cystic fibrosis and to Caucasian couples of European or Ashkenazi Jewish descent 
planning a pregnancy or seeking prenatal care. Ideally, screening is performed before 
conception or during the first or early second trimester. Information about cystic fibrosis 
screening also should be provided to patients in other racial and ethnic groups who are at 
lower risk (Kiss et al., 2004). 
Group B Streptococcal (GBS) Infection 
The American College of Obstetricians and Gynecologists (2002c) and the 
CDC (2002b) recommend that vaginal and rectal GBS cultures be obtained in all women 
between 35 and 37 weeks. Intrapartum antimicrobial prophylaxis is given for those 
whose cultures are positive. Women with GBS bacteriuria or a previous infant with 
invasive disease are given empirical intrapartum prophylaxis.  
Gestational Diabetes 
All pregnant women should be screened for gestational diabetes mellitus, whether 
by history, clinical factors, or routine laboratory testing. Although laboratory testing 
between 24 and 28 weeks is the most sensitive approach, there may be pregnant women 
at low risk who are less likely to benefit from testing (American Academy of Pediatrics 
and American College of Obstetricians and Gynecologists, 2007). 
 
Gonococcal Infection 
Risk factors for gonorrhea are similar for those for Chlamydia (American 
Academy of Pediatrics and American College of Obstetricians and Gynecologists, 
2007). The American Academy of Pediatrics and American College of Obstetricians 
and Gynecologists (2007) recommend that pregnant women with risk factors or 
symptoms be tested for gonorrhea at an early prenatal visit and again in the third 
trimester. Treatment is given for gonorrhea as well as possible coexisting chlamydial 
infection. 
Special Screening for Genetic Diseases 
Selected screening should be offered to couples at increased risk based on family 
history or the ethnic or racial background (American College of Obstetricians and 
Gynecologists, 2004c; 2005c). Some examples include testing for Tay-Sachs disease for 
people of Eastern European Jewish or French Canadian ancestry;  β-thalassemia for those 
of Mediterranean, Southeast Asian, Indian, Pakistani, or African ancestry; α-thalassemia 
for people of Southeast Asian or African ancestry; and sickle-cell anemia for people of 
African, Mediterranean, Middle Eastern, Caribbean, Latin American, or Indian descent.  
NUTRITION 
Recommendations for Weight Gain 
For the first half of the 20th century, it was recommended that weight gain during 
pregnancy be limited to less than 20 lb or 9.1 kg. It was believed that such restriction 
would prevent gestational hypertension and fetal macrosomia. By the 1970s, however, 
women were encouraged to gain at least 25 lb or 11.4 kg to prevent preterm birth and 
fetal-growth restriction, a recommendation supported by subsequent research 
(Ehrenberg et al., 2003).  
In 1990, the Institute of Medicine recommended a weight gain of 25 to 35 lb—
11.5 to 16 kg—for women with a normal prepregnancy body mass index (BMI). Weight 
gains recommended by the Institute of Medicine (1990) according to pre-pregnant BMI 
categories are shown in Table 7and these guidelines have been endorsed by American 
Academy of Pediatrics and American College of Obstetricians and Gynecologists 
(2007). It is problematic, however, that in 2003, 46 percent of women had weight gains 
above these guidelines (Catalano, 2007). 
TABLE XXVI. Recommended Ranges of Weight Gain during Singleton Gestations 
Stratified by Pre-pregnancy Body Mass Index a (Institute of Medicine, 1990): 
Weight-for-Height Category Recommended Total Weight Gain 
Category BMI kg lb 
Low < 19.8 12.5–18 28–40 
Normal 19.8–26 11.5–16 25–35 
High 26–29 7–11.5 15–25 
Obese > 29 ≥7 ≥15 
a The range for twin pregnancy is 35 to 45 lb (16 to 20 kg). Young adolescents (< 2 years 
after menarche) and African-American women should strive for gains at the upper end of 
the range. Shorter women (<62 in. or <157 cm) should strive for gains at the lower end of 
the range. BMI = body mass index. 
It has been emphasized by Catalano (2007) that when the Institute of Medicine 
guidelines were written, concern was focused on the low-birth weight infant, whereas 
currently the focus is on the obesity epidemic. This likely explains renewed interest in 
lower weight gains during pregnancy. Obesity is associated with significantly increased 
risks for gestational hypertension, preeclampsia, gestational diabetes, macrosomia, and 
cesarean delivery.  
The risk appears "dose related" to prenatal weight gain. In a population-based 
cohort of more than 120,000 obese pregnant women, Kiel et al. (2007) found that those 
who gained less than 15 pounds had the lowest rates of preeclampsia, large-for-
gestational age infants, and cesarean delivery. 
 Among 100,000 women with normal pre-pregnancy body mass index, DeVader 
et al. (2007) found that those who gained less than 25 pounds during pregnancy had a 
lower risk for preeclampsia, failed induction, cephalopelvic disproportion, cesarean 
delivery, and large-for-gestational age infants. This cohort, however, had an increased 
risk for small-for-gestational age infants. 
Over-nutrition 
There is irrefutable evidence that maternal weight gain during pregnancy 
influences birth weight. Martin et al. (2009) studied this using birth certificate data for 
2006.  
As shown in Figure (26), 60 percent of pregnant women gained 26 lb or more. 
Maternal weight gain had a positive correlation with birth weight and women with the 
greatest risk—14 percent—for delivering an infant weighing less than 2500 g were those 
with weight gains less than 16 lb. Nearly nineteen percent of births to women with such 
low weight gains were preterm (Martin et al., 2009). 
Cohen et al. (2001) studied more than 4000 pregnant women and concluded that 
ethnic differences in pregnancy outcomes were not explained by nutritional variations. 
 
FIGURE 26. Maternal weight gains in the United States reported on the birth 
certificate in 2006 (From Martin et al., 2009). 
Severe Under-nutrition 
Meaningful studies of nutrition in human pregnancy are exceedingly difficult to 
design because experimental dietary deficiency is not ethical. In those instances in which 
severe nutritional deficiencies have been induced as a consequence of social, economic, 
or political disaster, coincidental events often have created many variables, the effects of 
which are not amenable to quantification. Some past experiences suggest, however, that 
in otherwise healthy women, a state of near starvation is required to establish clear 
differences in pregnancy outcome. During the severe European winter of 1944–1945, 
nutritional deprivation of known intensity prevailed in a well-circumscribed area of The 
Netherlands occupied by the German military (Kyle and Pichard, 2006).  
 
At the lowest point during this Dutch Hunger Winter, rations reached 450 
kcal/day, with generalized rather than selective malnutrition. Smith (1947) analyzed the 
outcomes of pregnancies that were in progress during this 6-month famine. Median infant 
birth weights decreased approximately 250 g and rose again after food became available. 
This indicated that birth weight can be influenced significantly by starvation during later 
pregnancy. The perinatal mortality rate, however, was not altered, nor was the incidence 
of malformations significantly increased. Interestingly, the frequency of pregnancy 
"toxemia" was found to decline. 
Evidence of impaired brain development has been obtained in some animal 
fetuses whose mothers had been subjected to intense dietary deprivation. Subsequent 
intellectual development was studied by Stein et al. (1972) in young male adults whose 
mothers had been starved during pregnancy. The comprehensive study was made possible 
because all males at age 19 underwent compulsory examination for military service. It 
was concluded that severe dietary deprivation during pregnancy caused no detectable 
effects on subsequent mental performance. 
A number of studies of the long-term consequences to this cohort of children born 
to nutritionally deprived women have been performed and were reviewed by Kyle and 
Pichard (2006). Progeny exposed in mid to late pregnancy were lighter, shorter, and 
thinner at birth, and they had a higher incidence of subsequent diminished glucose 
tolerance, hypertension, reactive airway disease, dyslipidemia, and coronary artery 
disease.  
Weight Retention after Pregnancy 
Not all the weight gained during pregnancy is lost during and immediately after 
delivery (Hytten, 1991). Schauberger et al. (1992) studied prenatal and postpartum 
weights in 795 Wisconsin women. Their average weight gain was 28.6 lb or 12.8 kg.  
Most maternal weight loss was at delivery—approximately 12 lb or 5.5 kg—and 
in the ensuing 2 weeks thereafter—approximately 9 lb or 4 kg. An additional 5.5 lb or 2.5 
kg was lost between 2 weeks and 6 months postpartum. Thus, average total weight loss 
resulted in an average retained pregnancy weight of 3 lb or 1.4 kg. Overall, the more 
weight gained during pregnancy, the more that was lost postpartum. Interestingly, there is 
no relationship between pre-pregnancy BMI or prenatal weight gain and weight retention 
(American Academy of Pediatrics and American College of Obstetricians and 
Gynecologists, 2007). 
Recommended Dietary Allowances: 
Periodically, the Food and Nutrition Board of the Institute of Medicine (2008) 
publishes recommended dietary allowances, including those for pregnant or lactating 
women. The latest recommendations are summarized in table XXVII. Certain prenatal 
vitamin–mineral supplements may lead to intakes well in excess of the recommended 
allowances. Moreover, the use of excessive supplements, which often are self-prescribed, 
has led to concern about nutrient toxicities during pregnancy.  
Those with potentially toxic effects include iron, zinc, selenium, and vitamins A, 
B6, C, and D. In particular, excessive vitamin A—more than 10,000 IU per day—may be 
teratogenic. Vitamin and mineral intake more than twice the recommended daily dietary 
allowance shown in table XXVII should be avoided (American Academy of Pediatrics 




TABLE XXVII. Recommended Daily Dietary Allowances for Adolescent and Adult 
Pregnant and Lactating Women (From the Food and Nutrition Board of the 
Institute of Medicine, 2008): 
 Pregnant Lactating 
Age (years) 14–18 19–50 14–18 19–50 
Fat-soluble vitamins 
  Vitamin A 750 μg 770 μg 1200 μg 1300 μg 
  Vitamin Da 5 μg 5 μg 5 μg 5 μg 
  Vitamin E 15 mg 15mg 19 mg 19 mg 
  Vitamin Ka 75 μg 90 μg 75 μg 90 μg 
Water-soluble vitamins 
  Vitamin C 80 mg 85 mg 115 mg 120 mg 
  Thiamin 1.4 mg 1.4 mg 1.4 mg 1.4 mg 
  Riboflavin 1.4 mg 1.4 mg 1.6 mg 1.6 mg 
  Niacin 18 mg 18 mg 17 mg 17 mg 
  Vitamin B6 1.9 mg 1.9 mg 2 mg 2 mg 
  Folate 600 μg 600 μg 500 μg 500 μg 
  Vitamin B12 2.6 μg 2.6 μg 2.8 μg 2.8 μg 
Minerals 
  Calciuma 1300 mg 1000 mg 1300 mg 1000 mg 
  Sodiuma 1.5 g 1.5 g 1.5 g 1.5 g 
  Potassiuma 4.7 g 4.7 g 5.1 g 5.1 g 
  Iron 27 mg 27 mg 10 mg 9 mg 
  Zinc 12 mg 11 mg 13 mg 12 mg 
  Iodine 220 μg 220 μg 290 μg 290 μg 
  Selenium 60 μg 60 μg 70 μg 70 μg 
 
Continue TABLE XXVII. Recommended Daily Dietary Allowances for Adolescent 
and Adult Pregnant and Lactating Women (From the Food and Nutrition Board of 
the Institute of Medicine, 2008): 
Other 
  Protein 71 g 71 g 71 g 71 g 
  Carbohydrate 175 g 175 g 210 g 210 g 
  Fibera 28 g 28 g 29 g 29 g 
a Recommendations measured as Adequate Intake (AI). 
Calories 
As shown in Figure 27, pregnancy requires an additional 80,000 kcal—most are 
accumulated in the last 20 weeks. To meet this demand, a caloric increase of 100 to 300 
kcal per day is recommended during pregnancy (American Academy of Pediatrics and 
American College of Obstetricians and Gynecologists, 2007). 
 
FIGURE 27. Cumulative kilocalories required for pregnancy (From Chamberlain 
and Broughton-Pipkin, 1998). 
Calories are necessary for energy, and whenever caloric intake is inadequate, 
protein is metabolized rather than being spared for its vital role in fetal growth and 
development. Total physiological requirements during pregnancy are not necessarily the 
sum of ordinary non-pregnant requirements plus those specific to pregnancy. For 
example, the additional energy required during pregnancy may be compensated in whole 
or in part by reduced physical activity (Hytten, 1991). 
Protein 
To the basic protein needs of the non-pregnant woman are added the demands for 
growth and remodeling of the fetus, placenta, uterus, and breasts, as well as increased 
maternal blood volume. During the second half of pregnancy, approximately 1000 g of 
protein are deposited, amounting to 5 to 6 g/day (Hytten and Leitch, 1971).  
Minerals 
The intakes recommended by the Institute of Medicine (2008) for a variety of 
minerals are presented in Table 8. With the exception of iron, practically all diets that 
supply sufficient calories for appropriate weight gain will contain enough minerals to 
prevent deficiency if iodized foods are ingested. 
Iron 
Of the approximately 300 mg of iron transferred to the fetus and placenta and the 
500 mg incorporated into the expanding maternal hemoglobin mass, nearly all is used 
after mid-pregnancy. During that time, iron requirements imposed by pregnancy and 
maternal excretion total approximately 7 mg per day (Pritchard and Scott, 1970). 
 
 
Scott et al. (1970) established that as little as 30 mg of elemental iron, supplied as 
ferrous gluconate, sulfate, or fumarate and taken daily throughout the latter half of 
pregnancy, provides sufficient iron to meet the requirements of pregnancy and to protect 
preexisting iron stores. This amount will also provide for iron requirements for lactation. 
The pregnant woman may benefit from 60 to 100 mg of iron per day if she is large, has 
twin fetuses, begins supplementation late in pregnancy, takes iron irregularly, or has a 
somewhat depressed hemoglobin level. The woman who is overtly anemic from iron 
deficiency responds well to oral supplementation with iron salts. 
Because iron requirements are slight during the first 4 months of pregnancy, it is 
not necessary to provide supplemental iron during this time. Withholding iron 
supplementation during the first trimester of pregnancy avoids the risk of aggravating 
nausea and vomiting.Ingestion of iron at bedtime or on an empty stomach aids absorption 
and appears to minimize the possibility of an adverse gastrointestinal reaction (Gill et al., 
2009). 
Calcium 
The pregnant woman retains approximately 30 g of calcium, most of which is 
deposited in the fetus late in pregnancy (Pitkin, 1985). This amount of calcium 
represents only approximately 2.5 percent of total maternal calcium, most of which is in 
bone, and which can readily be mobilized for fetal growth. Moreover, Heaney and 
Skillman (1971) demonstrated increased calcium absorption by the intestine and 
progressive retention throughout pregnancy. Efforts to prevent preeclampsia using 
calcium supplementation have not proven efficacious, and it is not recommended for 




Severe zinc deficiency may lead to poor appetite, suboptimal growth, and 
impaired wound healing. Profound zinc deficiency may cause dwarfism and 
hypogonadism. Although the level of zinc supplementation that is safe for pregnant 
women has not been clearly established, recommended daily intake during pregnancy is 
approximately 12 mg (Osendrap et al., 2001). 
Goldenberg et al. (1995) randomly assigned 580 indigent women to daily 25-mg 
zinc supplementation or placebo beginning at mid-pregnancy. Plasma zinc levels were 
significantly higher in women who received supplements. Infants born to zinc-
supplemented women were slightly larger-mean increase 125 g-and had a slightly larger 
head circumference-mean 4 mm.  
Later, Osendarp et al. (2001) randomly assigned 420 women in Bangladesh to 
receive either daily 30-mg zinc supplementation or placebo from 12 to 16 weeks until 
delivery. Although supplementation did not improve birth weight, low-birth weight 
infants of mothers who received zinc had reduced risks of acute diarrhea, dysentery, and 
impetigo. In a follow-up study of these infants at 13 months, zinc supplementation was 
not found to confer any benefits on developmental outcome (Hamadani et al., 2002). 
Iodine 
The use of iodized salt and bread products is recommended during pregnancy to 
offset the increased fetal requirements and maternal renal losses of iodine. Despite this, 
iodine intake has declined substantially in the past 15 years, and in some areas, it is 
probably inadequate. Interest in increasing dietary iodine was heightened by reports 
linking subclinical maternal hypothyroidism to adverse pregnancy outcomes and possible 
neuro developmental defects in children studied at age 7 years (Casey et al., 2005; 
Haddow et al., 1999).  
Severe maternal iodine deficiency predisposes offspring to endemic cretinism, 
characterized by multiple severe neurological defects. In parts of China and Africa where 
this condition is endemic, iodide supplementation very early in pregnancy prevents some 
cases of cretinism (Cao et al., 1994). 
Magnesium 
Deficiency of magnesium as the consequence of pregnancy has not been 
recognized. Undoubtedly, during prolonged illness with no magnesium intake, the plasma 
level might become critically low, as it would in the absence of pregnancy. It has been 
observed that magnesium deficiency during pregnancy complicated by the consequences 
of previous intestinal bypass surgery. Sibai et al. (1989) randomly assigned 400 
normotensive primigravid women to 365 mg elemental magnesium supplementation or 
placebo tablets from 13 to 24 weeks. Supplementation did not improve any measures of 
pregnancy outcome. 
Trace Metals 
Copper, selenium, chromium, and manganese all have important roles in certain 
enzyme functions. In general, most are provided by an average diet. A severe 
geochemical selenium deficiency has been identified in a large area of China. Deficiency 
is manifested by a frequently fatal cardiomyopathy in young children and women of 
childbearing age. Conversely, selenium toxicity resulting from over-supplementation also 
has been observed (Food and Nutrition Board of the Institute of Medicine, 2008). 
Potassium 
The concentration of potassium in maternal plasma decreases by approximately 
0.5 mEq/L by mid-pregnancy. Potassium deficiency develops in the same circumstances 
as when a woman is not pregnant (Brown et al., 1986). 
Fluoride 
There is no evidence that supplemental fluoride during pregnancy is beneficial 
(Institute of Medicine, 1990).  
Horowitz and Heifetz (1967) concluded that there were no additional benefits 
from maternal ingestion of fluoridated water if the offspring ingested such water from 
birth. 
Sa RorizFonteles et al. (2005) studied microdrill biopsies of deciduous teeth and 
concluded that prenatal fluoride provided no additional fluoride uptake compared with 
postnatal fluoride alone. Supplemental fluoride ingested by lactating women does not 
increase the fluoride concentration in breast milk (Ekstrand et al., 1981). 
Folic Acid 
The CDC (2004) estimated that the number of pregnancies affected by neural-
tube defects has decreased from 4000 pregnancies per year to approximately 3000 per 
year since mandatory fortification of cereal products with folic acid in 1998. Perhaps 
more than half of all neural-tube defects can be prevented with daily intake of 400 ug of 
folic acid throughout the peri-conceptional period (CDC, 1999).  
ACOG, 2003b stated that Putting 140 μg of folic acid into each 100 μg of grain 
products may increase the folic acid intake of the average American woman of 
childbearing age by 100 μg per day. Because nutritional sources alone are insufficient, 
however, folic acid supplementation is still recommended 
ins. Unfortunately, surveys continue to suggest that many women, especially 
among minorities, remain unaware of the recommendations regarding folic acid 
supplementation (Perlow, 2001; Rinsky-Eng and Miller, 2002). 
 
Vitamin A 
Dietary intake of vitamin A in the United States appears to be adequate, and 
routine supplementation during pregnancy is not recommended by the ACOG (1998b). 
Conversely, there is an association of birth defects with very high doses during 
pregnancy—10,000 to 50,000 IU daily. These malformations are similar to those 
produced by the vitamin A derivative isotretinoin—Accutane—which is a potent 
teratogen. Beta-carotene, the precursor of vitamin A found in fruits and vegetables, has 
not been shown to produce vitamin A toxicity. 
Vitamin A deficiency is an endemic nutrition problem in the developing world. 
West (2003) estimates that worldwide, 6 million pregnant women suffer from night 
blindness secondary to vitamin A deficiency.  
Vitamin B12 
Maternal plasma vitamin B12 levels decrease in normal pregnancy and result 
mostly from reduced plasma levels of carrier proteins—transcobalamins. Vitamin B12 
occurs naturally only in foods of animal origin, and strict vegetarians may give birth to 
infants whose B12 stores are low. Likewise, because breast milk of a vegetarian mother 
contains little vitamin B12, the deficiency may become profound in the breast-fed infant 
(Higginbottom et al., 1978). Excessive ingestion of vitamin C also can lead to a 
functional deficiency of vitamin B12. Although its role is still controversial, low levels of 
vitamin B12 preconceptionally, similar to folate, may increase the risk of neural-tube 
defects (Molloy et al., 2009; Thompson et al., 2009). 
Vitamin B6—Pyridoxine 
Limited clinical trials in pregnant women have failed to demonstrate any benefits 
of vitamin B6 supplements (Thaver et al., 2006). 
For women at high risk for inadequate nutrition—for example, substance abusers, 
adolescents, and those with multifetal gestations—a daily 2-mg supplement is 
recommended (Staroselsky et al., 2007). 
Vitamin B6, when combined with the antihistamine doxylamine, has been found 
helpful in many cases of nausea and vomiting of pregnancy (Boskovic et al., 2003; 
Staroselsky et al., 2007). 
Vitamin C 
The recommended dietary allowance for vitamin C during pregnancy is 80 to 85 
mg/day—about 20 percent more than when non-pregnant (Table 8). A reasonable diet 
should readily provide this amount. The maternal plasma level declines during pregnancy, 
whereas the cord level is higher, a phenomenon observed with most water-soluble 
vitamins (Gregory et al., 2006). 
Pragmatic Nutritional Surveillance 
Institute of Medicine,(2008) stated that although the science of nutrition 
continues in its perpetual struggle to identify the ideal amounts of protein, calories, 
vitamins, and minerals for the pregnant woman and her fetus, those directly responsible 
for their care may best discharge their duties as follows: 
1. In general, advise the pregnant woman to eat what she wants in amounts she 
desires and salted to taste. 
2. Ensure that there is ample food available in the case of socioeconomically 
deprived women. 
3. Monitor weight gain, with a goal of approximately 25 to 35 lb in women with a 
normal BMI. 
4. Periodically explore food intake by dietary recall to discover the occasional 
nutritionally absurd diet. 
5. Give tablets of simple iron salts that provide at least 27 mg of iron daily. Give 
folate supplementation before and in the early weeks of pregnancy. 
6. Recheck the hematocrit or hemoglobin concentration at 28 to 32 weeks to detect 
any significant decrease. 
COMMON CONCERNS 
Employment 
In the absence of complications, most women can continue to work until the onset 
of labor (American Academy of Pediatrics and American College of Obstetricians 
and Gynecologists, 2007). More than half of the children in the United States are born to 
working mothers. Federal law prohibits employers from excluding women from job 
categories on the basis that they are or might become pregnant (Annas, 1991). The 
Family Medical Leave Act requires that covered employers must grant up to 12 
workweeks of unpaid leave to an employee for the birth and care of a newborn child 
(United States Department of Labor, 2008).  
Some types of work, however, may increase pregnancy complication risks. 
Mozurkewich et al. (2000) reviewed 29 studies that involved more than 160,000 
pregnancies. With physically demanding work, women had a 20- to 60-percent increase 
in rates of preterm birth, fetal-growth restriction, or gestational hypertension. In a 
prospective study of more than 900 healthy nulliparas, Higgins et al. (2002) found that 
women who worked had a fivefold risk of preeclampsia.  
Newman et al. (2001) reported outcomes in 2929 women with singleton 
pregnancies studied by the Maternal-Fetal Medicine Units Network. Occupational 
fatigue-estimated by the number of hours standing, intensity of physical and mental 
demands, and environmental stressors—was associated with an increased risk of preterm 
membrane rupture. For women reporting the highest degrees of fatigue, the risk was 7.4 
percent. 
Thus, any occupation that subjects the pregnant woman to severe physical strain 
should be avoided. Ideally, no work or play should be continued to the extent that undue 
fatigue develops. Adequate periods of rest should be provided. It seems prudent to advise 
women with previous pregnancy complications that are at risk to recur-for example, 
preterm birth-to minimize physical work. 
Exercise 
In general, pregnant women do not need to limit exercise, provided they do not 
become excessively fatigued or risk injury (Clapp et al., 2000). 
Clapp et al. (2000) randomly assigned 46 pregnant women who did not exercise 
regularly to either no exercise or to weight-bearing exercise beginning at 8 weeks. 
Exercise consisted of treadmill running, step aerobics, or stair stepper use for 20 minutes 
three to five times each week. They did this throughout pregnancy at intensity between 55 
and 60 percent of the pre-conceptional maximum aerobic capacity. Both placental size 
and birth weight were significantly greater in the exercise group.  
The American College of Obstetricians and Gynecologists (2002b) advises a 
thorough clinical evaluation be conducted before recommending an exercise program. In 
the absence of contraindications listed in Table XXVIII, pregnant women should be 
encouraged to engage in regular, moderate-intensity physical activity 30 minutes or more 
a day. Each activity should be reviewed individually for its potential risk. Activities with 
a high risk of falling or abdominal trauma should be avoided. Similarly, scuba diving 




TABLE XXVIII. Absolute and Relative Contraindications to Aerobic Exercise 
during Pregnancy (American College of Obstetricians and Gynecologists, 2002b): 
Absolute Contraindications 
 Hemodynamically significant heart disease  
 Restrictive lung disease  
 Incompetent cervix/cerclage 
 Multifetal gestation at risk for preterm labor  
 Persistent second- or third-trimester bleeding  
 Placenta previa after 26 weeks  
 Preterm labor during the current pregnancy  
 Ruptured membranes 
 Preeclampsia/pregnancy-induced hypertension 
Relative Contraindications 
 Severe anemia  
 Unevaluated maternal cardiac arrhythmia  
 Chronic bronchitis  
 Poorly controlled type 1 diabetes  
 Extreme morbid obesity  
 Extreme underweight (BMI <12)  
 History of extremely sedentary lifestyle  
 Fetal-growth restriction in current pregnancy  
 Poorly controlled hypertension  
 Orthopedic limitations  
 Poorly controlled seizure disorder  
 Poorly controlled hyperthyroidism  
 Heavy smoker 
 
In the setting of certain pregnancy complications, it is wise to abstain from 
exercise and even limit physical activity. For example, some women with hypertensive 
disorders caused by pregnancy may benefit from being sedentary, as many women with 
preterm labor, placenta previa, or multifetal gestation; those suspected of having a 
growth-restricted fetus; or those with severe cardiac or pulmonary disease (American 
College of Obstetricians and Gynecologists, 2002b). 
Fish Consumption 
Fish are an excellent source of protein, are low in saturated fats, and contain 
omega-3 fatty acids. Because nearly all fish and shellfish contain trace amounts of 
mercury, pregnant and lactating women are advised to avoid specific types of fish with 
potentially high methylmercury levels (Hibbeln et al., 2007). 
These include shark, swordfish, king mackerel, and tile fish. It is further 
recommended that pregnant women ingest no more than 12 ounces or two servings of 
canned tuna per week and no more than 6 ounces of albacore or "white" tuna (United 
States Environmental Protection Agency, 2008). If the mercury content of locally 
caught fish is unknown, then overall fish consumption should be limited to 6 ounces per 
week. The recent Avon Longitudinal Study of Parents and Children (ALSPAC) study, 
however, reported beneficial effects on pregnancy outcomes in women who consumed 
340 g or more of seafood weekly (Hibbeln et al., 2007). 
Travel 
Automobile Travel 
The American College of Obstetricians and Gynecologists (1998a) has 
formulated guidelines for use of automobile passenger restraints during pregnancy. 
Women should be encouraged to wear properly positioned three-point restraints 
throughout pregnancy while riding in automobiles.  
The lap belt portion of the restraining belt should be placed under the abdomen 
and across her upper thighs. The belt should be comfortably snug. The shoulder belt also 
should be snugly positioned between the breasts. Available information suggests that 
airbags should not be disabled for the pregnant woman (American College of 
Obstetricians and Gynecologists, 1998a). 
Air Travel 
In general, air travel by the healthy woman has no harmful effect on pregnancy 
(Aerospace Medical Association, 2003). Travel in properly pressurized aircraft offers no 
unusual risk. Thus, in the absence of obstetrical or medical complications, the American 
Academy of Pediatrics and American College of Obstetricians and Gynecologists 
(2007) have concluded that pregnant women can safely fly up to 36 weeks. It is 
recommended that pregnant women observe the same precautions for air travel as the 
general population, including periodic movement of the lower extremities, ambulation at 
least hourly, and use of seatbelts while seated. A significant risk with travel, especially 
international travel, is acquisition of infectious diseases or developing a complication 
remote from adequate facilities (Ryan et al., 2002). 
Coitus 
It is generally accepted that in healthy pregnant women, sexual intercourse 
usually is not harmful. Whenever abortion or preterm labor threatens, however, coitus 
should be avoided. Nearly 10,000 women enrolled in a prospective investigation by the 
Vaginal Infection and Prematurity Study Group was interviewed regarding sexual activity 
(Read and Klebanoff, 1993). They reported a decreased frequency of sexual intercourse 
with advancing gestation. By 36 weeks, 72 percent had intercourse less than once weekly. 
According to Bartellas et al. (2000), the decrease is attributed to decreased desire in 58 
percent and fear of harm to the pregnancy in 48 percent. 
Intercourse late in pregnancy specifically has not been found to be harmful. 
Grudzinskas et al. (1979) found no association between gestational age at delivery and 
the frequency of coitus during the last 4 weeks of pregnancy.  
Sayle et al. (2001) found no increased and actually a decreased risk of delivery 
within 2 weeks of intercourse. Tan et al. (2007) studied women scheduled for nonurgent 
labor induction and found that spontaneous labor ensued in half of each group who had 
and did not have intercourse. 
Dental Care 
Examination of the teeth should be included in the prenatal examination, and 
good dental hygiene is encouraged. Periodontal disease has been linked to preterm labor. 
Unfortunately, its treatment improves dental health but does not prevent preterm birth 
(Michalowicz et al., 2006). Dental caries are not aggravated by pregnancy. Importantly, 
pregnancy is not a contraindication to dental treatment including dental radiographs 
(Giglio et al., 2009). 
Immunization 
Current recommendations for immunizations during pregnancy are summarized in 
Table 10. Over the past decade, well-publicized concerns regarding childhood exposure 
to the thimerosal preservative in some vaccines led to parental prohibition. These results 
have proven groundless, but controversy continues (Sugarman, 2007; Thompson et al., 
2007; Tozzi et al., 2009). 
Thus, they are recommended for use in pregnancy. The American College of 
Obstetricians and Gynecologists (2003a) stresses that current information on the safety 
of vaccines given during pregnancy is subject to change (Table XXIX). 
TABLE XXIX. Recommendations for Immunization during Pregnancy (Adapted 
from the CDC, Recommendations of the Advisory Committee on Immunization 






Dose Schedule Comments 
Live Attenuated Virus Vaccines 
Measles Contraindicated Single dose SC, preferably as 
MMR (Two doses necessary for 
students entering institutions of 
higher education, newly hired 




Breast feeding is not a 
contraindication 




Rubella Contraindicated, but 
congenital rubella 
syndrome has never 
been described after 
vaccine 
Single dose SC, preferably as 
MMR 
Teratogenicity of 
vaccine is theoretical 









women in the 
Primary: Two doses of enhanced-
potency inactivated virus SC at 
4–8 week intervals and a 3rd dose 
Vaccine indicated for 
susceptible women 




except women at 
increased risk of 
exposure  
6–12 months after 2nd dose 
Immediate protection: One dose 
oral polio vaccine (in outbreak) 
areas or in other high-
risk situations 
Continue TABLE XXIX. Recommendations for Immunization during Pregnancy 
(Adapted from the CDC, Recommendations of the Advisory Committee on 






Dose Schedule Comments 
Yellow fever Travel to high-risk areas Single dose SC Limited theoretical risk 
outweighed by risk of 
yellow fever 
Varicella Contraindicated, but no 
adverse outcomes reported in 
pregnancy 
Two doses needed: 2nd 
dose given 4–8 weeks 
after 1st dose 
Teratogenicity of 
vaccine is theoretical. 
Vaccination of 
susceptible women 




Contraindicated in pregnant 
women and in their household 
contacts 
One dose SC, multiple 
pricks with lancet 
Only vaccine known to 
cause fetal harm 
Other 
Influenza All pregnant women, 
regardless of trimester during 
flu season (Nov.-Mar.) 




Rabies Indications for prophylaxis 
not altered by pregnancy; 
each case considered 
Public health 
authorities to be 
consulted for 
Killed-virus vaccine 
individually indications, dosage, 
and route of 
administration 
Continue TABLE XXIX. Recommendations for Immunization during Pregnancy 
(Adapted from the CDC, Recommendations of the Advisory Committee on 






Dose Schedule Comments 
Hepatitis B Pre-exposure and 
postexposure for women at 
risk of infection 
Three-dose series IM 
at 0, 1, and 6 months 
Used with hepatitis B 
immune globulin for some 
exposures. Exposed newborn 
needs birth-dose vaccination 
and immune globulin as soon 
as possible. All infants 
should receive birth dose of 
vaccine 
Hepatitis A Pre-exposure and 
postexposure if at risk 
(international travel) 
Two-dose schedule 
IM, 6 months apart 
Inactivated virus 
Inactivated Bacterial Vaccines 
Pneumococcus Indications not altered by 
pregnancy. Recommended 
for women with asplenia; 
metabolic, renal, cardiac, 
or pulmonary diseases; 
immunosuppression; or 
smokers 
In adults, one dose 
only; consider repeat 




Meningococcus Indications not altered by One dose; tetravalent Antimicrobial prophylaxis if 
pregnancy; vaccination 
recommended in outbreaks 
vaccine significant exposure 
Continue TABLE XXIX. Recommendations for Immunization during Pregnancy 
(Adapted from the CDC, Recommendations of the Advisory Committee on 






Dose Schedule Comments 




exposure or travel 
to endemic areas 
Killed 
Primary: 2 injections IM 4 
weeks apart 
Booster: One dose; schedule 
not yet determined 
Killed, injectable vaccine 
or live attenuated oral 
vaccine. Oral vaccine 
preferred 
Anthrax  Six-dose primary 
vaccination, then annual 
booster vaccination 
Preparation from cell-free 
filtrate of B. anthracis. No 
dead or live bacteria. 
Teratogenicity of vaccine 
theoretical 
Toxoids 
Tetanus-diphtheria Lack of primary 
series, or no 
booster within past 
10 years 
Primary: Two doses IM at 
1–2 month interval with 3rd 
dose 6–12 months after the 
2nd 
Booster: Single dose IM 
every 10 years after 






Updating immune status 
should be part of 
antepartum care 
Continue TABLE XXIX. Recommendations for Immunization during Pregnancy 
(Adapted from the CDC, Recommendations of the Advisory Committee on 









Specific Immune Globulins 
Hepatitis B Postexposure prophylaxis Depends on 
exposure  
given with hepatitis B virus vaccine; 
exposed newborn needs immediate 
prophylaxis 
Rabies Postexposure prophylaxis 1/2 dose at 
injury site, half 
dose in deltoid 
Used in conjunction with rabies killed-
virus vaccine 
Tetanus Postexposure prophylaxis One dose IM Used in conjunction with tetanus 
toxoid 
Varicella Considered for exposed 
pregnant women to protect 
against maternal, not 
congenital, infection 




Indicated also for newborns or women 
who developed varicella within 4 days 
before delivery or 2 days following 
delivery 
Standard Immune Globulins 
Hepatitis A virus 
vaccine should be 




and high risk 
0.02 mL/kg IM 
in one dose 
Immune globulin should be given as 
soon as possible & within 2 weeks of 
exposure; infants born to women who 
incubating the virus or are acutely ill 
at delivery should receive one dose of 
0.5 mL as soon as possible after birth 
ID = intradermally; IM = intramuscularly; MMR = measles, mumps, rubella; PO = 
orally: and SC = subcutaneously. 
All women who will be pregnant during the influenza season should be offered 
vaccination, regardless of their stage of pregnancy. Those with underlying medical 
conditions that increase the risk for complications should be offered the vaccine before 
flu season starts (American Academy of Pediatrics and American College of 
Obstetricians and Gynecologists, 2007). 
Zaman et al. (2008) showed that prenatal maternal vaccination reduced influenza 
incidence in the first 6 months by 63 percent in infants born to these women. Moreover, it 
reduced all febrile respiratory illnesses in these children by a third. 
Women who are susceptible to rubella during pregnancy should receive MMR—
measles-mumps-rubella—vaccination postpartum. Although this vaccine is not 
recommended during pregnancy, congenital rubella syndrome has never resulted from its 
inadvertent use. There is no contraindication to MMR vaccination while breast feeding 
(ACOG, 2002d). 
Biological Warfare and Vaccines 
The tragic events of September 11, 2001, and the ongoing threat of bioterrorism 
require familiarity with smallpox and anthrax vaccines during pregnancy. The smallpox 
vaccine is made with live attenuated vaccinia virus related to smallpox and to cowpox 
viruses. Fetal vaccinia infection is rare, but it may result in abortion, stillbirth, or neonatal 
death (CDC, 2006a). 
Thus, in non-emergency circumstances, vaccination is contraindicated during 
pregnancy and in women who might become pregnant within 28 days of vaccination 
(CDC, 2006a). If, however, vaccination is inadvertently performed in early pregnancy, 
this is not grounds for termination (Suarez and Hankins, 2002). 
 
If the pregnant woman is at risk because of exposure to smallpox—either as a 
direct victim of a bioterrorist attack or as a close contact of an individual case—the risks 
from clinical smallpox substantially outweigh any potential risk from vaccination 
(Suarez and Hankins, 2002). 
Anthrax vaccination has been limited principally to individuals who are 
occupationally exposed, such as special veterinarians, laboratory workers, and members 
of the armed forces. The vaccine contains no live virus and thus would not be expected to 
pose significant risk to the fetus. Wiesen and Littell (2002) studied the reproductive 
outcomes of 385 women in the United States Army who became pregnant after 
vaccination and reported no adverse effects on fertility or pregnancy outcome. 
Caffeine 
In 1980, the FDA advised pregnant women to limit caffeine intake. The Fourth 
International Caffeine Workshop concluded shortly thereafter that there was no evidence 
that caffeine had increased teratogenic or reproductive risks (Dews et al., 1984). Caffeine 
is not a teratogen for small laboratory animals, but if given in massive doses it potentiates 
mutagenic effects of radiation and some chemicals. When infused intravenously into 
sheep, caffeine decreases uterine blood flow by 5 to 10 percent (Conover et al., 1983). 
American Dietetic Association (2002) recommends that caffeine intake during 
pregnancy be limited to less than 300 mg daily, or approximately three, 5-oz cups of 
percolated coffee. 
Nausea and Vomiting 
These are common complaints during the first half of pregnancy. Nausea and 
vomiting of varying severity usually commence between the first and second missed 
menstrual period and continue until 14 to 16 weeks. Although nausea and vomiting tend 
to be worse in the morning—thus erroneously termed morning sickness, they frequently 
continue throughout the day.  
Seldom is the treatment of nausea and vomiting of pregnancy so successful that 
the affected expectant mother is afforded complete relief. Fortunately, the unpleasantness 
and discomfort usually can be minimized. Eating small meals at more frequent intervals 
but stopping short of satiation is valuable. Borrelli et al. (2005) did a systematic 
literature search and reported that the herbal remedy, ginger, was likely effective. Mild 
symptoms usually respond to vitamin B6 given along with doxylamine, but some women 
require phenothiazine or H1-receptor blocker anti-emetics. In some women, vomiting 
may be so severe that dehydration, electrolyte and acid–base disturbances, and starvation 
ketosis become serious problems. This is termed hyperemesis gravidarum (American 
College of Obstetricians and Gynecologists, 2004b). 
Backache 
Low back pain to some extent is reported in nearly 70 percent of pregnant women 
(Wang et al., 2004). Minor degrees follow excessive strain or fatigue and excessive 
bending, lifting, or walking. Orvieto et al. (1994) studied 449 women and reported that 
back pain increased with duration of gestation. Prior low back pain and obesity were risk 
factors. Back pain can be reduced by having women squat rather than bend over when 
reaching down, providing back support with a pillow when sitting down, and avoiding 
high-heeled shoes. Severe back pain should not be attributed simply to pregnancy until a 
thorough orthopedic examination has been conducted. Muscular spasm and tenderness, 
which often are classified clinically as acute strain or fibrositis, respond well to 
analgesics, heat, and rest. Some women with severe back and hip pain may have 
pregnancy-associated osteoporosis (Dunne et al., 1993).  
Norén et al. (2002) studied the long-term outcomes of 231 women who had some 
type of back pain during pregnancy. Residual pain 3 years after delivery was reported by 
approximately 20 percent. Women with lumbar back and posterior pelvic pain were at 
greatest risk for disability, which was attributed to impaired back extensor and hip 
abductor muscle functions. 
Varicosities 
These enlarged veins generally result from congenital predisposition and are 
exaggerated by prolonged standing, pregnancy, and advancing age. Usually varicosities 
become more prominent as pregnancy advances, as weight increases, and as the length of 
time spent upright is prolonged. Femoral venous pressure increases appreciably as 
pregnancy advances. The symptoms produced by varicosities vary from cosmetic 
blemishes and mild discomfort at the end of the day to severe discomfort that requires 
prolonged rest with elevated feet. Treatment is generally limited to periodic rest with leg 
elevation, elastic stocking use, or both. Surgical correction during pregnancy generally is 
not advised, although occasionally the symptoms may be so severe that injection, 
ligation, or even stripping of the veins is necessary. Vulvar varicosities may be aided by 
application of a foam rubber pad suspended across the vulva by a belt. Rarely, large 
varicosities may rupture, resulting in profuse hemorrhage (Higgins et al., 2002). 
Hemorrhoids 
Varicosities of the rectal veins may first appear during pregnancy because of 
increased venous pressure. More often, pregnancy causes an exacerbation or a recurrence 
of previous hemorrhoids. Pain and swelling usually are relieved by topically applied 
anesthetics, warm soaks, and stool-softening agents. Thrombosis of an external 
hemorrhoid can cause considerable pain, but the clot usually can be evacuated by incising 
the vein wall under topical anesthesia (Higgins et al., 2002). 
Heartburn 
This symptom is one of the most common complaints of pregnant women and is 
caused by reflux of gastric contents into the lower esophagus. The increased frequency of 
regurgitation during pregnancy most likely results from the upward displacement and 
compression of the stomach by the uterus, combined with relaxation of the lower 
esophageal sphincter (Chamberlain and Broughton-Pipkin, 1998). 
In most pregnant women, symptoms are mild and are relieved by a regimen of 
more frequent but smaller meals and avoidance of bending over or lying flat. Antacids 
may provide considerable relief. Aluminum hydroxide, magnesium trisilicate, or 





The cravings of pregnant women for strange foods are termed pica. At times, 
nonfoods such as ice-pagophagia, starch-amylophagia, or clay—geophagia may 
predominate. This desire has been considered by some to be triggered by severe iron 
deficiency. Although some women crave these items, and although the craving usually is 
ameliorated after correction of iron deficiency, not all pregnant women with pica are 
necessarily iron deficient. Indeed, if strange "foods" dominate the diet, iron deficiency 
will be aggravated or will develop eventually (Dutta, 1992). 
Patel et al. (2004) from the University of Alabama at Birmingham prospectively 
completed a dietary inventory on more than 3000 women during the second trimester. 
The prevalence of pica was 4 percent. The most common nonfood items ingested were 
starch in 64 percent, dirt in 14 percent, sourdough in 9 percent, and ice in 5 percent. The 
prevalence of anemia was 15 percent in women with pica compared with 6 percent in 
those without it. The rate of spontaneous preterm birth at less than 35 weeks was twice as 
high in women with pica. 
Ptyalism 
Women during pregnancy are occasionally distressed by profuse salivation. 
Although usually unexplained, the cause of such ptyalism sometimes appears to be 
stimulation of the salivary glands by the ingestion of starch (CDC, 2008a). 
 
Sleeping and Fatigue 
Beginning early in pregnancy, many women experience fatigue and need 
increased amounts of sleep. This likely is due to the soporific effect of progesterone(s). 
Moreover, sleep efficiency is diminished because rapid eye movement sleep is decreased 
and non-REM sleep prolonged (Pien and Schwab, 2004). 
Fatigue and non-restful sleep may be exacerbated by morning sickness. By the 
late second trimester, total nocturnal sleep duration is decreased, and women usually 
begin to complain of sleep disturbances. Approximately half of women begin snoring 
(Izci et al., 2005). 
By the third trimester, nearly all women have altered sleep. Although total 
nocturnal sleep time is similar to non-pregnancy, sleep efficiency is perturbed because 
REM sleep is decreased. Daytime naps and mild sedatives at bedtime such as 
diphenhydramine (Benadryl) are usually helpful (Pien and Schwab, 2004). 
Leukorrhea 
Pregnant women commonly develop increased vaginal discharge, which in many 
instances is not pathological. Increased mucus secretion by cervical glands in response to 
hyperestrogenemia is undoubtedly a contributing factor. Occasionally, troublesome 
leukorrhea is the result of vulvovaginal infection. The majority of these in adult women 
are caused by bacterial vaginosis, candidiasis, or trichomoniasis (Eckert, 2006). 
Cord Blood Banking 
In the past 20 years, umbilical cord blood transplantation has been successfully 
performed more than 7000 times to treat hematopoietic cancers and a variety of genetic 
conditions in children and adults (Moise, 2005).  
There are two types of cord blood banks. Public banks promote allogenic 
donation, for use by a related or unrelated recipient, similar to blood product donation. 
Whereas private banks were initially developed to store stem cells for future autologous 
use, these banks charge fees for initial processing and annual storage. The American 
College of Obstetricians and Gynecologists (2008) has concluded that if woman 
requests information on umbilical cord banking, information regarding advantages and 
disadvantages of public versus private banking should be disclosed. Some states have 
passed legislation that requires physicians to inform patients about cord blood banking 
options. Importantly, few transplants have been performed by using cord blood stored in 
the absence of a known indication in the recipient (Thornley et al., 2009). 
The likelihood that cord blood would be used for the donor couple's child or 
family member is considered remote—at most, approximately 1 in 2700 individuals. It is 
recommended that directed donation be considered when an immediate family member 
carries the diagnosis of a specific condition known to be treatable by hematopoietic 
transplantation (American College of Obstetricians and Gynecologists, 2008). 
Antenatal Care in Egypt 
One of the priorities of the Egyptian government's maternal and child health 
program is to provide medical care during pregnancy to ensure the survival of both 
mother and child (Roudi-Fahimi, 2003). 
Maternal mortality is a major global concern that affects families and thus society. 
Surveys to determine the causes of maternal deaths (MD) are the primary tools on which 
interventions have been based. Two National Maternal Mortality Surveys (NMMSs) were 
performed in 1992–93 and 2000 in Egypt. The results from these surveys indicated that 
the maternal mortality ratio (MMR) in Egypt had decreased by 52% from 174/100 000 
live births in 1992–93 to 84/100 000 live births in 2000 (Campbell and Gipson, 1993; 
2001). 
The 1992 maternal health survey identified both unavoidable and avoidable 
factors contributing to maternal deaths in Egypt. Substandard care was a major avoidable 
factor that caused maternal mortality in 1992–93 and it remained the second key factor in 
2000. Access to ANC, recognizing danger signs and seeking professional care can be 
effective only if quality professional services are available (Attaweel and Gipson, 1996). 
In response, the Ministry of Health and Population (MOHP), in collaboration with 
international partners such as the USAID-funded Healthy Mother/Healthy Child program, 
implemented by John Snow Inc., designed and implemented a series of activities to 
improve quality of care. For example, the ministry upgraded maternal and neonatal health 
facilities and improved the logistics system throughout the country, but with a special 
focus on Upper Egypt and rural hospitals. The interventions paid special attention to 
essential obstetric care and the management of obstetric and neonatal emergencies. They 
included extensive training needs assessments, detailed situational analyses and 
community diagnoses, and studies that show maternal mortality can be reduced in all 
socioeconomic settings through investment in the appropriate interventions to ensure 
essential obstetric care and appropriate management of obstetric emergencies. Efforts are 
being made to strengthen those aspects of antenatal care most likely to have an effect on 
the outcome of pregnancy (Gipson, 1998). 
It is important for the pregnant woman to be cared for by a physician who can 
correctly take a full history and conduct a complete physical examination, then diagnose 
any problems and manage the pregnancy. Women, families, and traditional birth 
attendants (days) need to have enough information to recognize the danger signs of 
pregnancy and the puerperium so they can seek care promptly in an appropriate facility 
(WHO, 2005). 
 
The Egypt National Maternal Mortality Study 2001 reported that poor quality 
antenatal care was found to contribute to 15% of maternal deaths and to 13 maternal 
deaths per 100,000 live births. It played a more important role in death associated with 
hypertensive diseases (34%). In cardiac disease lack of antenatal care and poor quality 
antenatal dare were considered to be avoidable factors in19% and 28% of cases, 
respectively. To obtain information on the utilization of antenatal care services, the Egypt 
Demographic and Health Survey (EDHS) included several questions relating to the 
source of antenatal care, number and timing of visits, and tetanus toxoid vaccinations. 
This section discusses these antenatal care issues (Copeland and Gipson, 2002). 
Source of Antenatal Care 
According to EDHS, the survey results indicate that many mothers do not seek 
antenatal care. Among births in the five years before the EDHS, only53 percent received 
antenatal care from a trained medical provider (EDHS, 1993). 
In virtually all cases, the mother received antenatal care from a doctor. Antenatal 
care was more likely to be sought from a private sector provider than at a government 
health facility; mothers reported that they went to a private provider in the case of 77 
percent of the births in which antenatal care was received. Antenatal care from a trained 
provider is much more common for urban births (69 percent) than rural births (43 
percent).The proportion of births whose mothers received antenatal care from a trained 
provider is highest in the Urban Governorates (74 percent), followed by urban areas in 
Lower Egypt (68 percent) and Upper Egypt (62 percent). The mothers of more than half 
the live births in rural areas in both Lower Egypt and Upper Egypt did not receive any 
antenatal care during pregnancy (EDHS, 1993). 
 
 
Number and Timing of Antenatal Care Visits 
Both the number and timing of antenatal care visits are considered to be of great 
importance with respect to pregnancy outcome. Antenatal care can be more effective 
when it is sought early in the pregnancy and is received regularly throughout the 
pregnancy. If an Egyptian mother seeks antenatal care, she is likely to make more than 
one visit. However, even among mothers who seek care, the median number of visits is 
only 3.5. Among mothers who obtained antenatal care, the majority report the first 
pregnancy check occurred at or before the fifth month of pregnancy. The median time at 
which mothers started antenatal visits is 3.2monthesthe number of antenatal care visits is 
related to the likelihood that a birth occurred at a health facility. The percentage delivered 
at a health facility was 13 percent among births in which no antenatal care was received 
compared to 25 percent among births in which the mother reported 1-3 antenatal care 
visits and 58 percent among births in which there were 4 or more antenatal visits (EDHS, 
1993). 
Tetanus Toxoid Vaccinations 
Neonatal tetanus is one of the major causes of death in young infants. To fully 
protect against neonatal tetanus, it is recommended that mothers receive two tetanus 
toxoid injections during pregnancy. However, if a woman has been vaccinated during a 
previous pregnancy, she may only require a booster dose for a current pregnancy, and five 
doses of tetanus toxoid are considered to provide lifetime protection. In order to estimate 
the extent of tetanus toxoid coverage during pregnancy, the EDHS collected data on 
whether the women received tetanus toxoid vaccinations for each pregnancy in the five 
years preceding the survey and if so, the number of injections. For more than two-fifths 
of the births (43 percent), mothers did not receive a tetanus toxoid vaccination; for 17 
percent, the mothers received one dose, and, for 41 percent, the mothers received two or 
more doses (Graham et al., 2001). 
The current level of tetanus toxoid coverage is five times higher than the level 
reported in the 1988 EDHS when mothers reported receiving tetanus toxoid vaccinations 
for only 11 percent of births (Sayed et al., 1989). The marked increase is most likely a 
response to a public campaign to improve tetanus toxoid coverage that was conducted 
during the period between the two EDHS surveys. A documented, reduction in MMR 
over a relatively short time demonstrates the collective effect of an integrated national 
Safe Motherhood programme aimed at making improvements at the community, health-
care delivery site and health-care professional levels. The intensive training received by 
the medical personnel apparently had a positive effect on reducing the MMR in the 1990s 
in Egypt. It is more difficult to quantify what direct impact infrastructural improvements, 
increased utilization of ANC and the presence of skilled attendants at birth have had 








PATIENT AND METHODS 
TYPE AND SITE OF THE STUDY: 
This prospective study was conducted to evaluate the importance of antenatal care 
booking of pre-eclampsia risk factors and its effect on maternal and fetal outcomes. It 
was carried on 150 pregnant women who attending the Department of Obstetrics and 
Gynecology. 
INCLUSION CRITERIA OF THE STUDIED WOMEN 
On admission to the hospital, eligible women were approached by the physician 
and informed of the study. A written consent was obtained. The included pregnant women 
had diagnosed with preeclampsia according to the International Society for the Study of 
Hypertension in Pregnancy (ISSHP) classification (National High Blood Pressure 
Education Program Working Group on High Blood Pressure in Pregnancy, 2000).
 
Preeclampsia is defined as hypertension of at least 140/90 mmHg measured on 2 
separate occasions at least 4 hours apart and arising de novo in previously normotensive 
women after the 20th week of gestation, accompanied by significant proteinuria with or 
without suggestive clinical symptoms, all of which are resolved by 6 weeks post-partum. 
Definition of Pre-eclampsia in pregnancy:   
o Systolic blood pressure of ≥140 mmHg in on 2 or more separate occasions at least 
4 hours apart or, 
o Diastolic blood pressure of ≥90 mmHg in on 2 or more separate occasions at least 
4 hours apart. 
Definition of severe Pre-eclampsia in pregnancy: 
o Systolic blood pressure of ≥170 mmHg in any one occasion or, 
o Diastolic blood pressure of ≥110 mmHg in any one occasion. 
Definition of proteinuria in pregnancy:    
o Significant proteinuria in one 24 hours collection with total protein excretion of 
≥300mg/l of per 24 hours or, 
o Two clean-catch mid-stream or catheter specimens of urine collected ≥4 hours 
apart with ≥2+ on reagent strip.   
Suggestive clinical symptoms: 
o Symptoms including headache, photophobia, visual disturbance, epigastric pain 
and alteration in the conscious state. 
The women with or without regular antenatal care follow-up of pregnancy were 
recruited from outpatient clinic of Gynecology and Obstetrics Department. 
METHODS 
All the patients were subjected to: 
FULL MEDICAL HISTORY:       
 Demographic data. 
 Complaint and history of present illness. 
 Obstetric history. 
 Socioeconomic status. 
 Drug history. 
 Co-morbid conditions. 
 Review of other systems. 
 Past history. 
 Family history. 
RECORDING BLOOD PRESSURE IN PREGNANCY: 
 Blood pressure was determined using an average of two
 
consecutive sitting blood 
pressure readings using mercury sphygmomanometer, five minutes apart then the 
mean value was calculated. 
 The woman should be seated comfortably with her legs resting on a flat surface. 
 The supine posture was avoided because of the supine hypotension syndrome. 
 Measurement of blood pressure was undertaken in both arms at the initial visit to 
exclude rare vascular abnormalities such as aortic coarctation, subclavian stenosis 
and aortic dissection. 
 The systolic blood pressure wass accepted as the first sound heard (Korotkoff 1) 
and the diastolic blood pressure was accepted as the disappearance of sounds 
completely (Korotkoff 5). 
 When Korotkoff 5 is absent, Korotkoff 4 (muffling) was accepted. 
 Appropriate cuff size was used for accurate blood pressure recording. A large cuff 
with an inflatable bladder covering 80% of the arm circumference was used if the 
upper arm circumference is greater than 33 cm. This helps to minimise over-
diagnosis of hypertension during pregnancy. 
 In labour, the blood pressure was measured in the left arm in lateral recumbent 
position.   
LABORATORY INVESTIGATIONS: 
 Complete blood picture (CBC): for RBCs count, hemoglobin level, white 
blood cells (WBCs), differential of WBCs, platelet count (using Sysmex 
K-800 cell counter). 
 Fasting blood sugar (using Dimension ES chemical auto-analyzer). 
 Liver function tests (using Dimension ES chemical auto-analyzer): 
- Serum aspartate transaminase (AST). 
- Serum alanine transaminase (ALT). 
- Albumin. 
 Kidney function tests included; blood urea and serum creatinine (using 
Dimension ES chemical auto-analyzer). 
 Complete urine analysis for the presence of protein, casts, red blood cells 
(RBCs) and pus. 
 Protein in 24 hours urine collection. 
ULTRASOUND SETTINGS: 
A 3.5 MHz real-time linear array ultrasound scanner was used to follow-up the 
fetal growth during antenatal care settings. 
CARDIOTOCOGRAM (CTG): 
  CTG was used to monitor several different measures: uterine contractions and 




  It was performed for all newborns at both 1 and 5 min, for the assessment of the 
neonatal outcome. It depends upon observing certain signs concerning the vital functions 
as pulse, respiratory rate, color and cerebral oxygenation as tone and reflex irritability. 
DATA MANAGEMENT AND STATISTICAL ANALYSIS 
A sample size of 150 women was required to obtain a power of 90% with an 
assumption of α as 0.05. Data collected throughout history, basic clinical examination, 
laboratory investigations and ultrasound results were coded, entered and analyzed using 
Microsoft Excel software. Gathered data were then imported and processed using 
Statistical Package of Social Sciences version 20 (IBM SPSS version 20 Inc., Chicago, 
IL, USA). Quantitative data were expressed as means ± standard deviation (SD) and 
qualitative data were expressed as frequency (numbers) and percentages. The results for 
all categorical variables were given in the form of rates (%). 
The independent data of the study was conducted and analyzed. Definitive 
statistics were used for the analysis of the socio-demographic and other variables. Firstly, 
the relation between the dependent and independent variables was studied using the t-test. 
T-test was used to test significance of differences for the studied variables that follow 
normal distribution. Second, the significant variables were subjected to multivariate 
logistic regression analysis. Logistic regression analysis was performed to identify 




 An informed consent was taken from all the participants before taking any data or 
doing any investigations. 
The consent contained: 
o Explanation of the study aim in a simple manner to be understood by the 
common people. 
o No harmful maneuvers was performed or used. 
o All data were considered confidential and were not used outside this study 
without patient’s approval. 
o All samples were used in the research only. 
o Researcher phone number and all possible communicating methods were 
identified to the participants to return at any time for any explanation. 
o All participants were announced by the result of the study. 
o Participants have the right to withdraw from the study at any time without 
giving any reason. 
o Signature or fingerprints of the participants. 
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This prospective study was conducted to evaluate the importance of antenatal care 
booking of pre-eclampsia risk factors and its effect on maternal and fetal outcomes. It 
was carried on 150 pregnant women with pre-eclampsia aged between 19-35 years, who 
attending the Department of Obstetrics and Gynecology, Suez Canal University Hospital. 
Table (1) shows the socio-demographic characteristics of the studied patients. The 
most common age of the patients was between 20-30 years (40%) (Chart 1). The majority 
of the patients were from rural regions (80%) (Chart 2). About 57% of the studied women 
were primipara, while about 43% of them were multipara (Chart 3). Almost all patients 
were not working (92.7%). Only 5.3% of the patients had smoking history. The majority 
of the patients were of middle social class (80%) and also of middle education (76%). 
About 83% of them were complaining of lower abdominal pain, 9.3% complaining of 
decreased fetal movements and 6% complaining of headache.  
 
Chart 1. The age distribution among the studied patients. 
Table (1) Socio-demographic characteristics of the studied patients (n=150): 
 Total (n=150) 
No. % 
Age  <20 years  55 36.7 
20-30 years  60 40.0 
>30 years  35 23.3 
Residence  Urban 30 20.0 
Rural 120 80.0 
Parity  Primiparous 86 57.3 
Multiparous  64 42.7 
Occupation  Employed  11 7.3 
Unemployed 139 92.7 
Smoking Smoker  8 5.3 







Social class Low  29 19.3 
Middle 120 80.0 
High 1 0.7 
Education  Low  30 20.0 
Middle 114 76.0 
High 6 4.0 
Complaint  Lower abdominal pain 125 83.4 
Decrease fetal movements 14 9.3 













Chart 3. The distribution of the studied patients according to parity. 
 
Table (2) shows the complications occurred to the studied patients during the 
current pregnancy. In the first trimester, 2.7% of the patients suffered from hyperemesis 
gravidarum, 12.7% suffered from urinary tract infections, and 4.7% suffered from 
threatened abortion. Gestational diabetes affect 9.3% of the patients in the second 
trimester and 16% of the patients in the third trimester, while gestational hypertension 
affect 37.3% of the patients in the second trimester and 86.6% of the patients in the third 
trimester. During third trimester, 10.7% of the patients gave a history of vaginal bleeding, 
34.7% gave a history of premature rupture of membranes and 57.3% gave a history of 

















Table (2) Complications occurred to the studied patients during the current 
pregnancy (n=150): 
 Total (n=150) 
No. % 
1st trimester     
Hyperemesis gravidarum  No 146 97.3 
Yes  4 2.7 
Urinary tract infections No 131 87.3 
Yes  19 12.7 
Threatened abortion  No 143 95.3 
Yes  7 4.7 
Vaginal discharge  No 102 68.0 
Yes  48 32.0 
2nd trimester    
Gestational diabetes   No 136 90.7 
Yes  14 9.3 
Gestational hypertension   No 94 62.7 
Yes  56 37.3 
Alarming signs  No 141 94.0 
Yes  9 6.0 
3rd trimester    
Gestational diabetes   No 126 84.0 
Yes  24 16.0 
Gestational hypertension   No 20 13.3 
Yes  130 86.7 
Vaginal bleeding No 134 89.3 
Yes  16 10.7 
Premature rupture of membranes No 98 65.3 
Yes  52 34.7 
Abdominal pain No 64 42.7 
Yes  86 57.3 
 
Table (3) shows the history of complications occurred to the studied patients 
during previous pregnancies. About 13% of the patients had previous history of 
postpartum hemorrhage, 12.7% had previous history of preterm labor, 10.7% had 
previous history of gestational hypertension, and 10.7% had previous history of pre-
eclampsia.  
Table (3) History of complications occurred to the studied patients during previous 
pregnancies (n=150): 
 Total (n=150) 
No. % 
Gestational Diabetes   1 0.7 
Gestational hypertension   16 10.7 
Preterm labor  19 12.7 
Oligo-hydramnios  2 1.3 
Postpartum hemorrhage  20 13.3 
Previous history of pre-eclampsia 16 10.7 
 






















Table (4) shows the antenatal control during 1st trimester of the studied patients. 
About 63% of the patients came for antenatal care from 3 to ≥4 times, while 
approximately 37% of them came for antenatal care from 0 to 2 times. Sixty eight percent 
of the studied patients came for blood pressure control and 67.3% of them came for 
ultrasonographic evaluations. Only 4.7% of the studied women administrated of 
methyldopa during this period.    
Table (4) Antenatal control during 1st trimester of the studied patients (n=150): 
 Total (n=150) 
No. % 
1st trimester     
No. of antenatal visits   0-2 56 37.3 
3-≥4 94 62.7 
Blood pressure control    No 48 32.0 
Yes  102 68.0 
Ultrasonographic evaluation     No 49 32.7 
Yes  101 67.3 
Administration of methyldopa  No 143 95.3 






Table (5) shows the antenatal control during 2nd trimester of the studied patients. 
About 71% of the patients came for antenatal care from 3 to ≥4 times, while 
approximately 29% of them came for antenatal care from 0 to 2 times. About 75% of the 
patients came for blood pressure control and 74% of them came for ultrasonographic 
evaluations. CTG was performed for 8.7% of the studied women and Doppler 
examination was performed for 36% of them. Only 8% of the studied women 
administrated of methyldopa during this period.    
Table (5) Antenatal control during 2nd trimester of the studied patients (n=150): 
 Total (n=150) 
No. % 
2nd trimester    
No. of antenatal visits   0-2 44 29.4 
3-≥4 106 70.6 
Blood pressure control    No 38 25.3 
Yes  112 74.7 
Ultrasonographic evaluation     No 39 26.0 
Yes  111 74.0 
Cardiotocography (CTG) No 137 91.3 
Yes  13 8.7 
Doppler examination  No 96 64.0 
Yes  54 36.0 
Administration of methyldopa  No 138 92.0 
Yes  12 8.0 
 
Table (6) shows the antenatal control during 3rd trimester of the studied patients. 
About 82% of the patients came for antenatal care from 3 to ≥4 times, while 
approximately 18% of them came for antenatal care from 0 to 2 times. About 91% of the 
patients came for blood pressure control and 92% of them came for ultrasonographic 
evaluations. CTG was performed for 38.7% of the studied women and Doppler 
examination was performed for 54.7% of them. The majority of the studied women 
(82%) administrated of methyldopa during this period.    
Table (6) Antenatal control during 3rd trimester of the studied patients (n=150): 
 Total (n=150) 
No. % 
3rd trimester    
No. of antenatal visits   0-2 27 18.0 
3-≥4 123 82.0 
Blood pressure control    No 13 8.7 
Yes  137 91.3 
Ultrasonographic evaluation     No 12 8.0 
Yes  138 92.0 
Cardiotocography (CTG) No 92 61.3 
Yes  58 38.7 
Doppler examination  No 68 45.3 
Yes  82 54.7 
Administration of methyldopa No 27 18.0 
Yes  123 82.0 
 
Table (7) shows the vital signs and laboratory investigations of the studied 
patients. The mean systolic blood pressure and diastolic blood pressure were elevated 
(140.4±14.4 mmHg and 92.9±7.3 mmHg, respectively). The mean body mass index was 
29.3±3.2 kg/m2, which is overweight range. 
Table (7) Vital signs and laboratory investigations of the studied patients (n=150): 
 Total (n=150) 
Mean SD 
Systolic blood pressure 140.40 14.384 
Diastolic blood pressure 92.85 7.338 
Heart rate 92.56 8.448 
Temperature  36.28 3.148 
Respiratory rate 16.14 1.722 
Body mass index 29.27 3.151 
Hemoglobin  11.26 7.153 
Hematocrit  32.86 6.988 
Red blood corpuscles  4.42 3.394 
White blood count 11.57 12.413 
Prothrombin time  16.85 14.804 
Partial thromboplastin time 33.91 24.588 
International normalized ratio 2.22 11.460 
Random blood sugar 112.69 85.688 
Platelets  225.86 103.304 
Alanine transaminase 34.71 45.975 
Aspartate transaminase 44.44 105.477 
Serum creatinine  1.17 1.867 
 
Table (8) shows maternal outcome measures of the studied patients. The incidence 
of postpartum hemorrhage, eclampsia, intensive care unit (ICU) admission, blood 
transfusion, infection, maternal mortality, and overall bad maternal outcome among the 
studied patients were 4%, 4%, 8.7%, 13.3%, 9.3%, 1.3%, and 22.7%, respectively.  
Table (8) Maternal outcome measures of the studied patients (n=150): 
 
No. % 
Maternal outcome    
Postpartum hemorrhage No 144 96.0 
Yes  6 4.0 
Eclampsia    No 144 96.0 
Yes  6 4.0 
Intensive care unit admission No 137 91.3 
Yes  13 8.7 
Blood transfusion   No 130 86.7 
Yes  20 13.3 
Infection   No 136 90.7 
Yes  14 9.3 
Maternal mortality  No 148 98.7 
Yes  2 1.3 
Overall maternal outcome  Good outcome 116 77.3 
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Chart 5. Maternal outcome measures of the studied patients. 
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Chart 6. Overall maternal outcome of the studied patients. 
Table (9) shows fetal outcome measures of the studied patients. The incidence rate 
of low birth-weight, intra-uterine growth retardation (IUGR), low Apgar score, no 
spontaneous cry, cyanosis, no spontaneous breathing, negative neonatal reflexes, 
congenital anomalies, abnormal cardiac examination, neonatal intensive care unit (NICU) 
admission, infection, neonatal mortality, and overall bad fetal outcome among the studied 
patients were 11.3%, 3.3%, 13.3%, 33.3%, 30%, 29.3%, 26%, 13.3%, 19.3%, 13.3%, 














Chart 8. Overall fetal outcome of the studied patients. 
Table (9) Fetal outcome measures of the studied patients (n=150): 
 
No. % 
Fetal outcome   
Gender   Male 80 53.3 
Female  70 46.7 
Weight  ≤2.5 kg 17 11.3 
>2.5 kg  133 88.7 
Intra-uterine growth retardation (IUGR) No 145 96.7 
Yes  5 3.3 
Apgar score at 5 minutes  <7 20 13.3 
≥7  130 86.7 
Spontaneous cry No 50 33.3 
Yes  100 66.7 
Cyanosis  No 105 70.0 
Yes  45 30.0 
Spontaneous breathing No 44 29.3 
Yes  106 70.7 
Neonatal reflexes  Positive  111 74.0 
Negative  39 26.0 
Congenital anomalies  No 130 86.7 
Yes  20 13.3 
Cardiac examination Normal 121 80.7 
Abnormal 29 19.3 
Neonatal intensive care unit admission  No 130 86.7 
Yes  20 13.3 
Infection  No 140 93.3 
Yes  10 6.7 
Preterm (<37 weeks) No 92 61.3 
Yes  58 38.7 
Neonatal mortality No 142 94.7 
Yes  8 5.3 
Overall fetal outcome Good outcome 89 59.3 
Bad outcome 61 40.7 
Table (10) shows the socio-demographic predictors of maternal outcome in the 
studied patients. Women with higher age (>30 years) had about 3-folds (OR=3.2) higher 
risk of developing bad outcome. Smoker patients had about 2-folds (OR=2.2) higher risk 
of developing bad outcome. Low social class women had about 4-folds (OR=3.6) higher 
risk of developing bad outcome. Women complaining of decreased fetal movements had 
about 3-folds (OR=3.1) higher risk of developing bad outcome. 
Table (10) Regression analysis model of socio-demographic predictors of maternal 
outcome in the studied patients (n=150): 
  
Coefficients 
Odds ratio (OR) p-value 
B Beta 
(Constant) 9.422  4.679 0.002** 
Age (>30 years) 0.479 0.851 3.214 0.015* 
Residence  0.227 0.282 1.971 0.089 
Parity (primiparous) -0.293 -0.281 1.73 0.127 
Unemployed .119 .082 0.999 0.320 
Smokers .197 .180 2.202 0.029* 
Low social class -0.429 -0.533 3.568 0.009** 
Low educational level  -0.063 -0.122 0.841 0.428 
Low fetal movement -0.52 -0.557 3.078 0.018* 




Table (11) shows the current pregnancy predictors of maternal outcome in the 
studied patients. Women with hyperemesis gravidarum had about 3-folds (OR=2.9) 
higher risk of developing bad outcome. Women with gestational diabetes had about 4-
folds (OR=3.9) higher risk of developing bad outcome. Women with gestational 
hypertension had about 3-folds (OR=3.4) higher risk of developing bad outcome. Women 
with vaginal bleeding had about 3-folds (OR=2.6) higher risk of developing bad 
outcome. Women with premature rupture of membranes (PROM) had about 3-folds 
(OR=2.7) higher risk of developing bad outcome. 
Table (11) Regression analysis model of current pregnancy predictors of maternal 
outcome in the studied patients (n=150): 
  
Coefficients 
Odds ratio (OR) p-value 
B Beta 
(Constant) .524  3.667 0.0001** 
Hyperemesis  .621 .239 2.913 0.004** 
Urinary tract infection .111 .088 0.987 0.325 
Threatened abortion  -.186 -.094 1.141 0.256 
Vaginal discharge -.153 -.171 1.897 0.060 
Alarming signs  .294 .167 1.844 0.067 
Gestational diabetes  -.683 -.731 3.927 0.006** 
Gestational hypertension -.655 -.780 3.402 0.01** 
Vaginal bleeding  .292 .216 2.603 0.01** 
PROM  -.492 -.763 2.739 0.029* 
Abdominal pain .011 .013 0.137 0.892 
*Significant p<0.05, **highly significant p<0.01, premature rupture of membranes 
(PROM). 
 
Table (12) shows the previous pregnancies predictors of maternal outcome in the 
studied patients. Women with previous history of gestational diabetes had about 3-folds 
(OR=2.6) higher risk of developing bad outcome. Women with previous history of 
gestational hypertension had about 2-folds (OR=1.9) higher risk of developing bad 
outcome. Women with previous history of oligo-hydramnios had about 3-folds (OR=2.9) 
higher risk of developing bad outcome. Women with previous history of postpartum 
hemorrhage had about 4-folds (OR=3.8) higher risk of developing bad outcome.  
Table (12) Regression analysis model of previous pregnancies predictors of maternal 
outcome in the studied patients (n=150): 
  




(Constant) .077  1.603 0.114 
Previous history of gestational Diabetes   -1.16 -.462 2.631 0.01** 
Previous history of gestational hypertension   -.283 -.378 1.904 0.05* 
Previous history of preterm labor  -.027 -.040 0.292 0.772 
Previous history of oligo-hydramnios  .988 .550 2.867 0.006** 
Previous history of postpartum hemorrhage  .439 .671 3.783 0.007** 
Previous history of pre-eclampsia -.164 -.229 1.149 0.255 






Table (13) shows the antenatal control predictors of maternal outcome in the 
studied patients. Women with uncontrolled blood pressure during first trimester had about 
2-folds (OR=1.9) higher risk of developing bad outcome. Women who didn’t perform 
ultrasonographic evaluation during second and third trimesters had about 2-folds and 3-
folds (OR=1.8 and 2.8, respectively) higher risk of developing bad outcome. Women who 
didn’t administrate methyldopa during third trimester had about 3-folds (OR=2.8) higher 
risk of developing bad outcome.  
Table (13) Regression analysis model of antenatal control predictors of maternal 
outcome in the studied patients (n=150): 
  
Coefficients 
Odds ratio (OR) p-value 
B Beta 
1st number visits .051 .161 0.807 0.421 
1st blood pressure control -.409 -.455 1.948 0.05* 
1st ultrasonography  .114 .127 0.599 0.550 
1stmedication -.002 -.001 0.012 0.991 
2nd number visits .049 .146 0.590 0.556 
2nd blood pressure control .089 .093 0.518 0.605 
2nd ultrasonography -.366 -.384 1.761 0.05* 
2nd CTG -.065 -.044 0.557 0.578 
2nd Doppler .033 .038 0.369 0.713 
2nd medication .023 .015 0.188 0.851 
3rd number visits -.056 -.123 0.865 0.389 
3rd blood pressure control .050 .034 0.278 0.782 
3rd ultrasonography -.521 -.338 2.780 0.006** 
3rdCTG -.063 -.074 0.632 0.529 
3rdDoppler .061 .073 0.678 0.499 
3rd administration of methyldopa  .391 .501 2.769 0.028* 
*Significant p<0.05, **highly significant p<0.01.  
Table (14) shows the vital signs and laboratory predictors of maternal outcome in 
the studied patients. The significant predictors of bad maternal outcome were higher 
systolic blood pressure, higher diastolic blood pressure, lower hart rate, lower 
hemoglobin, higher hematocrit, higher partial thromboplastin time, and higher 
international normalized ratio. 
Table (14) Regression analysis model of vital signs and laboratory predictors of 
maternal outcome in the studied patients (n=150): 
  
Coefficients 
Odds ratio (OR) p-value 
B Beta 
(Constant) -2.636  -2.86 0.005** 
Systolic blood pressure -0.019 -0.588 -3.747 0.007** 
Diastolic blood pressure -0.016 -0.399 -3.814 0.007** 
Heart rate .016 .321 2.926 0.004** 
Temperature  .001 .011 .131 0.896 
Respiratory rate .009 .038 .440 0.660 
Body mass index .012 .097 1.147 0.254 
Hemoglobin  0.125 0.666 2.673 0.032* 
Hematocrit  -0.065 -1.02 -3.578 0.009** 
Red blood corpuscles  -.005 -.047 -.576 0.566 
White blood count .000 .013 .148 0.883 
Prothrombin time  .025 .971 1.990 0.049* 
Partial thromboplastin time -.010 -.628 -2.05 0.043* 
International normalized ratio -.027 -.825 -2.11 0.037* 
Random blood sugar .000 .103 1.020 0.310 
Platelets  .000 -.089 -1.01 0.315 
Alanine transaminase -.001 -.058 -.374 0.709 
Aspartate transaminase .001 .107 .720 0.473 
Serum creatinine  .028 .140 1.128 0.262 
*Significant p<0.05, **highly significant p<0.01.  
 
Table (15) shows the fetal outcome predictors of overall maternal outcome in the 
studied patients. Women with low birth-weight neonates had about 2-folds (OR=1.8) 
higher risk of developing bad outcome. Women who had neonates without spontaneous 
crying, with cyanosis and/or admitted to NICU had about 2-folds (OR=2.3, 2.3 and 2.1, 
respectively) higher risk of developing bad outcome.  
Table (15) Regression analysis model of fetal outcome predictors of overall maternal 
outcome in the studied patients (n=150): 
  
Coefficients 
Odds ratio (OR) p-value 
B Beta 
(Constant) .469  2.727 0.007** 
Gender   .001 .001 0.031 0.976 
Weight (≤2.5 kg) .004 .159 1.828 0.05* 
Spontaneous cry .159 .192 2.325 0.022* 
Cyanosis  .149 .168 2.270 0.025* 
Spontaneous breathing .053 .062 0.742 0.459 
Neonatal reflexes  .075 .084 1.294 0.198 
Congenital anomalies  .099 .088 1.087 0.279 
Cardiac examination -.001 -.001 0.007 0.994 
NICU admission  .235 .208 2.118 0.036* 
Infection  .043 .028 0.545 0.587 
Neonatal mortality  -.155 -.033 0.739 0.461 
*Significant p<0.05, **highly significant p<0.01, beat per minute (bpm), neonatal 





Table (16) shows the number and percentage of adequate and inadequate antenatal 
care booking visits among the studied patients. Approximately 84% of the studied 
patients attended adequate antenatal care visits (>4 visits), while 16% of them attended 
inadequate antenatal care visits (0-3 visits).  
Table (16) Number and percentages of adequate and inadequate antenatal care 




Adequate (>4) 126 84.0 













Table (17) shows the maternal outcome according to number of antenatal care 
booking visits of the studied patients. There were significantly higher incidence rate and 
higher risk of postpartum hemorrhage, eclampsia and ICU admission among women with 
inadequate booking visits than among women with adequate booking visits (16.7% 
versus 1.6%, OR=12.4; 20.8% versus 0.8%, OR=32.9; and 37.5% versus 3.2%, OR=18.3; 
respectively). 
 Women with no or inadequate booking visits also had significantly higher 
frequencies of blood transfusion and infection in comparison to women with adequate 
booking visits (45.8% and 25% versus 7.1% and 6.3%, respectively). 
Overall, there was 12-folds higher risk of bad maternal outcome among women 
with inadequate booking visits than among women with adequate booking visits (66.7% 









Table (17) Incidence rate of maternal outcome, odds ratio (OR) and 95% confident 




visits (>4) (n=126)   
Inadequate booking 




No. % No. % 
Postpartum 
hemorrhage 
No 124 98.4 20 83.3 12.4 2.1-
72.2 
0.006** 
Yes  2 1.6 4 16.7 
Eclampsia    No 125 99.2 19 79.2 32.9 3.6-
297 
0.0004** 
Yes  1 0.8 5 20.8 
ICU No 122 96.8 15 62.5 18.3 5.02-
66.8 
<0.0001** 
Yes  4 3.2 9 37.5 
Blood 
transfusion   
No 117 92.9 13 54.2 11.0 3.8-
31.5 
<0.0001** 
Yes  9 7.1 11 45.8 
Infection   No 118 93.7 18 75.0 4.9 1.5-
15.8 
0.011* 
Yes  8 6.3 6 25.0 
Maternal 
mortality  
No 125 99.2 23 95.8 5.4 0.3-
90 
0.30 
Yes  1 0.8 1 4.2 
Preterm labor  No 88 69.8 4 16.7 11.6 3.7-
36.2 
<0.0001** 
Yes  38 30.2 20 83.3 
Overall maternal 
outcome  
Good outcome 108 85.7 8 33.3 12 4.5-
32.1 
<0.0001** 
Bad outcome 18 14.3 16 66.7 
ICU (intensive care unit), Odds ratio (OR), confident interval (CI). 
 
Table (18) shows the fetal outcome according to number of antenatal care booking 
visits of the studied patients. There were significantly higher incidence rate and higher 
risk of low neonatal birth-weight, no spontaneous cry and cyanotic babies, NICU 
admission, preterm neonates and neonatal mortality among women with inadequate 
booking visits than among women with adequate booking visits (33.3% versus 7.1%, 
OR=6.5; 58.3% versus 28.6%, OR=3.5; 50% versus 26.2%, OR=2.8; 37.5% versus 8.7%, 
OR=6.3; 83.3% versus 30.2%, OR=11.6; and 29.2% versus 0.8%, OR=51.5; 
respectively). 
 Overall, there was 53-folds higher risk of bad fetal outcome among women with 
inadequate booking visits than among women with adequate booking visits (95.8% 


























Table (18) Incidence rate of fetal outcome, odds ratio (OR) and 95% confident 




visits (>4) (n=126)   
Inadequate booking 




No. % No. % 
Weight  ≤2.5 kg 9 7.1 8 33.3 6.5 2.2-
19.2 
0.001** 
>2.5 kg  117 92.9 16 66.7 
IUGR No 122 96.8 23 95.8 1.3 0.14-
12.4 
0.59 
Yes  4 3.2 1 4.2 
Apgar score at 5 
minutes  
<7 14 11.1 6 25.0 2.7 0.91-
7.8 
0.072 
≥7  112 88.9 18 75.0 
Spontaneous cry No 36 28.6 14 58.3 3.5 1.4-
8.6 
0.009** 
Yes  90 71.4 10 41.7 
Cyanosis  No 93 73.8 12 50.0 2.8 1.2-
6.9 
0.037* 
Yes  33 26.2 12 50.0 
Spontaneous 
breathing 
No 33 26.2 11 45.8 2.4 0.97-
5.8 
0.052 
Yes  93 73.8 13 54.2 
Neonatal reflexes  Positive  95 75.4 16 66.7 1.5 0.6-
3.9 
0.52 
Negative  31 24.6 8 33.3 
Congenital 
anomalies  
No 109 86.5 21 87.5 0.92 0.25-
3.4 
0.60 
Yes  17 13.5 3 12.5 
Cardiac 
examination 
Normal 101 80.2 20 83.3 0.81 0.25-
2.5 
0.79 
Abnormal 25 19.8 4 16.7 
NICU admission  No 115 91.3 15 62.5 6.3 2.2-
17.6 
<0.0001** 
Yes  11 8.7 9 37.5 
Infection  No 118 93.7 22 91.7 1.3 0.27-
6.7 
0.50 
Yes  8 6.3 2 8.3 
Preterm (<37 
weeks) 
No 88 69.8 4 16.7 11.6 3.7-
36.1 
<0.0001** 
Yes  38 30.2 20 83.3 
Neonatal 
mortality 
No 125 99.2 17 70.8 51.5 6-
444.4 
<0.0001** 
Yes  1 0.8 7 29.2 
Overall fetal 
outcome 
Good outcome 88 69.8 1 4.2 53.3 7-
408.8 
<0.0001** 
Bad outcome 38 30.2 23 95.8 




















Pre-eclampsia occurs in about 3-5% of pregnancies and is an important cause of 
fetal and maternal morbidity and mortality worldwide. Studies have shown that women 
with a history of pre-eclampsia are at increased risk of cardiovascular diseases, 
suggesting that pre-eclampsia and cardiovascular diseases may share common causes or 
mechanisms (Irgens et al., 2001; Smith et al., 2001; Rodie et al., 2004; Ray et al., 
2005). 
In healthy pregnancies adaptive changes take place in women’s physiology to 
meet demands of the rapidly developing fetus. Gestational hyperlipidemia, a degree of 
insulin resistance, and up-regulation of inflammatory markers are among changes that 
occur. In pregnancies complicated by pre-eclampsia these normally adaptive metabolic 
responses are further exaggerated (Rodie et al., 2004). 
Several studies have shown that women with preeclampsia have unfavorable risk 
profiles in pregnancy, associated with levels of serum lipids, body mass, and blood 
pressure (Rodie et al., 2004; Ray et al., 2005).  
It remains uncertain if these characteristics reflect primary causes of pre-
eclampsia or if they are secondary markers of the disease process. It is also uncertain 
whether the increased risk of cardiovascular disease subsequent to pre-eclampsia is due to 
exposures during that pregnancy or due to underlying biological traits of the mother 
(Magnussen et al., 2007). 
In the developed world, antenatal care serves an integral role in facilitating 
improved pregnancy outcome, leading to a reduction in perinatal death (Failing et al., 
2004).    
The concept of the unbooked mother has traditionally been associated with 
women in developing countries who are unable or unwilling to access healthcare facilities 
(Mutihir and Nyiputen, 2007).  
In studies of unbooked deliveries in African countries, older women of lower 
socioeconomic status (Fawcus et al., 1992) and high parity (Mutihir and Nyiputen, 
2007) have been identified as the groups most likely not to book for antenatal care and 
therefore more likely to have preterm babies and incur maternal mortality (Mutihir and 
Nyiputen, 2007; Owolabi et al., 2008).  
Treacy et al. (2002), reporting on the perinatal outcome of unbooked women in 
Ireland, had a disproportionately high rate of preterm delivery, low birth-weight babies 
and NICU admissions.   
The concept of being unbooked may be changing in that instead of the typical 
picture of the unbooked woman being older, of low socioeconomic status (Fawcus et al., 
1992) and high parity (Mutihir and Nyiputen, 2007), unbooked women may now be 
young healthy women with poor knowledge on how to access health care in the country.  
Kotelchuck (1994) developed the adequacy of prenatal care utilization (APCU) 
index. It categorized ANC utilization by two independent and distinctive dimensions: 
adequacy of initiation of antenatal care and adequacy of received services. The adequacy 
of the timing of initiation of antenatal care indicated by early initiation, WHO 
recommended that registration before or at 16 weeks of gestation, is considered as "early 
initiation" (Alexnder et al., 1996). 
 
By studying risk factors, these issues could be tackled. Few studies have 
investigated potentially risk factors in relation to risk of pre-eclampsia. We carried out 
this prospective study to reach an overall estimate for the importance of antenatal care 
booking of the risk of pre-eclampsia. This provides an evidence-based from which 
healthcare professionals can assess each pregnant woman's risk of pre-eclampsia at her 
booking visit and tailor her antenatal care according to need.  
This study included 150 women. The most common age of the patients was 
between 20-30 years (40%). About 57% of the studied women were primipara, while 
about 43% of them were multipara. Women with pre-eclampsia had lower prevalence of 
smoking history (5.3%). Women with higher educational level had lower risk of pre-
eclampsia (4%).  
A similar study was performed by Magnussen et al. (2007). They included 133 
women. The mean age at baseline was 25.4 years for women.  The proportion of 
nulliparous women was higher than multiparous women (64% versus 36.1%, 
respectively). Smoker women had a lower risk of pre-eclampsia compared with women 
who did not smoke (18.7% versus 81.3%, respectively). Higher educational level was 
associated with reduced risk of pre-eclampsia (6%).  
Women aged ≥ 40 had approaching twice the risk of developing pre-eclampsia, 
whether they were primiparous or multiparous (relative risk 1.68, 95% confidence 
interval 1.23 to 2.29, and 1.96, 1.34 to 2.87, respectively) (Bianco et al., 1996). National-
wide data suggest that the risk of pre-eclampsia increases by 30% for every additional 
year of age past 34 years (Saftlas et al., 1990). 
 
As mentioned, our study observed that about 57% of the studied women were 
primipara, while about 43% of them were multipara with a higher risk ratio of 
preeclampsia (1.3) in primiparous women. Parity was not a significant predictor of poor 
maternal outcomes (t=-1.7, p=0.13).   
In three cohort studies, nulliparity almost triples the risk for pre-eclampsia (2.91, 
1.28 to 6.61) (Coonrod et al., 1995; Lawoyin and Ani, 1996; Lee et al., 2000); this is 
supported by adjusted odds ratios for nulliparity from two other cohort studies (Khan et 
al., 1996; Hartikainen et al., 1998). In several studies, women with pre-eclampsia are 
twice as likely to be nulliparous as women without pre-eclampsia (2.35, 1.80 to 3.06) 
(Eskenazi et al., 1991; Stone et al., 1994; Chen et al., 2000; Odegard et al., 2000; 
Stamilio et al., 2000; Duckitt and Harrington, 2005).  
In our study, despite only 5.3% of the patients had smoking history, the presence 
of smoking history was a significant predictor of bad maternal outcome (t=2.2, p=0.029).  
The results of studies that examine the effects of smoking on pre-eclampsia had 
controversial findings. On one side, Salafia and Shiverick (1999) found similar results 
as ours that women who smoke and develop pre-eclampsia seem to have a poorer 
outcome than women with preeclampsia who do not smoke.  
On the other side, several studies have indicated that the risk of preeclampsia is 
lower in women who smoke than in women who do not smoke, but it is not fully 
understood how smoking may reduce the risk (Conde-Agudelo et al., 1999; Bainbridge 
et al., 2005; Magnussen et al., 2007). 
 
Exposure to nicotine, carbon monoxide, stimulation of nitric oxide production, 
lowering of anti-angiogenic factors, or a decreased immune response have been advanced 
as possible explanations for this observation (Conde-Agudelo et al.,  1999; Bainbridge 
et al., 2005; Beste et al., 2005). This may indicate a synergy between smoking and pre-
eclampsia or, alternatively, that smoking may mask the symptoms of pre-eclampsia. 
In our study, about 13% had previous history of preterm labor, about 11% had 
previous history of pre-eclampsia, about 11% had previous history of hypertension, and 
about 1% had history of diabetes. History of diabetes and hypertension, but not previous 
pre-eclampsia, was significant predictors of bad maternal outcomes. The prevalence of 
postpartum hemorrhage, eclampsia, ICU admission, blood transfusion, infection, 
maternal mortality, and overall bad maternal outcome among the studied pre-eclamptic 
patients were 4%, 4%, 8.7%, 13.3%, 9.3%, 1.3%, and 22.7%, respectively. The 
prevalence of NICU admission, infection, neonatal mortality, and overall bad fetal 
outcome among the studied pre-eclamptic patients were 13.3%, 6.7%, 5.3%, and 40.7%, 
respectively. 
In the same way, Magnussen and his colleagues (2007) found that about 27% of 
the studied women had preterm labor, 11.3% had previous pre-eclampsia, 5% had 
hypertension, and 1.5% had previous history of diabetes.  
Attia et al. (2012) data revealed that pregnancy outcomes in the unbooked 
mothers were poorer than in the booked mothers due higher incidence of preeclampsia 
and PROM, where its percentage was as follow; 8% in unbooked mothers versus 2% 
booked mothers and 17% in unbooked mothers versus 11% booked mothers, 
respectively. Results of this study showed high prevalence of NICU admission and 
perinatal morbidity (15% and 20%). 
The higher incidence of antenatal complications such as pregnancy induced 
hypertension is a factor that leads to poor outcomes in the infant and the mother 
(Owolabi et al., 2008). 
Other studies have assessed cardiovascular risk factors measured in ongoing 
pregnancies (Wolf et al., 2002; Duckitt and Harrington, 2005; Ray et al., 2006), and 
some have reported associations between pre-eclampsia and pre-pregnancy obesity, 
chronic hypertension, and hypercholesterolaemia (Thadhani et al., 1999; O’Brien et al., 
2003). 
Women who have pre-eclampsia in a first pregnancy have seven times the risk of 
pre-eclampsia in a second pregnancy (7.19, 5.85 to 8.83) (Lee et al., 2000; Makkonen et 
al., 2000; Dukler et al., 2001). Women with pre-eclampsia in their second pregnancy are 
also more than seven times more likely to have a history of pre-eclampsia in their first 
pregnancy than women in their second pregnancy who do not develop pre-eclampsia 
(7.61, 4.3 to 13.47) (Chen et al., 2000; Odegard et al., 2000; Makkonen et al., 2000; 
Stamilio et al., 2000; Dukler et al., 2001; Duckitt and Harrington, 2005). 
The likelihood of pre-eclampsia nearly quadruples if diabetes is present before 
pregnancy (3.56, 2.54 to 4.99) (Lee et al., 2000; Maxwell et al., 2001). Pre-existing 
hypertension, in a population based nested case-control study, Davies et al. (1970) found 
that the prevalence of chronic hypertension was higher in women who developed pre-
eclampsia than women who did not (12.1% v 0.3%). McCowan et al. (1996) compared 
outcomes in 129 women with chronic hypertension who did not develop superimposed 
pre-eclampsia with 26 women with chronic hypertension who did.  
Women with superimposed pre-eclampsia had significantly higher rates of 
perinatal morbidity (odds ratio 8.8, 2.6 to 39.0), small for gestational age infants (5.6, 1.8 
to 16.0), and delivery before 32 weeks (15.0, 5.7 to 38.0). A diastolic blood pressure 
before 20 weeks of either ≥ 110 mm Hg (5.2, 1.5 to 17.2) or ≥ 100 mm Hg (3.2, 1.0 to 
7.8) is most predictive of the development of superimposed pre-eclampsia (Duckitt and 
Harrington, 2005). 
Healthy pregnancies are typically characterized by insulin resistance compared 
with the non-pregnant state, including up-regulation of maternal carbohydrate and lipid 
metabolism (Rodie et al., 2004; Sibai et al., 2005).  
These adaptive responses to pregnancy meet demands of the rapidly developing 
fetus, and in pre-eclamptic pregnancies these metabolic up-regulations seem to be 
exaggerated compared with uncomplicated pregnancies (Rodie et al., 2004; Sibai et al., 
2005). 
Therefore the excessive metabolic changes of pre-eclamptic pregnancies may be 
regarded as a stress test for maternal cardiovascular function (Sattar and Greer, 2002).  
Several studies have linked pre-eclampsia with higher risk of future 
cardiovascular disease of the mother (Irgens et al., 2001; Smith et al., 2001; Ray et al., 
2005), suggesting that pre-eclampsia and cardiovascular diseases may share common 
patho-physiological mechanisms (Rodie et al., 2004).  
The pathogenesis of pre-eclampsia is uncertain, but predisposition to endothelial 
dysfunction is thought to play a crucial part (Rodie et al., 2004; Sibai et al., 2005; Ness 
and Sibai, 2006).  
Risk factors for pre-eclampsia such as chronic hypertension, renal disease, and 
diabetes are all conditions where endothelial dysfunction is a common feature (Rodie et 
al., 2004; Sibai et al., 2005).   
Furthermore, unfavorable lipid levels are associated with endothelial dysfunction 
and may precede the development of atheromatous disease (Goode et al., 1995). Studies 
have also shown acute atherosis in vessels of the placenta bed in pre-eclamptic women. 
Finally, it would be possible to test the causal effect of some of these risk factors—such 
as increased low density lipoprotein cholesterol or triglyceride levels—on risk of pre-
eclampsia by relating genotypes associated with different average levels of these factors 
to risk of pre-eclampsia and utilizing the principle of mendelian randomization (Smith 
and Ebrahim, 2004). 
Regarding the antenatal control of our studied patients, about 63% of the patients 
came for antenatal care from 3 to 4 times during the first trimester of pregnancy. About 
71% of the patients came for antenatal care from 3 to 4 times during the second trimester. 
About 82% of the patients came for antenatal care from 3 to 4 times during the third 
trimester. 
Attia et al. (2012) study found that 46% of booked mothers attended first ANC 
visit during first 16 weeks of pregnancy, 38% of booked mothers attended first ANC visit 
in the period between 16th and 28th weeks of pregnancy and 16% of booked mothers 
attended first ANC visit after 28 weeks of pregnancy. 
Early initiation of prenatal care is important to prevent and treat obstetric and 
medical complications (as preeclampsia). It reduces the risk of occurrence of the 
congenital anomalies which may arise from exposure of the fetus to irradiation, drugs or 
intrauterine infections in the early pregnancy (WHO, 1997). 
In our study, the mean systolic blood pressure and diastolic blood pressure were 
elevated (140.4±14.4 mmHg and 92.9±7.3 mmHg, respectively). The mean body mass 
index was 29.3±3.2 kg/m2, which is overweight range. Higher systolic and diastolic blood 
pressures, but not high body mass index, significantly predict bad maternal outcome. 
Also, one of the significant predictors of bad maternal outcome was uncontrolled blood 
pressure during first trimester. 
Similarly, Magnussen and his colleagues (2007) found that about 41% of the 
studied women had systolic blood pressure ≥130 mmHg and 38% of them had diastolic 
blood pressure ≥78 mmHg. About 52% of those women had body mass index ≥25 kg/m2 
(overweight). 
Regarding blood pressure at booking, Reiss et al. (1987) matched 30 women with 
pre-eclampsia for age, race, and parity with normotensive control women. Both systolic 
and diastolic blood pressures were significantly higher in the first trimester for women 
who later developed pre-eclampsia. Sibai et al. (1995) found that higher systolic and 
diastolic blood pressures at the first visit were associated with an increased incidence of 
pre-eclampsia (3.8% in women with diastolic blood pressure of < 55 mm Hg, 7.4% in 
those with diastolic blood pressure 70-84 mm Hg). However, their recruitment was 
limited to women with a first blood pressure reading of ≤ 135/85 mm Hg. 
In a population based nested case-control study Odegard et al. (2000) found that 
a systolic blood pressure ≥ 130 mm Hg compared with < 110 mm Hg at the first visit 
before 18 weeks was significantly associated with the development of pre-eclampsia later 
in pregnancy (adjusted odds ratio 3.6, 2.0 to 6.6). The association with a diastolic 
pressure ≥ 80 mm Hg compared with < 60 mm Hg was similar but not significant (1.8, 
0.7 to 4.6). 
In a case-control study Stamilio et al. (2000) found that a mean arterial pressure 
> 90 mm Hg at the first prenatal visit was significantly associated with the development 
of severe pre-eclamptic toxaemia (relative risk 3.7, 2.1 to 6.6). 
In our study, the mean body mass index was 29.3±3.2 kg/m2, which is overweight 
range. Body mass index was not a significant predictor of poor maternal outcomes (t=1.1, 
p=0.25). Confounding factors can affect the relation between body mass index and 
maternal outcomes as women with raised body mass index may be older and more at risk 
of chronic hypertension.  
Although the studies that looked at body mass index before pregnancy all used 
different ranges, they all showed effects in the same direction, suggesting an overall 
doubling of risk of pre-eclampsia with a raised body mass index (2.47, 1.66 to 3.67) (Lee 
et al., 2000; Stone et al., 1994; Fields et al., 1996; Bianco et al., 1998; Thadhani et al., 
1999).  
One cohort study showed that women with a body mass index > 35 before 
pregnancy had over four times the risk of pre-eclampsia compared with women with a 
pre-pregnancy body mass index of 19-27 (4.39, 3.52, 5.49) (Bianco et al., 1998).  
All studies that looked at raised compared with normal body mass index at 
booking found that the risk of pre-eclampsia is increased by 50% (Sibai et al., 1997; 
Bowers et al., 1999; Van Hoorn et al., 2002; Duckitt and Harrington, 2005).  
Notably, a body mass index > 35 at booking doubles the pre-eclampsia risk (one 
cohort study, 2.12, 1.56 to 2.88) (Sibai et al., 1997). A study comparing low and normal 
body mass index at booking found that the risk of pre-eclampsia was significantly 
reduced with a body mass index < 20 (odds ratio 0.76, 0.62 to 0.92) (Sebire et al., 2001). 
Several advantages and potentially success factors of this study must be 
considered.  
Firstly, socio-demographic factors are potential risk factors and significant 
predicators of adverse maternal outcomes. In the present study, we accounted for five of 
these factors (maternal age, residence, occupation, social class and maternal education), 
and we were able to evaluate the relation between these socioeconomic factors and 
maternal outcomes because these data were sufficient for statistical calculation. Two of 
these socio-demographic factors were significant predictors of bad maternal outcome 
(higher age, and lower social class).  
Secondly, our study was population-based. So, the effect of different racial origin 
on adverse maternal outcomes was neglected and the results had not been confounded by 
this matter as the results were similar among the homogenous population characteristics 
considered in our study.  
Thirdly, the accuracy of specific diagnoses on this study has been extensively 
investigated and the main researcher had applied the defined criteria appropriately.  
Fourthly, adjustments for several variables were performed and this decreases the 
potential hazards for the confounding factors.  
Fifthly, accuracy of gestational age estimated from the date of last menstrual 
period and confirmed by ultrasonographic evaluation is a well recognized accurate 
method in epidemiological research. When we replicated the entire analyses using 
gestational age estimated from physical and neurological assessments of the new-born in 
comparison to that based on last menstrual period and ultrasonographic evaluation, the 
results were essentially unchanged.  
Finally, it should be emphasized that our study was carried out in developing 
countries and its findings may therefore be applicable to other similar developing 
populations. 
In conclusion, antenatal care booking with addressing of pre-eclampsia risk 
factors provided an effective method to identify the significant predictors of poor 










Pre-eclampsia occurs in about 3-5% of pregnancies and is an important cause of 
fetal and maternal morbidity and mortality worldwide. Studies have shown that women 
with a history of pre-eclampsia are at increased risk of cardiovascular diseases, 
suggesting that pre-eclampsia and cardiovascular diseases may share common causes or 
mechanisms. 
In the developed world, antenatal care serves an integral role in facilitating 
improved pregnancy outcome, leading to a reduction in perinatal death. The concept of 
the unbooked mother has traditionally been associated with women in developing 
countries who are unable or unwilling to access healthcare facilities.  
By studying risk factors, these issues could be tackled. Few studies have 
investigated potentially risk factors in relation to risk of pre-eclampsia. We carried out 
this prospective study to reach an overall estimate for the importance of antenatal care 
booking of the risk of pre-eclampsia. This provides an evidence-based from which 
healthcare professionals can assess each pregnant woman's risk of pre-eclampsia at her 
booking visit and tailor her antenatal care according to need.  
This study included 150 women. The most common age of the patients was 
between 20-30 years (40%). About 57% of the studied women were primipara, while 
about 43% of them were multipara. Parity was not a significant predictor of poor 
maternal outcomes (t=-1.7, p=0.13).   
Women with pre-eclampsia had lower prevalence of smoking history (5.3%). 
Women with higher educational level had lower risk of pre-eclampsia (4%).  
In our study, despite only 5.3% of the patients had smoking history, the presence 
of smoking history was a significant predictor of bad maternal outcome (t=2.2, p=0.029).  
In our study, about 13% had previous history of preterm labor, about 11% had 
previous history of pre-eclampsia, about 11% had previous history of hypertension, and 
about 1% had history of diabetes. History of diabetes and hypertension, but not previous 
pre-eclampsia, was significant predictors of bad maternal outcomes. The prevalence of 
postpartum hemorrhage, eclampsia, ICU admission, blood transfusion, infection, 
maternal mortality, and overall bad maternal outcome among the studied pre-eclamptic 
patients were 4%, 4%, 8.7%, 13.3%, 9.3%, 1.3%, and 22.7%, respectively. The 
prevalence of NICU admission, infection, neonatal mortality, and overall bad fetal 
outcome among the studied pre-eclamptic patients were 13.3%, 6.7%, 5.3%, and 40.7%, 
respectively. 
Regarding the antenatal control of our studied patients, about 63% of the patients 
came for antenatal care from 3 to 4 times during the first trimester of pregnancy. About 
71% of the patients came for antenatal care from 3 to 4 times during the second trimester. 
About 82% of the patients came for antenatal care from 3 to 4 times during the third 
trimester. 
In our study, the mean systolic blood pressure and diastolic blood pressure were 
elevated (140.4±14.4 mmHg and 92.9±7.3 mmHg, respectively). The mean body mass 
index was 29.3±3.2 kg/m2, which is overweight range. Higher systolic and diastolic blood 
pressures, but not high body mass index, significantly predict bad maternal outcome. 
Also, one of the significant predictors of bad maternal outcome was uncontrolled blood 
pressure during first trimester. 
In our study, the mean body mass index was 29.3±3.2 kg/m2, which is overweight 
range. Body mass index was not a significant predictor of poor maternal outcomes (t=1.1, 
p=0.25). Confounding factors can affect the relation between body mass index and 
maternal outcomes as women with raised body mass index may be older and more at risk 
of chronic hypertension.  
In conclusion, antenatal care booking with addressing of pre-eclampsia risk 
factors provided an effective method to identify the significant predictors of poor 


































Regarding the collected results of the present work the following conclusions can be 
suggested: 
 Predictors of maternal outcome includes:  
o Higher age (triple risk). 
o Smoking (double risk). 
o Low social class (quadruple risk). 
o Decreased fetal movements (triple risk). 
o Hyper-emesis gravidarum (triple risk). 
o Gestational diabetes (quadruple risk). 
o Gestational hypertension (triple risk). 
o Vaginal bleeding (triple risk). 
o PROM (triple risk). 
o Previous history of gestational diabetes (triple risk). 
o Previous history of gestational hypertension (double risk). 
o Previous history of oligo-hydramnios (triple risk). 
o Previous history of postpartum hemorrhage (quadruple risk). 
o Uncontrolled blood pressure during 1st trimester (double risk). 
o Not performing ultrasonography evaluation during 2nd & 3rd trimesters (double 
and triple risk, respectively). 
o Not administrating methyldopa during 3rd trimester (triple risk). 
o Higher systolic and diastolic blood pressure (quadruple risk). 
o Lower heart rate (triple risk). 
o Lower hemoglobin (triple risk). 
o Higher PT, PTT and INR (double risk). 
o Low neonatal birth-weight (double risk). 
o Neonates without spontaneous crying, with cyanosis and/or admitted to NICU 
(double risk). 
 Approximately 16% of the studied patients attended inadequate antenatal care visits (0-3 
visits).  
 There were significantly higher incidence rate and higher risk of postpartum hemorrhage, 
eclampsia, ICU admission, blood transfusion, infection and overall bad maternal outcome 
among women with inadequate booking visits than among women with adequate booking 
visits. 
 There were significantly higher incidence rate and higher risk of low neonatal birth-
weight, no spontaneous cry and cyanotic babies, NICU admission, preterm neonates, 
neonatal mortality and overall bad fetal outcome among women with inadequate booking 
visits than among women with adequate booking visits. 
 Overall conclusion, the antenatal care booking visits during pregnancy of the studied 

























Regarding the collected results of the present work the following recommendation 
can be suggested: 
o There is an urgent need to promote antenatal care utilization, ensure supervised 
delivery by trained attendants and eliminate deliveries under substandard 
conditions.  
o Improvement in the socioeconomic conditions of the population and the removal 
of fee for service in maternal care services will go a long way to improve the 
availability and accessibility of good quality antenatal care and delivery services 
that are urgently needed. 
o The need to clear information on general aspects of ANC to the expectant   
mother should be established. 
o Training on simple and effective way of providing ANC should be given to health 
care providers. 
o Further studies including larger sample size and other factors affecting the 
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